2025-11-02 00:09:30.477 [34mINFO [0;39m [background-preinit] [36mo.h.validator.internal.util.Version[0;39m - HV000001: Hibernate Validator 8.0.1.Final
2025-11-02 00:09:30.569 [34mINFO [0;39m [main] [36mcom.nckh.yte.YteApplication[0;39m - Starting YteApplication using Java 17.0.12 with PID 20568 (C:\Users\nhatn\java_project\yte\target\classes started by nhatn in C:\Users\nhatn\java_project\yte)
2025-11-02 00:09:30.570 [39mDEBUG[0;39m [main] [36mcom.nckh.yte.YteApplication[0;39m - Running with Spring Boot v3.1.4, Spring v6.0.12
2025-11-02 00:09:30.572 [34mINFO [0;39m [main] [36mcom.nckh.yte.YteApplication[0;39m - No active profile set, falling back to 1 default profile: "default"
2025-11-02 00:09:32.456 [34mINFO [0;39m [main] [36mo.s.d.r.c.RepositoryConfigurationDelegate[0;39m - Bootstrapping Spring Data JPA repositories in DEFAULT mode.
2025-11-02 00:09:32.735 [34mINFO [0;39m [main] [36mo.s.d.r.c.RepositoryConfigurationDelegate[0;39m - Finished Spring Data repository scanning in 263 ms. Found 7 JPA repository interfaces.
2025-11-02 00:09:33.710 [34mINFO [0;39m [main] [36mo.s.b.w.e.tomcat.TomcatWebServer[0;39m - Tomcat initialized with port(s): 8081 (http)
2025-11-02 00:09:33.719 [34mINFO [0;39m [main] [36mo.a.coyote.http11.Http11NioProtocol[0;39m - Initializing ProtocolHandler ["http-nio-8081"]
2025-11-02 00:09:33.723 [34mINFO [0;39m [main] [36mo.a.catalina.core.StandardService[0;39m - Starting service [Tomcat]
2025-11-02 00:09:33.724 [34mINFO [0;39m [main] [36mo.a.catalina.core.StandardEngine[0;39m - Starting Servlet engine: [Apache Tomcat/10.1.13]
2025-11-02 00:09:33.887 [34mINFO [0;39m [main] [36mo.a.c.c.C.[Tomcat].[localhost].[/][0;39m - Initializing Spring embedded WebApplicationContext
2025-11-02 00:09:33.888 [34mINFO [0;39m [main] [36mo.s.b.w.s.c.ServletWebServerApplicationContext[0;39m - Root WebApplicationContext: initialization completed in 3239 ms
2025-11-02 00:09:34.134 [34mINFO [0;39m [main] [36mo.h.jpa.internal.util.LogHelper[0;39m - HHH000204: Processing PersistenceUnitInfo [name: default]
2025-11-02 00:09:34.232 [34mINFO [0;39m [main] [36morg.hibernate.Version[0;39m - HHH000412: Hibernate ORM core version 6.2.9.Final
2025-11-02 00:09:34.237 [34mINFO [0;39m [main] [36morg.hibernate.cfg.Environment[0;39m - HHH000406: Using bytecode reflection optimizer
2025-11-02 00:09:34.543 [34mINFO [0;39m [main] [36mo.h.b.i.BytecodeProviderInitiator[0;39m - HHH000021: Bytecode provider name : bytebuddy
2025-11-02 00:09:34.777 [34mINFO [0;39m [main] [36mo.s.o.j.p.SpringPersistenceUnitInfo[0;39m - No LoadTimeWeaver setup: ignoring JPA class transformer
2025-11-02 00:09:34.796 [34mINFO [0;39m [main] [36mcom.zaxxer.hikari.HikariDataSource[0;39m - HikariPool-1 - Starting...
2025-11-02 00:09:35.167 [34mINFO [0;39m [main] [36mcom.zaxxer.hikari.pool.HikariPool[0;39m - HikariPool-1 - Added connection org.postgresql.jdbc.PgConnection@66d2885c
2025-11-02 00:09:35.170 [34mINFO [0;39m [main] [36mcom.zaxxer.hikari.HikariDataSource[0;39m - HikariPool-1 - Start completed.
2025-11-02 00:09:35.657 [34mINFO [0;39m [main] [36mo.h.b.i.BytecodeProviderInitiator[0;39m - HHH000021: Bytecode provider name : bytebuddy
2025-11-02 00:09:36.779 [34mINFO [0;39m [main] [36mo.h.e.t.j.p.i.JtaPlatformInitiator[0;39m - HHH000490: Using JtaPlatform implementation: [org.hibernate.engine.transaction.jta.platform.internal.NoJtaPlatform]
2025-11-02 00:09:37.035 [34mINFO [0;39m [main] [36mo.s.o.j.LocalContainerEntityManagerFactoryBean[0;39m - Initialized JPA EntityManagerFactory for persistence unit 'default'
2025-11-02 00:09:37.494 [39mDEBUG[0;39m [main] [36mcom.nckh.yte.security.JwtAuthFilter[0;39m - Filter 'jwtAuthFilter' configured for use
2025-11-02 00:09:38.217 [31mWARN [0;39m [main] [36mo.s.b.a.o.j.JpaBaseConfiguration$JpaWebConfiguration[0;39m - spring.jpa.open-in-view is enabled by default. Therefore, database queries may be performed during view rendering. Explicitly configure spring.jpa.open-in-view to disable this warning
2025-11-02 00:09:38.436 [39mDEBUG[0;39m [main] [36mo.s.w.s.m.m.a.RequestMappingHandlerMapping[0;39m - 31 mappings in 'requestMappingHandlerMapping'
2025-11-02 00:09:38.543 [39mDEBUG[0;39m [main] [36mo.s.w.s.h.SimpleUrlHandlerMapping[0;39m - Patterns [/webjars/**, /**, /swagger-ui*/*swagger-initializer.js, /swagger-ui*/**] in 'resourceHandlerMapping'
2025-11-02 00:09:38.628 [34mINFO [0;39m [main] [36mo.s.s.web.DefaultSecurityFilterChain[0;39m - Will secure any request with [org.springframework.security.web.session.DisableEncodeUrlFilter@569b3009, org.springframework.security.web.context.request.async.WebAsyncManagerIntegrationFilter@23d0f6be, org.springframework.security.web.context.SecurityContextHolderFilter@7a79a5d6, org.springframework.security.web.header.HeaderWriterFilter@2a728076, org.springframework.web.filter.CorsFilter@48cebb78, org.springframework.security.web.authentication.logout.LogoutFilter@4f2a0909, com.nckh.yte.security.JwtAuthFilter@38f3dbbf, org.springframework.security.web.savedrequest.RequestCacheAwareFilter@1eaf4e77, org.springframework.security.web.servletapi.SecurityContextHolderAwareRequestFilter@4f466207, org.springframework.security.web.authentication.AnonymousAuthenticationFilter@45c10678, org.springframework.security.web.session.SessionManagementFilter@480f1311, org.springframework.security.web.access.ExceptionTranslationFilter@10efb806, org.springframework.security.web.access.intercept.AuthorizationFilter@72e5206]
2025-11-02 00:09:38.746 [39mDEBUG[0;39m [main] [36mo.s.w.s.m.m.a.RequestMappingHandlerAdapter[0;39m - ControllerAdvice beans: 0 @ModelAttribute, 0 @InitBinder, 1 RequestBodyAdvice, 1 ResponseBodyAdvice
2025-11-02 00:09:38.819 [39mDEBUG[0;39m [main] [36mo.s.w.s.m.m.a.ExceptionHandlerExceptionResolver[0;39m - ControllerAdvice beans: 1 @ExceptionHandler, 1 ResponseBodyAdvice
2025-11-02 00:09:39.115 [34mINFO [0;39m [main] [36mo.a.coyote.http11.Http11NioProtocol[0;39m - Starting ProtocolHandler ["http-nio-8081"]
2025-11-02 00:09:39.151 [34mINFO [0;39m [main] [36mo.s.b.w.e.tomcat.TomcatWebServer[0;39m - Tomcat started on port(s): 8081 (http) with context path ''
2025-11-02 00:09:39.174 [34mINFO [0;39m [main] [36mcom.nckh.yte.YteApplication[0;39m - Started YteApplication in 9.467 seconds (process running for 10.171)
2025-11-02 00:10:30.261 [34mINFO [0;39m [http-nio-8081-exec-3] [36mo.a.c.c.C.[Tomcat].[localhost].[/][0;39m - Initializing Spring DispatcherServlet 'dispatcherServlet'
2025-11-02 00:10:30.261 [34mINFO [0;39m [http-nio-8081-exec-3] [36mo.s.web.servlet.DispatcherServlet[0;39m - Initializing Servlet 'dispatcherServlet'
2025-11-02 00:10:30.262 [39mDEBUG[0;39m [http-nio-8081-exec-3] [36mo.s.web.servlet.DispatcherServlet[0;39m - Detected StandardServletMultipartResolver
2025-11-02 00:10:30.262 [39mDEBUG[0;39m [http-nio-8081-exec-3] [36mo.s.web.servlet.DispatcherServlet[0;39m - Detected AcceptHeaderLocaleResolver
2025-11-02 00:10:30.262 [39mDEBUG[0;39m [http-nio-8081-exec-3] [36mo.s.web.servlet.DispatcherServlet[0;39m - Detected FixedThemeResolver
2025-11-02 00:10:30.265 [39mDEBUG[0;39m [http-nio-8081-exec-3] [36mo.s.web.servlet.DispatcherServlet[0;39m - Detected org.springframework.web.servlet.view.DefaultRequestToViewNameTranslator@308d8de8
2025-11-02 00:10:30.266 [39mDEBUG[0;39m [http-nio-8081-exec-3] [36mo.s.web.servlet.DispatcherServlet[0;39m - Detected org.springframework.web.servlet.support.SessionFlashMapManager@2f08e6d3
2025-11-02 00:10:30.267 [39mDEBUG[0;39m [http-nio-8081-exec-3] [36mo.s.web.servlet.DispatcherServlet[0;39m - enableLoggingRequestDetails='false': request parameters and headers will be masked to prevent unsafe logging of potentially sensitive data
2025-11-02 00:10:30.268 [34mINFO [0;39m [http-nio-8081-exec-3] [36mo.s.web.servlet.DispatcherServlet[0;39m - Completed initialization in 6 ms
2025-11-02 00:10:30.288 [39mDEBUG[0;39m [http-nio-8081-exec-3] [36mo.s.security.web.FilterChainProxy[0;39m - Securing OPTIONS /api/auth/login
2025-11-02 00:10:30.339 [39mDEBUG[0;39m [http-nio-8081-exec-4] [36mo.s.security.web.FilterChainProxy[0;39m - Securing POST /api/auth/login
2025-11-02 00:10:30.354 [39mDEBUG[0;39m [http-nio-8081-exec-4] [36mo.s.s.w.a.AnonymousAuthenticationFilter[0;39m - Set SecurityContextHolder to anonymous SecurityContext
2025-11-02 00:10:30.369 [39mDEBUG[0;39m [http-nio-8081-exec-4] [36mo.s.w.s.m.m.a.RequestMappingHandlerMapping[0;39m - Mapped to com.nckh.yte.controller.AuthController#login(LoginRequest)
2025-11-02 00:10:30.374 [39mDEBUG[0;39m [http-nio-8081-exec-4] [36mo.s.security.web.FilterChainProxy[0;39m - Secured POST /api/auth/login
2025-11-02 00:10:30.379 [39mDEBUG[0;39m [http-nio-8081-exec-4] [36mo.s.web.servlet.DispatcherServlet[0;39m - POST "/api/auth/login", parameters={}
2025-11-02 00:10:30.381 [39mDEBUG[0;39m [http-nio-8081-exec-4] [36mo.s.w.s.m.m.a.RequestMappingHandlerMapping[0;39m - Mapped to com.nckh.yte.controller.AuthController#login(LoginRequest)
2025-11-02 00:10:30.549 [39mDEBUG[0;39m [http-nio-8081-exec-4] [36mo.s.w.s.m.m.a.RequestResponseBodyMethodProcessor[0;39m - Read "application/json;charset=UTF-8" to [com.nckh.yte.dto.LoginRequest@7b756e05]
2025-11-02 00:10:30.989 [39mDEBUG[0;39m [http-nio-8081-exec-4] [36mo.s.s.a.d.DaoAuthenticationProvider[0;39m - Authenticated user
2025-11-02 00:10:31.093 [39mDEBUG[0;39m [http-nio-8081-exec-4] [36mo.s.w.s.m.m.a.HttpEntityMethodProcessor[0;39m - Using 'application/json', given [application/json] and supported [application/json, application/*+json]
2025-11-02 00:10:31.095 [39mDEBUG[0;39m [http-nio-8081-exec-4] [36mo.s.w.s.m.m.a.HttpEntityMethodProcessor[0;39m - Writing [com.nckh.yte.dto.AuthResponse@39db973a]
2025-11-02 00:10:31.107 [39mDEBUG[0;39m [http-nio-8081-exec-4] [36mo.s.web.servlet.DispatcherServlet[0;39m - Completed 200 OK
2025-11-02 00:10:31.493 [39mDEBUG[0;39m [http-nio-8081-exec-5] [36mo.s.security.web.FilterChainProxy[0;39m - Securing OPTIONS /api/patients
2025-11-02 00:10:31.500 [39mDEBUG[0;39m [http-nio-8081-exec-6] [36mo.s.security.web.FilterChainProxy[0;39m - Securing GET /api/patients
2025-11-02 00:10:31.581 [39mDEBUG[0;39m [http-nio-8081-exec-6] [36mo.s.w.s.m.m.a.RequestMappingHandlerMapping[0;39m - Mapped to com.nckh.yte.controller.PatientController#list()
2025-11-02 00:10:31.581 [39mDEBUG[0;39m [http-nio-8081-exec-6] [36mo.s.w.s.m.m.a.RequestMappingHandlerMapping[0;39m - Mapped to com.nckh.yte.controller.PatientController#list()
2025-11-02 00:10:31.584 [39mDEBUG[0;39m [http-nio-8081-exec-6] [36mo.s.w.s.m.m.a.RequestMappingHandlerMapping[0;39m - Mapped to com.nckh.yte.controller.PatientController#list()
2025-11-02 00:10:31.584 [39mDEBUG[0;39m [http-nio-8081-exec-6] [36mo.s.w.s.m.m.a.RequestMappingHandlerMapping[0;39m - Mapped to com.nckh.yte.controller.PatientController#list()
2025-11-02 00:10:31.587 [39mDEBUG[0;39m [http-nio-8081-exec-6] [36mo.s.w.s.m.m.a.RequestMappingHandlerMapping[0;39m - Mapped to com.nckh.yte.controller.PatientController#list()
2025-11-02 00:10:31.590 [39mDEBUG[0;39m [http-nio-8081-exec-6] [36mo.s.w.s.m.m.a.RequestMappingHandlerMapping[0;39m - Mapped to com.nckh.yte.controller.PatientController#list()
2025-11-02 00:10:31.591 [39mDEBUG[0;39m [http-nio-8081-exec-6] [36mo.s.w.s.m.m.a.RequestMappingHandlerMapping[0;39m - Mapped to com.nckh.yte.controller.PatientController#list()
2025-11-02 00:10:31.592 [39mDEBUG[0;39m [http-nio-8081-exec-6] [36mo.s.w.s.m.m.a.RequestMappingHandlerMapping[0;39m - Mapped to com.nckh.yte.controller.PatientController#list()
2025-11-02 00:10:31.594 [39mDEBUG[0;39m [http-nio-8081-exec-6] [36mo.s.security.web.FilterChainProxy[0;39m - Secured GET /api/patients
2025-11-02 00:10:31.594 [39mDEBUG[0;39m [http-nio-8081-exec-6] [36mo.s.web.servlet.DispatcherServlet[0;39m - GET "/api/patients", parameters={}
2025-11-02 00:10:31.595 [39mDEBUG[0;39m [http-nio-8081-exec-6] [36mo.s.w.s.m.m.a.RequestMappingHandlerMapping[0;39m - Mapped to com.nckh.yte.controller.PatientController#list()
2025-11-02 00:10:31.651 [39mDEBUG[0;39m [http-nio-8081-exec-6] [36mo.s.w.s.m.m.a.HttpEntityMethodProcessor[0;39m - Using 'application/json', given [*/*] and supported [application/json, application/*+json]
2025-11-02 00:10:31.652 [39mDEBUG[0;39m [http-nio-8081-exec-6] [36mo.s.w.s.m.m.a.HttpEntityMethodProcessor[0;39m - Writing [[com.nckh.yte.entity.User@168ab456]]
2025-11-02 00:10:31.660 [39mDEBUG[0;39m [http-nio-8081-exec-6] [36mo.s.web.servlet.DispatcherServlet[0;39m - Completed 200 OK
2025-11-02 00:10:40.959 [39mDEBUG[0;39m [http-nio-8081-exec-1] [36mo.s.security.web.FilterChainProxy[0;39m - Securing OPTIONS /api/ai/drug-info-full
2025-11-02 00:10:40.964 [39mDEBUG[0;39m [http-nio-8081-exec-2] [36mo.s.security.web.FilterChainProxy[0;39m - Securing POST /api/ai/drug-info-full
2025-11-02 00:10:40.987 [39mDEBUG[0;39m [http-nio-8081-exec-2] [36mo.s.w.s.m.m.a.RequestMappingHandlerMapping[0;39m - Mapped to com.nckh.yte.controller.DrugInfoDetailedController#getDrugInfoFull(Map)
2025-11-02 00:10:40.989 [39mDEBUG[0;39m [http-nio-8081-exec-2] [36mo.s.w.s.m.m.a.RequestMappingHandlerMapping[0;39m - Mapped to com.nckh.yte.controller.DrugInfoDetailedController#getDrugInfoFull(Map)
2025-11-02 00:10:40.990 [39mDEBUG[0;39m [http-nio-8081-exec-2] [36mo.s.w.s.m.m.a.RequestMappingHandlerMapping[0;39m - Mapped to com.nckh.yte.controller.DrugInfoDetailedController#getDrugInfoFull(Map)
2025-11-02 00:10:40.992 [39mDEBUG[0;39m [http-nio-8081-exec-2] [36mo.s.w.s.m.m.a.RequestMappingHandlerMapping[0;39m - Mapped to com.nckh.yte.controller.DrugInfoDetailedController#getDrugInfoFull(Map)
2025-11-02 00:10:40.993 [39mDEBUG[0;39m [http-nio-8081-exec-2] [36mo.s.security.web.FilterChainProxy[0;39m - Secured POST /api/ai/drug-info-full
2025-11-02 00:10:40.994 [39mDEBUG[0;39m [http-nio-8081-exec-2] [36mo.s.web.servlet.DispatcherServlet[0;39m - POST "/api/ai/drug-info-full", parameters={}
2025-11-02 00:10:40.995 [39mDEBUG[0;39m [http-nio-8081-exec-2] [36mo.s.w.s.m.m.a.RequestMappingHandlerMapping[0;39m - Mapped to com.nckh.yte.controller.DrugInfoDetailedController#getDrugInfoFull(Map)
2025-11-02 00:10:41.002 [39mDEBUG[0;39m [http-nio-8081-exec-2] [36mo.s.w.s.m.m.a.RequestResponseBodyMethodProcessor[0;39m - Read "application/json;charset=utf-8" to [{drug=penicillin}]
2025-11-02 00:10:41.267 [39mDEBUG[0;39m [http-nio-8081-exec-2] [36mo.s.web.client.RestTemplate[0;39m - HTTP GET https://api.fda.gov/drug/label.json?search=openfda.generic_name:%22penicillin%22%20OR%20openfda.brand_name:%22penicillin%22&limit=3&api_key=YOUR_OPENFDA_KEY
2025-11-02 00:10:41.279 [39mDEBUG[0;39m [http-nio-8081-exec-2] [36mo.s.web.client.RestTemplate[0;39m - Accept=[text/plain, application/json, application/*+json, */*]
2025-11-02 00:10:42.442 [39mDEBUG[0;39m [http-nio-8081-exec-2] [36mo.s.web.client.RestTemplate[0;39m - Response 403 FORBIDDEN
2025-11-02 00:10:42.459 [39mDEBUG[0;39m [http-nio-8081-exec-2] [36mo.s.web.client.RestTemplate[0;39m - HTTP GET https://api.fda.gov/drug/label.json?search=openfda.generic_name:%22penicillin%22%20OR%20openfda.brand_name:%22penicillin%22&limit=3
2025-11-02 00:10:42.460 [39mDEBUG[0;39m [http-nio-8081-exec-2] [36mo.s.web.client.RestTemplate[0;39m - Accept=[text/plain, application/json, application/*+json, */*]
2025-11-02 00:10:43.007 [39mDEBUG[0;39m [http-nio-8081-exec-2] [36mo.s.web.client.RestTemplate[0;39m - Response 200 OK
2025-11-02 00:10:43.011 [39mDEBUG[0;39m [http-nio-8081-exec-2] [36mo.s.web.client.RestTemplate[0;39m - Reading to [java.lang.String] as "application/json;charset=utf-8"
2025-11-02 00:10:44.327 [39mDEBUG[0;39m [http-nio-8081-exec-2] [36mo.s.web.client.RestTemplate[0;39m - HTTP POST https://api.openai.com/v1/chat/completions
2025-11-02 00:10:44.328 [39mDEBUG[0;39m [http-nio-8081-exec-2] [36mo.s.web.client.RestTemplate[0;39m - Accept=[text/plain, application/json, application/*+json, */*]
2025-11-02 00:10:44.330 [39mDEBUG[0;39m [http-nio-8081-exec-2] [36mo.s.web.client.RestTemplate[0;39m - Writing [{"messages":[{"role":"system","content":"B·∫°n l√† b√°c sƒ© y khoa, h√£y t√≥m t·∫Øt r√µ r√†ng, d·ªÖ hi·ªÉu b·∫±ng ti·∫øng Vi·ªát."},{"role":"user","content":"D∆∞·ªõi ƒë√¢y l√† th√¥ng tin ti·∫øng Anh v·ªÅ thu·ªëc \"BICILLIN L-A\":\nT√™n thu·ªëc: BICILLIN L-A\nC√¥ng d·ª•ng: INDICATIONS AND USAGE To reduce the development of drug-resistant bacteria and maintain the effectiveness of Bicillin L-A and other antibacterial drugs, Bicillin L-A should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Intramuscular penicillin G benzathine is indicated in the treatment of infections due to penicillin-G-sensitive microorganisms that are susceptible to the low and very prolonged serum levels common to this particular dosage form. Therapy should be guided by bacteriological studies (including sensitivity tests) and by clinical response. The following infections will usually respond to adequate dosage of intramuscular penicillin G benzathine: Mild-to-moderate infections of the upper-respiratory tract due to susceptible streptococci. Venereal infections \u2014Syphilis, yaws, bejel, and pinta. Medical Conditions in which Penicillin G Benzathine Therapy is indicated as Prophylaxis: Rheumatic fever and/or chorea \u2014Prophylaxis with penicillin G benzathine has proven effective in preventing recurrence of these conditions. It has also been used as follow-up prophylactic therapy for rheumatic heart disease and acute glomerulonephritis.\nC·∫£nh b√°o: Kh√¥ng c√≥\nT√°c d·ª•ng ph·ª•: ADVERSE REACTIONS As with other penicillins, untoward reactions of the sensitivity phenomena are likely to occur, particularly in individuals who have previously demonstrated hypersensitivity to penicillins or in those with a history of allergy, asthma, hay fever, or urticaria. As with other treatments for syphilis, the Jarisch-Herxheimer reaction has been reported. The following adverse reactions have been reported with Bicillin L-A during post-marketing experience: Skin and Appendages: Stevens-Johnson syndrome (SJS) and drug reaction with eosinophilia and systemic symptoms (DRESS). (See WARNINGS .) Immune System Disorders: Acute myocardial ischemia with or without myocardial infarction may occur as part of an allergic reaction (Kounis syndrome). The following have been reported with parenteral penicillin G (the active moiety in Bicillin L-A): General: Hypersensitivity reactions including the following: skin eruptions (maculopapular to exfoliative dermatitis), urticaria, laryngeal edema, fever, eosinophilia; other serum sickness-like reactions (including chills, fever, edema, arthralgia, and prostration); and anaphylaxis including shock and death: severe cutaneous adverse reactions (SCAR), such as toxic epidermal necrolysis (TEN) and acute generalized exanthematous pustulosis (AGEP). (See WARNINGS .) Note: Urticaria, other skin rashes, and serum sickness-like reactions may be controlled with antihistamines and, if necessary, systemic corticosteroids. Whenever such reactions occur, penicillin G should be discontinued unless, in the opinion of the physician, the condition being treated is life-threatening and amenable only to therapy with penicillin G. Serious anaphylactic reactions require immediate emergency treatment with epinephrine. Oxygen, intravenous steroids, and airway management, including intubation, should also be administered as indicated. Gastrointestinal: Pseudomembranous colitis. Onset of pseudomembranous colitis symptoms may occur during or after antibacterial treatment. (See WARNINGS section.) Hematologic: Hemolytic anemia, leukopenia, thrombocytopenia. Neurologic: Neuropathy. Urogenital: Nephropathy. The following adverse events have been temporally associated with parenteral administration of penicillin G benzathine (a component of Bicillin L-A): Body as a Whole: Hypersensitivity reactions including allergic vasculitis, pruritus, fatigue, asthenia, and pain; aggravation of existing disorder; headache, Nicolau syndrome. Cardiovascular: Cardiac arrest; hypotension; tachycardia; palpitations; pulmonary hypertension; pulmonary embolism; vasodilation; vasovagal reaction; cerebrovascular accident; syncope. Gastrointestinal: Nausea, vomiting; blood in stool; intestinal necrosis. Hemic and Lymphatic: Lymphadenopathy. Injection Site: Injection site reactions including pain, inflammation, lump, abscess, necrosis, edema, hemorrhage, cellulitis, hypersensitivity, atrophy, ecchymosis, and skin ulcer. Neurovascular reactions including warmth, vasospasm, pallor, mottling, gangrene, numbness of the extremities, cyanosis of the extremities, and neurovascular damage. Metabolic: Elevated BUN, creatinine, and SGOT. Musculoskeletal: Joint disorder; periostitis; exacerbation of arthritis; myoglobinuria; rhabdomyolysis. Nervous System: Nervousness; tremors; dizziness; somnolence; confusion; anxiety; euphoria; transverse myelitis; seizures; coma. A syndrome manifested by a variety of CNS symptoms such as severe agitation with confusion, visual and auditory hallucinations, and a fear of impending death (Hoigne's syndrome), has been reported after administration of penicillin G procaine and, less commonly, after injection of the combination of penicillin G benzathine and penicillin G procaine. Other symptoms associated with this syndrome, such as psychosis, seizures, dizziness, tinnitus, cyanosis, palpitations, tachycardia, and/or abnormal perception in taste, also may occur. Respiratory: Hypoxia; apnea; dyspnea. Skin: Diaphoresis. Special Senses: Blurred vision; blindness. Urogenital: Neurogenic bladder; hematuria; proteinuria; renal failure; impotence; priapism.\nPh·ª• n·ªØ mang thai: Pregnancy Teratogenic effects Pregnancy Reproduction studies performed in the mouse, rat, and rabbit have revealed no evidence of impaired fertility or harm to the fetus due to penicillin G. Human experience with the penicillins during pregnancy has not shown any positive evidence of adverse effects on the fetus. There are, however, no adequate and well-controlled studies in pregnant women showing conclusively that harmful effects of these drugs on the fetus can be excluded. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.\n\nH√£y t√≥m t·∫Øt ng·∫Øn g·ªçn theo c√°c m·ª•c: C√¥ng d·ª•ng, Li·ªÅu d√πng, C·∫£nh b√°o, T√°c d·ª•ng ph·ª•, v√† L∆∞u √Ω cho ph·ª• n·ªØ mang thai."}],"model":"gpt-4o-mini"}] as "application/json"
2025-11-02 00:10:54.175 [39mDEBUG[0;39m [http-nio-8081-exec-2] [36mo.s.web.client.RestTemplate[0;39m - Response 200 OK
2025-11-02 00:10:54.181 [39mDEBUG[0;39m [http-nio-8081-exec-2] [36mo.s.web.client.RestTemplate[0;39m - Reading to [java.lang.String] as "application/json"
2025-11-02 00:10:54.188 [39mDEBUG[0;39m [http-nio-8081-exec-2] [36mo.s.web.client.RestTemplate[0;39m - HTTP POST https://api.openai.com/v1/chat/completions
2025-11-02 00:10:54.189 [39mDEBUG[0;39m [http-nio-8081-exec-2] [36mo.s.web.client.RestTemplate[0;39m - Accept=[text/plain, application/json, application/*+json, */*]
2025-11-02 00:10:54.190 [39mDEBUG[0;39m [http-nio-8081-exec-2] [36mo.s.web.client.RestTemplate[0;39m - Writing [{"messages":[{"role":"system","content":"B·∫°n l√† b√°c sƒ© y khoa, h√£y t√≥m t·∫Øt r√µ r√†ng, d·ªÖ hi·ªÉu b·∫±ng ti·∫øng Vi·ªát."},{"role":"user","content":"D∆∞·ªõi ƒë√¢y l√† th√¥ng tin ti·∫øng Anh v·ªÅ thu·ªëc \"Penicillin V Potassium\":\nT√™n thu·ªëc: Penicillin V Potassium\nC√¥ng d·ª•ng: INDICATIONS AND USAGE To reduce the development of drug-resistant bacteria and maintain the effectiveness of penicillin V potassium and other antibacterial drugs, penicillin V potassium should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Penicillin V potassium tablets are indicated in the treatment of mild to moderately severe infections due to penicillin G-sensitive microorganisms. Therapy should be guided by bacteriologic studies (including sensitivity tests) and by clinical response. NOTE: Severe pneumonia, empyema, bacteremia, pericarditis, meningitis, and arthritis should not be treated with penicillin V during the acute stage. Indicated surgical procedures should be performed. The following infections will usually respond to adequate dosage of penicillin V. Streptococcal Infections (without bacteremia) Mild-to-moderate infections of the upper respiratory tract, scarlet fever, and mild erysipelas. NOTE: Streptococci in groups A, C, G, H, L, and M are very sensitive to penicillin. Other groups, including group D (enterococcus), are resistant. Pneumococcal Infections Mild to moderately severe infections of the respiratory tract. Staphylococcal infections\u2013 penicillin G-sensitive Mild infections of the skin and soft tissues. NOTE: Reports indicate an increasing number of strains of staphylococci resistant to penicillin G, emphasizing the need for culture and sensitivity studies in treating suspected staphylococcal infections. Fusospirochetosis (Vincent\u2019s gingivitis and pharyngitis) Mild to moderately severe infections of the oropharynx usually respond to therapy with oral penicillin. NOTE: Necessary dental care should be accomplished in infections involving the gum tissue. Medical conditions in which oral penicillin therapy is indicated as prophylaxis: For the prevention of recurrence following rheumatic fever and/or chorea: Prophylaxis with oral penicillin on a continuing basis has proven effective in preventing recurrence of these conditions. Although no controlled clinical efficacy studies have been conducted, penicillin V has been suggested by the American Heart Association and the American Dental Association for use as an oral regimen for prophylaxis against bacterial endocarditis in patients who have congenital heart disease or rheumatic or other acquired valvular heart disease when they undergo dental procedures and surgical procedures of the upper respiratory tract 1 . Oral penicillin should not be used in those patients at particularly high risk for endocarditis (e.g., those with prosthetic heart valves or surgically constructed systemic pulmonary shunts). Penicillin V should not be used as adjunctive prophylaxis for genitourinary instrumentation or surgery, lower-intestinal tract surgery, sigmoidoscopy, and childbirth. Since it may happen that alpha hemolytic streptococci relatively resistant to penicillin may be found when patients are receiving continuous oral penicillin for secondary prevention of rheumatic fever, prophylactic agents other than penicillin may be chosen for these patients and prescribed in addition to their continuous rheumatic fever prophylactic regimen. NOTE: When selecting antibiotics for the prevention of bacterial endocarditis, the physician or dentist should read the full joint statement of the American Heart Association and the American Dental Association 1 .\nC·∫£nh b√°o: Kh√¥ng c√≥\nT√°c d·ª•ng ph·ª•: ADVERSE REACTIONS Although the incidence of reactions to oral penicillins has been reported with much less frequency than following parenteral therapy, it should be remembered that all degrees of hypersensitivity, including fatal anaphylaxis, have been reported with oral penicillin. The most common reactions to oral penicillin are nausea, vomiting, epigastric distress, diarrhea, and black hairy tongue. The hypersensitivity reactions reported are skin eruptions (maculopapular to exfoliative dermatitis), urticaria and other serum-sickness like reactions, laryngeal edema, and anaphylaxis. Fever and eosinophilia may frequently be the only reaction observed. Hemolytic anemia, leukopenia, thrombocytopenia, neuropathy, and nephropathy are infrequent reactions and usually associated with high doses of parenteral penicillin. To report SUSPECTED ADVERSE REACTIONS, contact Rising Health, LLC at 1-833-395-6928 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.\nPh·ª• n·ªØ mang thai: Kh√¥ng c√≥\n\nH√£y t√≥m t·∫Øt ng·∫Øn g·ªçn theo c√°c m·ª•c: C√¥ng d·ª•ng, Li·ªÅu d√πng, C·∫£nh b√°o, T√°c d·ª•ng ph·ª•, v√† L∆∞u √Ω cho ph·ª• n·ªØ mang thai."}],"model":"gpt-4o-mini"}] as "application/json"
2025-11-02 00:11:00.483 [39mDEBUG[0;39m [http-nio-8081-exec-2] [36mo.s.web.client.RestTemplate[0;39m - Response 200 OK
2025-11-02 00:11:00.488 [39mDEBUG[0;39m [http-nio-8081-exec-2] [36mo.s.web.client.RestTemplate[0;39m - Reading to [java.lang.String] as "application/json"
2025-11-02 00:11:00.494 [39mDEBUG[0;39m [http-nio-8081-exec-2] [36mo.s.web.client.RestTemplate[0;39m - HTTP POST https://api.openai.com/v1/chat/completions
2025-11-02 00:11:00.496 [39mDEBUG[0;39m [http-nio-8081-exec-2] [36mo.s.web.client.RestTemplate[0;39m - Accept=[text/plain, application/json, application/*+json, */*]
2025-11-02 00:11:00.496 [39mDEBUG[0;39m [http-nio-8081-exec-2] [36mo.s.web.client.RestTemplate[0;39m - Writing [{"messages":[{"role":"system","content":"B·∫°n l√† b√°c sƒ© y khoa, h√£y t√≥m t·∫Øt r√µ r√†ng, d·ªÖ hi·ªÉu b·∫±ng ti·∫øng Vi·ªát."},{"role":"user","content":"D∆∞·ªõi ƒë√¢y l√† th√¥ng tin ti·∫øng Anh v·ªÅ thu·ªëc \"Penicillin V Potassium\":\nT√™n thu·ªëc: Penicillin V Potassium\nC√¥ng d·ª•ng: INDICATIONS AND USAGE To reduce the development of drug-resistant bacteria and maintain the effectiveness of penicillin V potassium and other antibacterial drugs, penicillin V potassium should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Penicillin V potassium tablets are indicated in the treatment of mild to moderately severe infections due to penicillin G-sensitive microorganisms. Therapy should be guided by bacteriologic studies (including sensitivity tests) and by clinical response. NOTE: Severe pneumonia, empyema, bacteremia, pericarditis, meningitis, and arthritis should not be treated with penicillin V during the acute stage. Indicated surgical procedures should be performed. The following infections will usually respond to adequate dosage of penicillin V. Streptococcal Infections (without bacteremia) Mild-to-moderate infections of the upper respiratory tract, scarlet fever, and mild erysipelas. NOTE: Streptococci in groups A, C, G, H, L, and M are very sensitive to penicillin. Other groups, including group D (enterococcus), are resistant. Pneumococcal Infections Mild to moderately severe infections of the respiratory tract. Staphylococcal infections \u2013 penicillin G-sensitive Mild infections of the skin and soft tissues. NOTE: Reports indicate an increasing number of strains of staphylococci resistant to penicillin G, emphasizing the need for culture and sensitivity studies in treating suspected staphylococcal infections. Fusospirochetosis (Vincent\u2019s gingivitis and pharyngitis) Mild to moderately severe infections of the oropharynx usually respond to therapy with oral penicillin. NOTE: Necessary dental care should be accomplished in infections involving the gum tissue. Medical conditions in which oral penicillin therapy is indicated as prophylaxis: For the prevention of recurrence following rheumatic fever and/or chorea: Prophylaxis with oral penicillin on a continuing basis has proven effective in preventing recurrence of these conditions. Although no controlled clinical efficacy studies have been conducted, penicillin V has been suggested by the American Heart Association and the American Dental Association for use as an oral regimen for prophylaxis against bacterial endocarditis in patients who have congenital heart disease or rheumatic or other acquired valvular heart disease when they undergo dental procedures and surgical procedures of the upper respiratory tract 1 . Oral penicillin should not be used in those patients at particularly high risk for endocarditis (e.g., those with prosthetic heart valves or surgically constructed systemic pulmonary shunts). Penicillin V should not be used as adjunctive prophylaxis for genitourinary instrumentation or surgery, lower-intestinal tract surgery, sigmoidoscopy, and childbirth. Since it may happen that alpha hemolytic streptococci relatively resistant to penicillin may be found when patients are receiving continuous oral penicillin for secondary prevention of rheumatic fever, prophylactic agents other than penicillin may be chosen for these patients and prescribed in addition to their continuous rheumatic fever prophylactic regimen. NOTE: When selecting antibiotics for the prevention of bacterial endocarditis, the physician or dentist should read the full joint statement of the American Heart Association and the American Dental Association 1 .\nC·∫£nh b√°o: Kh√¥ng c√≥\nT√°c d·ª•ng ph·ª•: ADVERSE REACTIONS Although the incidence of reactions to oral penicillins has been reported with much less frequency than following parenteral therapy, it should be remembered that all degrees of hypersensitivity, including fatal anaphylaxis, have been reported with oral penicillin. The most common reactions to oral penicillin are nausea, vomiting, epigastric distress, diarrhea, and black hairy tongue. The hypersensitivity reactions reported are skin eruptions (maculopapular to exfoliative dermatitis), urticaria and other serum-sickness like reactions, laryngeal edema, and anaphylaxis. Fever and eosinophilia may frequently be the only reaction observed. Hemolytic anemia, leukopenia, thrombocytopenia, neuropathy, and nephropathy are infrequent reactions and usually associated with high doses of parenteral penicillin.\nPh·ª• n·ªØ mang thai: Kh√¥ng c√≥\n\nH√£y t√≥m t·∫Øt ng·∫Øn g·ªçn theo c√°c m·ª•c: C√¥ng d·ª•ng, Li·ªÅu d√πng, C·∫£nh b√°o, T√°c d·ª•ng ph·ª•, v√† L∆∞u √Ω cho ph·ª• n·ªØ mang thai."}],"model":"gpt-4o-mini"}] as "application/json"
2025-11-02 00:11:09.593 [39mDEBUG[0;39m [http-nio-8081-exec-2] [36mo.s.web.client.RestTemplate[0;39m - Response 200 OK
2025-11-02 00:11:09.604 [39mDEBUG[0;39m [http-nio-8081-exec-2] [36mo.s.web.client.RestTemplate[0;39m - Reading to [java.lang.String] as "application/json"
2025-11-02 00:11:09.607 [39mDEBUG[0;39m [http-nio-8081-exec-2] [36mo.s.w.s.m.m.a.HttpEntityMethodProcessor[0;39m - Using 'application/json', given [*/*] and supported [application/json, application/*+json]
2025-11-02 00:11:09.607 [39mDEBUG[0;39m [http-nio-8081-exec-2] [36mo.s.w.s.m.m.a.HttpEntityMethodProcessor[0;39m - Writing [{items=[{T√™n thu·ªëc=BICILLIN L-A, H√£ng s·∫£n xu·∫•t=Pfizer Laboratories Div Pfizer Inc, T√≥m t·∫Øt b√°c sƒ©=C√¥ (truncated)...]
2025-11-02 00:11:09.612 [39mDEBUG[0;39m [http-nio-8081-exec-2] [36mo.s.web.servlet.DispatcherServlet[0;39m - Completed 200 OK
2025-11-02 00:18:11.353 [34mINFO [0;39m [background-preinit] [36mo.h.validator.internal.util.Version[0;39m - HV000001: Hibernate Validator 8.0.1.Final
2025-11-02 00:18:11.424 [34mINFO [0;39m [main] [36mcom.nckh.yte.YteApplication[0;39m - Starting YteApplication using Java 17.0.12 with PID 22908 (C:\Users\nhatn\java_project\yte\target\classes started by nhatn in C:\Users\nhatn\java_project\yte)
2025-11-02 00:18:11.426 [39mDEBUG[0;39m [main] [36mcom.nckh.yte.YteApplication[0;39m - Running with Spring Boot v3.1.4, Spring v6.0.12
2025-11-02 00:18:11.427 [34mINFO [0;39m [main] [36mcom.nckh.yte.YteApplication[0;39m - No active profile set, falling back to 1 default profile: "default"
2025-11-02 00:18:12.886 [34mINFO [0;39m [main] [36mo.s.d.r.c.RepositoryConfigurationDelegate[0;39m - Bootstrapping Spring Data JPA repositories in DEFAULT mode.
2025-11-02 00:18:13.088 [34mINFO [0;39m [main] [36mo.s.d.r.c.RepositoryConfigurationDelegate[0;39m - Finished Spring Data repository scanning in 185 ms. Found 7 JPA repository interfaces.
2025-11-02 00:18:14.043 [34mINFO [0;39m [main] [36mo.s.b.w.e.tomcat.TomcatWebServer[0;39m - Tomcat initialized with port(s): 8081 (http)
2025-11-02 00:18:14.050 [34mINFO [0;39m [main] [36mo.a.coyote.http11.Http11NioProtocol[0;39m - Initializing ProtocolHandler ["http-nio-8081"]
2025-11-02 00:18:14.059 [34mINFO [0;39m [main] [36mo.a.catalina.core.StandardService[0;39m - Starting service [Tomcat]
2025-11-02 00:18:14.059 [34mINFO [0;39m [main] [36mo.a.catalina.core.StandardEngine[0;39m - Starting Servlet engine: [Apache Tomcat/10.1.13]
2025-11-02 00:18:14.275 [34mINFO [0;39m [main] [36mo.a.c.c.C.[Tomcat].[localhost].[/][0;39m - Initializing Spring embedded WebApplicationContext
2025-11-02 00:18:14.277 [34mINFO [0;39m [main] [36mo.s.b.w.s.c.ServletWebServerApplicationContext[0;39m - Root WebApplicationContext: initialization completed in 2768 ms
2025-11-02 00:18:14.670 [34mINFO [0;39m [main] [36mo.h.jpa.internal.util.LogHelper[0;39m - HHH000204: Processing PersistenceUnitInfo [name: default]
2025-11-02 00:18:14.865 [34mINFO [0;39m [main] [36morg.hibernate.Version[0;39m - HHH000412: Hibernate ORM core version 6.2.9.Final
2025-11-02 00:18:14.869 [34mINFO [0;39m [main] [36morg.hibernate.cfg.Environment[0;39m - HHH000406: Using bytecode reflection optimizer
2025-11-02 00:18:15.187 [34mINFO [0;39m [main] [36mo.h.b.i.BytecodeProviderInitiator[0;39m - HHH000021: Bytecode provider name : bytebuddy
2025-11-02 00:18:15.481 [34mINFO [0;39m [main] [36mo.s.o.j.p.SpringPersistenceUnitInfo[0;39m - No LoadTimeWeaver setup: ignoring JPA class transformer
2025-11-02 00:18:15.511 [34mINFO [0;39m [main] [36mcom.zaxxer.hikari.HikariDataSource[0;39m - HikariPool-1 - Starting...
2025-11-02 00:18:15.824 [34mINFO [0;39m [main] [36mcom.zaxxer.hikari.pool.HikariPool[0;39m - HikariPool-1 - Added connection org.postgresql.jdbc.PgConnection@7c226095
2025-11-02 00:18:15.826 [34mINFO [0;39m [main] [36mcom.zaxxer.hikari.HikariDataSource[0;39m - HikariPool-1 - Start completed.
2025-11-02 00:18:16.337 [34mINFO [0;39m [main] [36mo.h.b.i.BytecodeProviderInitiator[0;39m - HHH000021: Bytecode provider name : bytebuddy
2025-11-02 00:18:17.554 [34mINFO [0;39m [main] [36mo.h.e.t.j.p.i.JtaPlatformInitiator[0;39m - HHH000490: Using JtaPlatform implementation: [org.hibernate.engine.transaction.jta.platform.internal.NoJtaPlatform]
2025-11-02 00:18:17.799 [34mINFO [0;39m [main] [36mo.s.o.j.LocalContainerEntityManagerFactoryBean[0;39m - Initialized JPA EntityManagerFactory for persistence unit 'default'
2025-11-02 00:18:18.318 [39mDEBUG[0;39m [main] [36mcom.nckh.yte.security.JwtAuthFilter[0;39m - Filter 'jwtAuthFilter' configured for use
2025-11-02 00:18:18.969 [31mWARN [0;39m [main] [36mo.s.b.a.o.j.JpaBaseConfiguration$JpaWebConfiguration[0;39m - spring.jpa.open-in-view is enabled by default. Therefore, database queries may be performed during view rendering. Explicitly configure spring.jpa.open-in-view to disable this warning
2025-11-02 00:18:19.249 [39mDEBUG[0;39m [main] [36mo.s.w.s.m.m.a.RequestMappingHandlerMapping[0;39m - 31 mappings in 'requestMappingHandlerMapping'
2025-11-02 00:18:19.414 [39mDEBUG[0;39m [main] [36mo.s.w.s.h.SimpleUrlHandlerMapping[0;39m - Patterns [/webjars/**, /**, /swagger-ui*/*swagger-initializer.js, /swagger-ui*/**] in 'resourceHandlerMapping'
2025-11-02 00:18:19.491 [34mINFO [0;39m [main] [36mo.s.s.web.DefaultSecurityFilterChain[0;39m - Will secure any request with [org.springframework.security.web.session.DisableEncodeUrlFilter@4e9d1119, org.springframework.security.web.context.request.async.WebAsyncManagerIntegrationFilter@5d1907fb, org.springframework.security.web.context.SecurityContextHolderFilter@f4aec23, org.springframework.security.web.header.HeaderWriterFilter@60c68c7b, org.springframework.web.filter.CorsFilter@6079d219, org.springframework.security.web.authentication.logout.LogoutFilter@37f75ebf, com.nckh.yte.security.JwtAuthFilter@7e5c8c80, org.springframework.security.web.savedrequest.RequestCacheAwareFilter@7680beac, org.springframework.security.web.servletapi.SecurityContextHolderAwareRequestFilter@4e6add8d, org.springframework.security.web.authentication.AnonymousAuthenticationFilter@4ed90b04, org.springframework.security.web.session.SessionManagementFilter@5fc42998, org.springframework.security.web.access.ExceptionTranslationFilter@119f035f, org.springframework.security.web.access.intercept.AuthorizationFilter@19240b9]
2025-11-02 00:18:19.619 [39mDEBUG[0;39m [main] [36mo.s.w.s.m.m.a.RequestMappingHandlerAdapter[0;39m - ControllerAdvice beans: 0 @ModelAttribute, 0 @InitBinder, 1 RequestBodyAdvice, 1 ResponseBodyAdvice
2025-11-02 00:18:19.683 [39mDEBUG[0;39m [main] [36mo.s.w.s.m.m.a.ExceptionHandlerExceptionResolver[0;39m - ControllerAdvice beans: 1 @ExceptionHandler, 1 ResponseBodyAdvice
2025-11-02 00:18:19.975 [34mINFO [0;39m [main] [36mo.a.coyote.http11.Http11NioProtocol[0;39m - Starting ProtocolHandler ["http-nio-8081"]
2025-11-02 00:18:20.044 [34mINFO [0;39m [main] [36mo.s.b.w.e.tomcat.TomcatWebServer[0;39m - Tomcat started on port(s): 8081 (http) with context path ''
2025-11-02 00:18:20.061 [34mINFO [0;39m [main] [36mcom.nckh.yte.YteApplication[0;39m - Started YteApplication in 9.347 seconds (process running for 9.818)
2025-11-02 00:19:17.993 [34mINFO [0;39m [http-nio-8081-exec-4] [36mo.a.c.c.C.[Tomcat].[localhost].[/][0;39m - Initializing Spring DispatcherServlet 'dispatcherServlet'
2025-11-02 00:19:17.994 [34mINFO [0;39m [http-nio-8081-exec-4] [36mo.s.web.servlet.DispatcherServlet[0;39m - Initializing Servlet 'dispatcherServlet'
2025-11-02 00:19:17.994 [39mDEBUG[0;39m [http-nio-8081-exec-4] [36mo.s.web.servlet.DispatcherServlet[0;39m - Detected StandardServletMultipartResolver
2025-11-02 00:19:17.995 [39mDEBUG[0;39m [http-nio-8081-exec-4] [36mo.s.web.servlet.DispatcherServlet[0;39m - Detected AcceptHeaderLocaleResolver
2025-11-02 00:19:17.995 [39mDEBUG[0;39m [http-nio-8081-exec-4] [36mo.s.web.servlet.DispatcherServlet[0;39m - Detected FixedThemeResolver
2025-11-02 00:19:17.998 [39mDEBUG[0;39m [http-nio-8081-exec-4] [36mo.s.web.servlet.DispatcherServlet[0;39m - Detected org.springframework.web.servlet.view.DefaultRequestToViewNameTranslator@1e5921ec
2025-11-02 00:19:18.000 [39mDEBUG[0;39m [http-nio-8081-exec-4] [36mo.s.web.servlet.DispatcherServlet[0;39m - Detected org.springframework.web.servlet.support.SessionFlashMapManager@1aa64998
2025-11-02 00:19:18.001 [39mDEBUG[0;39m [http-nio-8081-exec-4] [36mo.s.web.servlet.DispatcherServlet[0;39m - enableLoggingRequestDetails='false': request parameters and headers will be masked to prevent unsafe logging of potentially sensitive data
2025-11-02 00:19:18.003 [34mINFO [0;39m [http-nio-8081-exec-4] [36mo.s.web.servlet.DispatcherServlet[0;39m - Completed initialization in 9 ms
2025-11-02 00:19:18.026 [39mDEBUG[0;39m [http-nio-8081-exec-4] [36mo.s.security.web.FilterChainProxy[0;39m - Securing OPTIONS /api/auth/login
2025-11-02 00:19:18.089 [39mDEBUG[0;39m [http-nio-8081-exec-5] [36mo.s.security.web.FilterChainProxy[0;39m - Securing POST /api/auth/login
2025-11-02 00:19:18.103 [39mDEBUG[0;39m [http-nio-8081-exec-5] [36mo.s.s.w.a.AnonymousAuthenticationFilter[0;39m - Set SecurityContextHolder to anonymous SecurityContext
2025-11-02 00:19:18.123 [39mDEBUG[0;39m [http-nio-8081-exec-5] [36mo.s.w.s.m.m.a.RequestMappingHandlerMapping[0;39m - Mapped to com.nckh.yte.controller.AuthController#login(LoginRequest)
2025-11-02 00:19:18.126 [39mDEBUG[0;39m [http-nio-8081-exec-5] [36mo.s.security.web.FilterChainProxy[0;39m - Secured POST /api/auth/login
2025-11-02 00:19:18.132 [39mDEBUG[0;39m [http-nio-8081-exec-5] [36mo.s.web.servlet.DispatcherServlet[0;39m - POST "/api/auth/login", parameters={}
2025-11-02 00:19:18.137 [39mDEBUG[0;39m [http-nio-8081-exec-5] [36mo.s.w.s.m.m.a.RequestMappingHandlerMapping[0;39m - Mapped to com.nckh.yte.controller.AuthController#login(LoginRequest)
2025-11-02 00:19:18.315 [39mDEBUG[0;39m [http-nio-8081-exec-5] [36mo.s.w.s.m.m.a.RequestResponseBodyMethodProcessor[0;39m - Read "application/json;charset=UTF-8" to [com.nckh.yte.dto.LoginRequest@1a57ab29]
2025-11-02 00:19:18.719 [39mDEBUG[0;39m [http-nio-8081-exec-5] [36mo.s.s.a.d.DaoAuthenticationProvider[0;39m - Authenticated user
2025-11-02 00:19:18.831 [39mDEBUG[0;39m [http-nio-8081-exec-5] [36mo.s.w.s.m.m.a.HttpEntityMethodProcessor[0;39m - Using 'application/json', given [application/json] and supported [application/json, application/*+json]
2025-11-02 00:19:18.831 [39mDEBUG[0;39m [http-nio-8081-exec-5] [36mo.s.w.s.m.m.a.HttpEntityMethodProcessor[0;39m - Writing [com.nckh.yte.dto.AuthResponse@d98ae5d]
2025-11-02 00:19:18.847 [39mDEBUG[0;39m [http-nio-8081-exec-5] [36mo.s.web.servlet.DispatcherServlet[0;39m - Completed 200 OK
2025-11-02 00:19:30.296 [39mDEBUG[0;39m [http-nio-8081-exec-7] [36mo.s.security.web.FilterChainProxy[0;39m - Securing OPTIONS /api/patients
2025-11-02 00:19:30.305 [39mDEBUG[0;39m [http-nio-8081-exec-8] [36mo.s.security.web.FilterChainProxy[0;39m - Securing GET /api/patients
2025-11-02 00:19:30.785 [39mDEBUG[0;39m [http-nio-8081-exec-8] [36mo.s.w.s.m.m.a.RequestMappingHandlerMapping[0;39m - Mapped to com.nckh.yte.controller.PatientController#list()
2025-11-02 00:19:30.793 [39mDEBUG[0;39m [http-nio-8081-exec-8] [36mo.s.w.s.m.m.a.RequestMappingHandlerMapping[0;39m - Mapped to com.nckh.yte.controller.PatientController#list()
2025-11-02 00:19:30.805 [39mDEBUG[0;39m [http-nio-8081-exec-8] [36mo.s.w.s.m.m.a.RequestMappingHandlerMapping[0;39m - Mapped to com.nckh.yte.controller.PatientController#list()
2025-11-02 00:19:30.811 [39mDEBUG[0;39m [http-nio-8081-exec-8] [36mo.s.w.s.m.m.a.RequestMappingHandlerMapping[0;39m - Mapped to com.nckh.yte.controller.PatientController#list()
2025-11-02 00:19:30.820 [39mDEBUG[0;39m [http-nio-8081-exec-8] [36mo.s.w.s.m.m.a.RequestMappingHandlerMapping[0;39m - Mapped to com.nckh.yte.controller.PatientController#list()
2025-11-02 00:19:30.827 [39mDEBUG[0;39m [http-nio-8081-exec-8] [36mo.s.w.s.m.m.a.RequestMappingHandlerMapping[0;39m - Mapped to com.nckh.yte.controller.PatientController#list()
2025-11-02 00:19:30.835 [39mDEBUG[0;39m [http-nio-8081-exec-8] [36mo.s.w.s.m.m.a.RequestMappingHandlerMapping[0;39m - Mapped to com.nckh.yte.controller.PatientController#list()
2025-11-02 00:19:30.840 [39mDEBUG[0;39m [http-nio-8081-exec-8] [36mo.s.w.s.m.m.a.RequestMappingHandlerMapping[0;39m - Mapped to com.nckh.yte.controller.PatientController#list()
2025-11-02 00:19:30.845 [39mDEBUG[0;39m [http-nio-8081-exec-8] [36mo.s.security.web.FilterChainProxy[0;39m - Secured GET /api/patients
2025-11-02 00:19:30.857 [39mDEBUG[0;39m [http-nio-8081-exec-8] [36mo.s.web.servlet.DispatcherServlet[0;39m - GET "/api/patients", parameters={}
2025-11-02 00:19:30.863 [39mDEBUG[0;39m [http-nio-8081-exec-8] [36mo.s.w.s.m.m.a.RequestMappingHandlerMapping[0;39m - Mapped to com.nckh.yte.controller.PatientController#list()
2025-11-02 00:19:31.158 [39mDEBUG[0;39m [http-nio-8081-exec-8] [36mo.s.w.s.m.m.a.HttpEntityMethodProcessor[0;39m - Using 'application/json', given [*/*] and supported [application/json, application/*+json]
2025-11-02 00:19:31.171 [39mDEBUG[0;39m [http-nio-8081-exec-8] [36mo.s.w.s.m.m.a.HttpEntityMethodProcessor[0;39m - Writing [[com.nckh.yte.entity.User@1486dd8e]]
2025-11-02 00:19:31.199 [39mDEBUG[0;39m [http-nio-8081-exec-8] [36mo.s.web.servlet.DispatcherServlet[0;39m - Completed 200 OK
2025-11-02 00:19:39.108 [39mDEBUG[0;39m [http-nio-8081-exec-1] [36mo.s.security.web.FilterChainProxy[0;39m - Securing OPTIONS /api/ai/drug-info-full
2025-11-02 00:19:39.112 [39mDEBUG[0;39m [http-nio-8081-exec-2] [36mo.s.security.web.FilterChainProxy[0;39m - Securing POST /api/ai/drug-info-full
2025-11-02 00:19:39.136 [39mDEBUG[0;39m [http-nio-8081-exec-2] [36mo.s.w.s.m.m.a.RequestMappingHandlerMapping[0;39m - Mapped to com.nckh.yte.controller.DrugInfoDetailedController#getDrugInfoFull(Map)
2025-11-02 00:19:39.137 [39mDEBUG[0;39m [http-nio-8081-exec-2] [36mo.s.w.s.m.m.a.RequestMappingHandlerMapping[0;39m - Mapped to com.nckh.yte.controller.DrugInfoDetailedController#getDrugInfoFull(Map)
2025-11-02 00:19:39.138 [39mDEBUG[0;39m [http-nio-8081-exec-2] [36mo.s.w.s.m.m.a.RequestMappingHandlerMapping[0;39m - Mapped to com.nckh.yte.controller.DrugInfoDetailedController#getDrugInfoFull(Map)
2025-11-02 00:19:39.139 [39mDEBUG[0;39m [http-nio-8081-exec-2] [36mo.s.w.s.m.m.a.RequestMappingHandlerMapping[0;39m - Mapped to com.nckh.yte.controller.DrugInfoDetailedController#getDrugInfoFull(Map)
2025-11-02 00:19:39.140 [39mDEBUG[0;39m [http-nio-8081-exec-2] [36mo.s.security.web.FilterChainProxy[0;39m - Secured POST /api/ai/drug-info-full
2025-11-02 00:19:39.141 [39mDEBUG[0;39m [http-nio-8081-exec-2] [36mo.s.web.servlet.DispatcherServlet[0;39m - POST "/api/ai/drug-info-full", parameters={}
2025-11-02 00:19:39.141 [39mDEBUG[0;39m [http-nio-8081-exec-2] [36mo.s.w.s.m.m.a.RequestMappingHandlerMapping[0;39m - Mapped to com.nckh.yte.controller.DrugInfoDetailedController#getDrugInfoFull(Map)
2025-11-02 00:19:39.147 [39mDEBUG[0;39m [http-nio-8081-exec-2] [36mo.s.w.s.m.m.a.RequestResponseBodyMethodProcessor[0;39m - Read "application/json;charset=utf-8" to [{drug=penicillin}]
2025-11-02 00:19:39.415 [39mDEBUG[0;39m [http-nio-8081-exec-2] [36mo.s.web.client.RestTemplate[0;39m - HTTP GET https://api.fda.gov/drug/label.json?search=openfda.generic_name:%22penicillin%22%20OR%20openfda.brand_name:%22penicillin%22&limit=3&api_key=YOUR_OPENFDA_KEY
2025-11-02 00:19:39.431 [39mDEBUG[0;39m [http-nio-8081-exec-2] [36mo.s.web.client.RestTemplate[0;39m - Accept=[text/plain, application/json, application/*+json, */*]
2025-11-02 00:19:40.650 [39mDEBUG[0;39m [http-nio-8081-exec-2] [36mo.s.web.client.RestTemplate[0;39m - Response 403 FORBIDDEN
2025-11-02 00:19:40.666 [39mDEBUG[0;39m [http-nio-8081-exec-2] [36mo.s.web.client.RestTemplate[0;39m - HTTP GET https://api.fda.gov/drug/label.json?search=openfda.generic_name:%22penicillin%22%20OR%20openfda.brand_name:%22penicillin%22&limit=3
2025-11-02 00:19:40.667 [39mDEBUG[0;39m [http-nio-8081-exec-2] [36mo.s.web.client.RestTemplate[0;39m - Accept=[text/plain, application/json, application/*+json, */*]
2025-11-02 00:19:41.007 [39mDEBUG[0;39m [http-nio-8081-exec-2] [36mo.s.web.client.RestTemplate[0;39m - Response 200 OK
2025-11-02 00:19:41.011 [39mDEBUG[0;39m [http-nio-8081-exec-2] [36mo.s.web.client.RestTemplate[0;39m - Reading to [java.lang.String] as "application/json;charset=utf-8"
2025-11-02 00:19:41.868 [39mDEBUG[0;39m [http-nio-8081-exec-2] [36mo.s.web.client.RestTemplate[0;39m - HTTP POST https://api.openai.com/v1/chat/completions
2025-11-02 00:19:41.870 [39mDEBUG[0;39m [http-nio-8081-exec-2] [36mo.s.web.client.RestTemplate[0;39m - Accept=[text/plain, application/json, application/*+json, */*]
2025-11-02 00:19:41.871 [39mDEBUG[0;39m [http-nio-8081-exec-2] [36mo.s.web.client.RestTemplate[0;39m - Writing [{"messages":[{"role":"system","content":"B·∫°n l√† b√°c sƒ© y khoa, h√£y t√≥m t·∫Øt r√µ r√†ng, d·ªÖ hi·ªÉu b·∫±ng ti·∫øng Vi·ªát."},{"role":"user","content":"D∆∞·ªõi ƒë√¢y l√† th√¥ng tin ti·∫øng Anh v·ªÅ thu·ªëc \"BICILLIN L-A\":\nT√™n thu·ªëc: BICILLIN L-A\nC√¥ng d·ª•ng: INDICATIONS AND USAGE To reduce the development of drug-resistant bacteria and maintain the effectiveness of Bicillin L-A and other antibacterial drugs, Bicillin L-A should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Intramuscular penicillin G benzathine is indicated in the treatment of infections due to penicillin-G-sensitive microorganisms that are susceptible to the low and very prolonged serum levels common to this particular dosage form. Therapy should be guided by bacteriological studies (including sensitivity tests) and by clinical response. The following infections will usually respond to adequate dosage of intramuscular penicillin G benzathine: Mild-to-moderate infections of the upper-respiratory tract due to susceptible streptococci. Venereal infections \u2014Syphilis, yaws, bejel, and pinta. Medical Conditions in which Penicillin G Benzathine Therapy is indicated as Prophylaxis: Rheumatic fever and/or chorea \u2014Prophylaxis with penicillin G benzathine has proven effective in preventing recurrence of these conditions. It has also been used as follow-up prophylactic therapy for rheumatic heart disease and acute glomerulonephritis.\nC·∫£nh b√°o: Kh√¥ng c√≥\nT√°c d·ª•ng ph·ª•: ADVERSE REACTIONS As with other penicillins, untoward reactions of the sensitivity phenomena are likely to occur, particularly in individuals who have previously demonstrated hypersensitivity to penicillins or in those with a history of allergy, asthma, hay fever, or urticaria. As with other treatments for syphilis, the Jarisch-Herxheimer reaction has been reported. The following adverse reactions have been reported with Bicillin L-A during post-marketing experience: Skin and Appendages: Stevens-Johnson syndrome (SJS) and drug reaction with eosinophilia and systemic symptoms (DRESS). (See WARNINGS .) Immune System Disorders: Acute myocardial ischemia with or without myocardial infarction may occur as part of an allergic reaction (Kounis syndrome). The following have been reported with parenteral penicillin G (the active moiety in Bicillin L-A): General: Hypersensitivity reactions including the following: skin eruptions (maculopapular to exfoliative dermatitis), urticaria, laryngeal edema, fever, eosinophilia; other serum sickness-like reactions (including chills, fever, edema, arthralgia, and prostration); and anaphylaxis including shock and death: severe cutaneous adverse reactions (SCAR), such as toxic epidermal necrolysis (TEN) and acute generalized exanthematous pustulosis (AGEP). (See WARNINGS .) Note: Urticaria, other skin rashes, and serum sickness-like reactions may be controlled with antihistamines and, if necessary, systemic corticosteroids. Whenever such reactions occur, penicillin G should be discontinued unless, in the opinion of the physician, the condition being treated is life-threatening and amenable only to therapy with penicillin G. Serious anaphylactic reactions require immediate emergency treatment with epinephrine. Oxygen, intravenous steroids, and airway management, including intubation, should also be administered as indicated. Gastrointestinal: Pseudomembranous colitis. Onset of pseudomembranous colitis symptoms may occur during or after antibacterial treatment. (See WARNINGS section.) Hematologic: Hemolytic anemia, leukopenia, thrombocytopenia. Neurologic: Neuropathy. Urogenital: Nephropathy. The following adverse events have been temporally associated with parenteral administration of penicillin G benzathine (a component of Bicillin L-A): Body as a Whole: Hypersensitivity reactions including allergic vasculitis, pruritus, fatigue, asthenia, and pain; aggravation of existing disorder; headache, Nicolau syndrome. Cardiovascular: Cardiac arrest; hypotension; tachycardia; palpitations; pulmonary hypertension; pulmonary embolism; vasodilation; vasovagal reaction; cerebrovascular accident; syncope. Gastrointestinal: Nausea, vomiting; blood in stool; intestinal necrosis. Hemic and Lymphatic: Lymphadenopathy. Injection Site: Injection site reactions including pain, inflammation, lump, abscess, necrosis, edema, hemorrhage, cellulitis, hypersensitivity, atrophy, ecchymosis, and skin ulcer. Neurovascular reactions including warmth, vasospasm, pallor, mottling, gangrene, numbness of the extremities, cyanosis of the extremities, and neurovascular damage. Metabolic: Elevated BUN, creatinine, and SGOT. Musculoskeletal: Joint disorder; periostitis; exacerbation of arthritis; myoglobinuria; rhabdomyolysis. Nervous System: Nervousness; tremors; dizziness; somnolence; confusion; anxiety; euphoria; transverse myelitis; seizures; coma. A syndrome manifested by a variety of CNS symptoms such as severe agitation with confusion, visual and auditory hallucinations, and a fear of impending death (Hoigne's syndrome), has been reported after administration of penicillin G procaine and, less commonly, after injection of the combination of penicillin G benzathine and penicillin G procaine. Other symptoms associated with this syndrome, such as psychosis, seizures, dizziness, tinnitus, cyanosis, palpitations, tachycardia, and/or abnormal perception in taste, also may occur. Respiratory: Hypoxia; apnea; dyspnea. Skin: Diaphoresis. Special Senses: Blurred vision; blindness. Urogenital: Neurogenic bladder; hematuria; proteinuria; renal failure; impotence; priapism.\nPh·ª• n·ªØ mang thai: Pregnancy Teratogenic effects Pregnancy Reproduction studies performed in the mouse, rat, and rabbit have revealed no evidence of impaired fertility or harm to the fetus due to penicillin G. Human experience with the penicillins during pregnancy has not shown any positive evidence of adverse effects on the fetus. There are, however, no adequate and well-controlled studies in pregnant women showing conclusively that harmful effects of these drugs on the fetus can be excluded. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.\n\nH√£y t√≥m t·∫Øt ng·∫Øn g·ªçn theo c√°c m·ª•c: C√¥ng d·ª•ng, Li·ªÅu d√πng, C·∫£nh b√°o, T√°c d·ª•ng ph·ª•, v√† L∆∞u √Ω cho ph·ª• n·ªØ mang thai."}],"model":"gpt-4o-mini"}] as "application/json"
2025-11-02 00:19:48.249 [39mDEBUG[0;39m [http-nio-8081-exec-2] [36mo.s.web.client.RestTemplate[0;39m - Response 200 OK
2025-11-02 00:19:48.251 [39mDEBUG[0;39m [http-nio-8081-exec-2] [36mo.s.web.client.RestTemplate[0;39m - Reading to [java.lang.String] as "application/json"
2025-11-02 00:19:48.258 [39mDEBUG[0;39m [http-nio-8081-exec-2] [36mo.s.web.client.RestTemplate[0;39m - HTTP POST https://api.openai.com/v1/chat/completions
2025-11-02 00:19:48.260 [39mDEBUG[0;39m [http-nio-8081-exec-2] [36mo.s.web.client.RestTemplate[0;39m - Accept=[text/plain, application/json, application/*+json, */*]
2025-11-02 00:19:48.260 [39mDEBUG[0;39m [http-nio-8081-exec-2] [36mo.s.web.client.RestTemplate[0;39m - Writing [{"messages":[{"role":"system","content":"B·∫°n l√† b√°c sƒ© y khoa, h√£y t√≥m t·∫Øt r√µ r√†ng, d·ªÖ hi·ªÉu b·∫±ng ti·∫øng Vi·ªát."},{"role":"user","content":"D∆∞·ªõi ƒë√¢y l√† th√¥ng tin ti·∫øng Anh v·ªÅ thu·ªëc \"Penicillin V Potassium\":\nT√™n thu·ªëc: Penicillin V Potassium\nC√¥ng d·ª•ng: INDICATIONS AND USAGE To reduce the development of drug-resistant bacteria and maintain the effectiveness of penicillin V potassium and other antibacterial drugs, penicillin V potassium should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Penicillin V potassium tablets are indicated in the treatment of mild to moderately severe infections due to penicillin G-sensitive microorganisms. Therapy should be guided by bacteriologic studies (including sensitivity tests) and by clinical response. NOTE: Severe pneumonia, empyema, bacteremia, pericarditis, meningitis, and arthritis should not be treated with penicillin V during the acute stage. Indicated surgical procedures should be performed. The following infections will usually respond to adequate dosage of penicillin V. Streptococcal Infections (without bacteremia) Mild-to-moderate infections of the upper respiratory tract, scarlet fever, and mild erysipelas. NOTE: Streptococci in groups A, C, G, H, L, and M are very sensitive to penicillin. Other groups, including group D (enterococcus), are resistant. Pneumococcal Infections Mild to moderately severe infections of the respiratory tract. Staphylococcal infections\u2013 penicillin G-sensitive Mild infections of the skin and soft tissues. NOTE: Reports indicate an increasing number of strains of staphylococci resistant to penicillin G, emphasizing the need for culture and sensitivity studies in treating suspected staphylococcal infections. Fusospirochetosis (Vincent\u2019s gingivitis and pharyngitis) Mild to moderately severe infections of the oropharynx usually respond to therapy with oral penicillin. NOTE: Necessary dental care should be accomplished in infections involving the gum tissue. Medical conditions in which oral penicillin therapy is indicated as prophylaxis: For the prevention of recurrence following rheumatic fever and/or chorea: Prophylaxis with oral penicillin on a continuing basis has proven effective in preventing recurrence of these conditions. Although no controlled clinical efficacy studies have been conducted, penicillin V has been suggested by the American Heart Association and the American Dental Association for use as an oral regimen for prophylaxis against bacterial endocarditis in patients who have congenital heart disease or rheumatic or other acquired valvular heart disease when they undergo dental procedures and surgical procedures of the upper respiratory tract 1 . Oral penicillin should not be used in those patients at particularly high risk for endocarditis (e.g., those with prosthetic heart valves or surgically constructed systemic pulmonary shunts). Penicillin V should not be used as adjunctive prophylaxis for genitourinary instrumentation or surgery, lower-intestinal tract surgery, sigmoidoscopy, and childbirth. Since it may happen that alpha hemolytic streptococci relatively resistant to penicillin may be found when patients are receiving continuous oral penicillin for secondary prevention of rheumatic fever, prophylactic agents other than penicillin may be chosen for these patients and prescribed in addition to their continuous rheumatic fever prophylactic regimen. NOTE: When selecting antibiotics for the prevention of bacterial endocarditis, the physician or dentist should read the full joint statement of the American Heart Association and the American Dental Association 1 .\nC·∫£nh b√°o: Kh√¥ng c√≥\nT√°c d·ª•ng ph·ª•: ADVERSE REACTIONS Although the incidence of reactions to oral penicillins has been reported with much less frequency than following parenteral therapy, it should be remembered that all degrees of hypersensitivity, including fatal anaphylaxis, have been reported with oral penicillin. The most common reactions to oral penicillin are nausea, vomiting, epigastric distress, diarrhea, and black hairy tongue. The hypersensitivity reactions reported are skin eruptions (maculopapular to exfoliative dermatitis), urticaria and other serum-sickness like reactions, laryngeal edema, and anaphylaxis. Fever and eosinophilia may frequently be the only reaction observed. Hemolytic anemia, leukopenia, thrombocytopenia, neuropathy, and nephropathy are infrequent reactions and usually associated with high doses of parenteral penicillin. To report SUSPECTED ADVERSE REACTIONS, contact Rising Health, LLC at 1-833-395-6928 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.\nPh·ª• n·ªØ mang thai: Kh√¥ng c√≥\n\nH√£y t√≥m t·∫Øt ng·∫Øn g·ªçn theo c√°c m·ª•c: C√¥ng d·ª•ng, Li·ªÅu d√πng, C·∫£nh b√°o, T√°c d·ª•ng ph·ª•, v√† L∆∞u √Ω cho ph·ª• n·ªØ mang thai."}],"model":"gpt-4o-mini"}] as "application/json"
2025-11-02 00:19:53.487 [39mDEBUG[0;39m [http-nio-8081-exec-2] [36mo.s.web.client.RestTemplate[0;39m - Response 200 OK
2025-11-02 00:19:53.488 [39mDEBUG[0;39m [http-nio-8081-exec-2] [36mo.s.web.client.RestTemplate[0;39m - Reading to [java.lang.String] as "application/json"
2025-11-02 00:19:53.492 [39mDEBUG[0;39m [http-nio-8081-exec-2] [36mo.s.web.client.RestTemplate[0;39m - HTTP POST https://api.openai.com/v1/chat/completions
2025-11-02 00:19:53.493 [39mDEBUG[0;39m [http-nio-8081-exec-2] [36mo.s.web.client.RestTemplate[0;39m - Accept=[text/plain, application/json, application/*+json, */*]
2025-11-02 00:19:53.494 [39mDEBUG[0;39m [http-nio-8081-exec-2] [36mo.s.web.client.RestTemplate[0;39m - Writing [{"messages":[{"role":"system","content":"B·∫°n l√† b√°c sƒ© y khoa, h√£y t√≥m t·∫Øt r√µ r√†ng, d·ªÖ hi·ªÉu b·∫±ng ti·∫øng Vi·ªát."},{"role":"user","content":"D∆∞·ªõi ƒë√¢y l√† th√¥ng tin ti·∫øng Anh v·ªÅ thu·ªëc \"Penicillin V Potassium\":\nT√™n thu·ªëc: Penicillin V Potassium\nC√¥ng d·ª•ng: INDICATIONS AND USAGE To reduce the development of drug-resistant bacteria and maintain the effectiveness of penicillin V potassium and other antibacterial drugs, penicillin V potassium should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Penicillin V potassium tablets are indicated in the treatment of mild to moderately severe infections due to penicillin G-sensitive microorganisms. Therapy should be guided by bacteriologic studies (including sensitivity tests) and by clinical response. NOTE: Severe pneumonia, empyema, bacteremia, pericarditis, meningitis, and arthritis should not be treated with penicillin V during the acute stage. Indicated surgical procedures should be performed. The following infections will usually respond to adequate dosage of penicillin V. Streptococcal Infections (without bacteremia) Mild-to-moderate infections of the upper respiratory tract, scarlet fever, and mild erysipelas. NOTE: Streptococci in groups A, C, G, H, L, and M are very sensitive to penicillin. Other groups, including group D (enterococcus), are resistant. Pneumococcal Infections Mild to moderately severe infections of the respiratory tract. Staphylococcal infections \u2013 penicillin G-sensitive Mild infections of the skin and soft tissues. NOTE: Reports indicate an increasing number of strains of staphylococci resistant to penicillin G, emphasizing the need for culture and sensitivity studies in treating suspected staphylococcal infections. Fusospirochetosis (Vincent\u2019s gingivitis and pharyngitis) Mild to moderately severe infections of the oropharynx usually respond to therapy with oral penicillin. NOTE: Necessary dental care should be accomplished in infections involving the gum tissue. Medical conditions in which oral penicillin therapy is indicated as prophylaxis: For the prevention of recurrence following rheumatic fever and/or chorea: Prophylaxis with oral penicillin on a continuing basis has proven effective in preventing recurrence of these conditions. Although no controlled clinical efficacy studies have been conducted, penicillin V has been suggested by the American Heart Association and the American Dental Association for use as an oral regimen for prophylaxis against bacterial endocarditis in patients who have congenital heart disease or rheumatic or other acquired valvular heart disease when they undergo dental procedures and surgical procedures of the upper respiratory tract 1 . Oral penicillin should not be used in those patients at particularly high risk for endocarditis (e.g., those with prosthetic heart valves or surgically constructed systemic pulmonary shunts). Penicillin V should not be used as adjunctive prophylaxis for genitourinary instrumentation or surgery, lower-intestinal tract surgery, sigmoidoscopy, and childbirth. Since it may happen that alpha hemolytic streptococci relatively resistant to penicillin may be found when patients are receiving continuous oral penicillin for secondary prevention of rheumatic fever, prophylactic agents other than penicillin may be chosen for these patients and prescribed in addition to their continuous rheumatic fever prophylactic regimen. NOTE: When selecting antibiotics for the prevention of bacterial endocarditis, the physician or dentist should read the full joint statement of the American Heart Association and the American Dental Association 1 .\nC·∫£nh b√°o: Kh√¥ng c√≥\nT√°c d·ª•ng ph·ª•: ADVERSE REACTIONS Although the incidence of reactions to oral penicillins has been reported with much less frequency than following parenteral therapy, it should be remembered that all degrees of hypersensitivity, including fatal anaphylaxis, have been reported with oral penicillin. The most common reactions to oral penicillin are nausea, vomiting, epigastric distress, diarrhea, and black hairy tongue. The hypersensitivity reactions reported are skin eruptions (maculopapular to exfoliative dermatitis), urticaria and other serum-sickness like reactions, laryngeal edema, and anaphylaxis. Fever and eosinophilia may frequently be the only reaction observed. Hemolytic anemia, leukopenia, thrombocytopenia, neuropathy, and nephropathy are infrequent reactions and usually associated with high doses of parenteral penicillin.\nPh·ª• n·ªØ mang thai: Kh√¥ng c√≥\n\nH√£y t√≥m t·∫Øt ng·∫Øn g·ªçn theo c√°c m·ª•c: C√¥ng d·ª•ng, Li·ªÅu d√πng, C·∫£nh b√°o, T√°c d·ª•ng ph·ª•, v√† L∆∞u √Ω cho ph·ª• n·ªØ mang thai."}],"model":"gpt-4o-mini"}] as "application/json"
2025-11-02 00:20:00.519 [39mDEBUG[0;39m [http-nio-8081-exec-2] [36mo.s.web.client.RestTemplate[0;39m - Response 200 OK
2025-11-02 00:20:00.521 [39mDEBUG[0;39m [http-nio-8081-exec-2] [36mo.s.web.client.RestTemplate[0;39m - Reading to [java.lang.String] as "application/json"
2025-11-02 00:20:00.527 [39mDEBUG[0;39m [http-nio-8081-exec-2] [36mo.s.w.s.m.m.a.HttpEntityMethodProcessor[0;39m - Using 'application/json', given [*/*] and supported [application/json, application/*+json]
2025-11-02 00:20:00.527 [39mDEBUG[0;39m [http-nio-8081-exec-2] [36mo.s.w.s.m.m.a.HttpEntityMethodProcessor[0;39m - Writing [{items=[{T√™n thu·ªëc=BICILLIN L-A, H√£ng s·∫£n xu·∫•t=Pfizer Laboratories Div Pfizer Inc, T√≥m t·∫Øt b√°c sƒ©=C√¥ (truncated)...]
2025-11-02 00:20:00.532 [39mDEBUG[0;39m [http-nio-8081-exec-2] [36mo.s.web.servlet.DispatcherServlet[0;39m - Completed 200 OK
2025-11-02 00:23:42.357 [39mDEBUG[0;39m [http-nio-8081-exec-9] [36mo.s.security.web.FilterChainProxy[0;39m - Securing POST /api/ai/drug-info-full
2025-11-02 00:23:42.381 [39mDEBUG[0;39m [http-nio-8081-exec-9] [36mo.s.w.s.m.m.a.RequestMappingHandlerMapping[0;39m - Mapped to com.nckh.yte.controller.DrugInfoDetailedController#getDrugInfoFull(Map)
2025-11-02 00:23:42.383 [39mDEBUG[0;39m [http-nio-8081-exec-9] [36mo.s.w.s.m.m.a.RequestMappingHandlerMapping[0;39m - Mapped to com.nckh.yte.controller.DrugInfoDetailedController#getDrugInfoFull(Map)
2025-11-02 00:23:42.384 [39mDEBUG[0;39m [http-nio-8081-exec-9] [36mo.s.w.s.m.m.a.RequestMappingHandlerMapping[0;39m - Mapped to com.nckh.yte.controller.DrugInfoDetailedController#getDrugInfoFull(Map)
2025-11-02 00:23:42.385 [39mDEBUG[0;39m [http-nio-8081-exec-9] [36mo.s.w.s.m.m.a.RequestMappingHandlerMapping[0;39m - Mapped to com.nckh.yte.controller.DrugInfoDetailedController#getDrugInfoFull(Map)
2025-11-02 00:23:42.385 [39mDEBUG[0;39m [http-nio-8081-exec-9] [36mo.s.security.web.FilterChainProxy[0;39m - Secured POST /api/ai/drug-info-full
2025-11-02 00:23:42.386 [39mDEBUG[0;39m [http-nio-8081-exec-9] [36mo.s.web.servlet.DispatcherServlet[0;39m - POST "/api/ai/drug-info-full", parameters={}
2025-11-02 00:23:42.386 [39mDEBUG[0;39m [http-nio-8081-exec-9] [36mo.s.w.s.m.m.a.RequestMappingHandlerMapping[0;39m - Mapped to com.nckh.yte.controller.DrugInfoDetailedController#getDrugInfoFull(Map)
2025-11-02 00:23:42.388 [39mDEBUG[0;39m [http-nio-8081-exec-9] [36mo.s.w.s.m.m.a.RequestResponseBodyMethodProcessor[0;39m - Read "application/json;charset=utf-8" to [{drug=penicillin}]
2025-11-02 00:23:42.389 [39mDEBUG[0;39m [http-nio-8081-exec-9] [36mo.s.web.client.RestTemplate[0;39m - HTTP GET https://api.fda.gov/drug/label.json?search=openfda.generic_name:%22penicillin%22%20OR%20openfda.brand_name:%22penicillin%22&limit=3&api_key=YOUR_OPENFDA_KEY
2025-11-02 00:23:42.390 [39mDEBUG[0;39m [http-nio-8081-exec-9] [36mo.s.web.client.RestTemplate[0;39m - Accept=[text/plain, application/json, application/*+json, */*]
2025-11-02 00:23:43.211 [39mDEBUG[0;39m [http-nio-8081-exec-9] [36mo.s.web.client.RestTemplate[0;39m - Response 403 FORBIDDEN
2025-11-02 00:23:43.215 [39mDEBUG[0;39m [http-nio-8081-exec-9] [36mo.s.web.client.RestTemplate[0;39m - HTTP GET https://api.fda.gov/drug/label.json?search=openfda.generic_name:%22penicillin%22%20OR%20openfda.brand_name:%22penicillin%22&limit=3
2025-11-02 00:23:43.216 [39mDEBUG[0;39m [http-nio-8081-exec-9] [36mo.s.web.client.RestTemplate[0;39m - Accept=[text/plain, application/json, application/*+json, */*]
2025-11-02 00:23:43.529 [39mDEBUG[0;39m [http-nio-8081-exec-9] [36mo.s.web.client.RestTemplate[0;39m - Response 200 OK
2025-11-02 00:23:43.532 [39mDEBUG[0;39m [http-nio-8081-exec-9] [36mo.s.web.client.RestTemplate[0;39m - Reading to [java.lang.String] as "application/json;charset=utf-8"
2025-11-02 00:23:44.409 [39mDEBUG[0;39m [http-nio-8081-exec-9] [36mo.s.web.client.RestTemplate[0;39m - HTTP POST https://api.openai.com/v1/chat/completions
2025-11-02 00:23:44.410 [39mDEBUG[0;39m [http-nio-8081-exec-9] [36mo.s.web.client.RestTemplate[0;39m - Accept=[text/plain, application/json, application/*+json, */*]
2025-11-02 00:23:44.411 [39mDEBUG[0;39m [http-nio-8081-exec-9] [36mo.s.web.client.RestTemplate[0;39m - Writing [{"messages":[{"role":"system","content":"B·∫°n l√† b√°c sƒ© y khoa, h√£y t√≥m t·∫Øt r√µ r√†ng, d·ªÖ hi·ªÉu b·∫±ng ti·∫øng Vi·ªát."},{"role":"user","content":"D∆∞·ªõi ƒë√¢y l√† th√¥ng tin ti·∫øng Anh v·ªÅ thu·ªëc \"BICILLIN L-A\":\nT√™n thu·ªëc: BICILLIN L-A\nC√¥ng d·ª•ng: INDICATIONS AND USAGE To reduce the development of drug-resistant bacteria and maintain the effectiveness of Bicillin L-A and other antibacterial drugs, Bicillin L-A should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Intramuscular penicillin G benzathine is indicated in the treatment of infections due to penicillin-G-sensitive microorganisms that are susceptible to the low and very prolonged serum levels common to this particular dosage form. Therapy should be guided by bacteriological studies (including sensitivity tests) and by clinical response. The following infections will usually respond to adequate dosage of intramuscular penicillin G benzathine: Mild-to-moderate infections of the upper-respiratory tract due to susceptible streptococci. Venereal infections \u2014Syphilis, yaws, bejel, and pinta. Medical Conditions in which Penicillin G Benzathine Therapy is indicated as Prophylaxis: Rheumatic fever and/or chorea \u2014Prophylaxis with penicillin G benzathine has proven effective in preventing recurrence of these conditions. It has also been used as follow-up prophylactic therapy for rheumatic heart disease and acute glomerulonephritis.\nC·∫£nh b√°o: Kh√¥ng c√≥\nT√°c d·ª•ng ph·ª•: ADVERSE REACTIONS As with other penicillins, untoward reactions of the sensitivity phenomena are likely to occur, particularly in individuals who have previously demonstrated hypersensitivity to penicillins or in those with a history of allergy, asthma, hay fever, or urticaria. As with other treatments for syphilis, the Jarisch-Herxheimer reaction has been reported. The following adverse reactions have been reported with Bicillin L-A during post-marketing experience: Skin and Appendages: Stevens-Johnson syndrome (SJS) and drug reaction with eosinophilia and systemic symptoms (DRESS). (See WARNINGS .) Immune System Disorders: Acute myocardial ischemia with or without myocardial infarction may occur as part of an allergic reaction (Kounis syndrome). The following have been reported with parenteral penicillin G (the active moiety in Bicillin L-A): General: Hypersensitivity reactions including the following: skin eruptions (maculopapular to exfoliative dermatitis), urticaria, laryngeal edema, fever, eosinophilia; other serum sickness-like reactions (including chills, fever, edema, arthralgia, and prostration); and anaphylaxis including shock and death: severe cutaneous adverse reactions (SCAR), such as toxic epidermal necrolysis (TEN) and acute generalized exanthematous pustulosis (AGEP). (See WARNINGS .) Note: Urticaria, other skin rashes, and serum sickness-like reactions may be controlled with antihistamines and, if necessary, systemic corticosteroids. Whenever such reactions occur, penicillin G should be discontinued unless, in the opinion of the physician, the condition being treated is life-threatening and amenable only to therapy with penicillin G. Serious anaphylactic reactions require immediate emergency treatment with epinephrine. Oxygen, intravenous steroids, and airway management, including intubation, should also be administered as indicated. Gastrointestinal: Pseudomembranous colitis. Onset of pseudomembranous colitis symptoms may occur during or after antibacterial treatment. (See WARNINGS section.) Hematologic: Hemolytic anemia, leukopenia, thrombocytopenia. Neurologic: Neuropathy. Urogenital: Nephropathy. The following adverse events have been temporally associated with parenteral administration of penicillin G benzathine (a component of Bicillin L-A): Body as a Whole: Hypersensitivity reactions including allergic vasculitis, pruritus, fatigue, asthenia, and pain; aggravation of existing disorder; headache, Nicolau syndrome. Cardiovascular: Cardiac arrest; hypotension; tachycardia; palpitations; pulmonary hypertension; pulmonary embolism; vasodilation; vasovagal reaction; cerebrovascular accident; syncope. Gastrointestinal: Nausea, vomiting; blood in stool; intestinal necrosis. Hemic and Lymphatic: Lymphadenopathy. Injection Site: Injection site reactions including pain, inflammation, lump, abscess, necrosis, edema, hemorrhage, cellulitis, hypersensitivity, atrophy, ecchymosis, and skin ulcer. Neurovascular reactions including warmth, vasospasm, pallor, mottling, gangrene, numbness of the extremities, cyanosis of the extremities, and neurovascular damage. Metabolic: Elevated BUN, creatinine, and SGOT. Musculoskeletal: Joint disorder; periostitis; exacerbation of arthritis; myoglobinuria; rhabdomyolysis. Nervous System: Nervousness; tremors; dizziness; somnolence; confusion; anxiety; euphoria; transverse myelitis; seizures; coma. A syndrome manifested by a variety of CNS symptoms such as severe agitation with confusion, visual and auditory hallucinations, and a fear of impending death (Hoigne's syndrome), has been reported after administration of penicillin G procaine and, less commonly, after injection of the combination of penicillin G benzathine and penicillin G procaine. Other symptoms associated with this syndrome, such as psychosis, seizures, dizziness, tinnitus, cyanosis, palpitations, tachycardia, and/or abnormal perception in taste, also may occur. Respiratory: Hypoxia; apnea; dyspnea. Skin: Diaphoresis. Special Senses: Blurred vision; blindness. Urogenital: Neurogenic bladder; hematuria; proteinuria; renal failure; impotence; priapism.\nPh·ª• n·ªØ mang thai: Pregnancy Teratogenic effects Pregnancy Reproduction studies performed in the mouse, rat, and rabbit have revealed no evidence of impaired fertility or harm to the fetus due to penicillin G. Human experience with the penicillins during pregnancy has not shown any positive evidence of adverse effects on the fetus. There are, however, no adequate and well-controlled studies in pregnant women showing conclusively that harmful effects of these drugs on the fetus can be excluded. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.\n\nH√£y t√≥m t·∫Øt ng·∫Øn g·ªçn theo c√°c m·ª•c: C√¥ng d·ª•ng, Li·ªÅu d√πng, C·∫£nh b√°o, T√°c d·ª•ng ph·ª•, v√† L∆∞u √Ω cho ph·ª• n·ªØ mang thai."}],"model":"gpt-4o-mini"}] as "application/json"
2025-11-02 00:23:50.644 [39mDEBUG[0;39m [http-nio-8081-exec-9] [36mo.s.web.client.RestTemplate[0;39m - Response 200 OK
2025-11-02 00:23:50.647 [39mDEBUG[0;39m [http-nio-8081-exec-9] [36mo.s.web.client.RestTemplate[0;39m - Reading to [java.lang.String] as "application/json"
2025-11-02 00:23:50.651 [39mDEBUG[0;39m [http-nio-8081-exec-9] [36mo.s.web.client.RestTemplate[0;39m - HTTP POST https://api.openai.com/v1/chat/completions
2025-11-02 00:23:50.652 [39mDEBUG[0;39m [http-nio-8081-exec-9] [36mo.s.web.client.RestTemplate[0;39m - Accept=[text/plain, application/json, application/*+json, */*]
2025-11-02 00:23:50.653 [39mDEBUG[0;39m [http-nio-8081-exec-9] [36mo.s.web.client.RestTemplate[0;39m - Writing [{"messages":[{"role":"system","content":"B·∫°n l√† b√°c sƒ© y khoa, h√£y t√≥m t·∫Øt r√µ r√†ng, d·ªÖ hi·ªÉu b·∫±ng ti·∫øng Vi·ªát."},{"role":"user","content":"D∆∞·ªõi ƒë√¢y l√† th√¥ng tin ti·∫øng Anh v·ªÅ thu·ªëc \"Penicillin V Potassium\":\nT√™n thu·ªëc: Penicillin V Potassium\nC√¥ng d·ª•ng: INDICATIONS AND USAGE To reduce the development of drug-resistant bacteria and maintain the effectiveness of penicillin V potassium and other antibacterial drugs, penicillin V potassium should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Penicillin V potassium tablets are indicated in the treatment of mild to moderately severe infections due to penicillin G-sensitive microorganisms. Therapy should be guided by bacteriologic studies (including sensitivity tests) and by clinical response. NOTE: Severe pneumonia, empyema, bacteremia, pericarditis, meningitis, and arthritis should not be treated with penicillin V during the acute stage. Indicated surgical procedures should be performed. The following infections will usually respond to adequate dosage of penicillin V. Streptococcal Infections (without bacteremia) Mild-to-moderate infections of the upper respiratory tract, scarlet fever, and mild erysipelas. NOTE: Streptococci in groups A, C, G, H, L, and M are very sensitive to penicillin. Other groups, including group D (enterococcus), are resistant. Pneumococcal Infections Mild to moderately severe infections of the respiratory tract. Staphylococcal infections\u2013 penicillin G-sensitive Mild infections of the skin and soft tissues. NOTE: Reports indicate an increasing number of strains of staphylococci resistant to penicillin G, emphasizing the need for culture and sensitivity studies in treating suspected staphylococcal infections. Fusospirochetosis (Vincent\u2019s gingivitis and pharyngitis) Mild to moderately severe infections of the oropharynx usually respond to therapy with oral penicillin. NOTE: Necessary dental care should be accomplished in infections involving the gum tissue. Medical conditions in which oral penicillin therapy is indicated as prophylaxis: For the prevention of recurrence following rheumatic fever and/or chorea: Prophylaxis with oral penicillin on a continuing basis has proven effective in preventing recurrence of these conditions. Although no controlled clinical efficacy studies have been conducted, penicillin V has been suggested by the American Heart Association and the American Dental Association for use as an oral regimen for prophylaxis against bacterial endocarditis in patients who have congenital heart disease or rheumatic or other acquired valvular heart disease when they undergo dental procedures and surgical procedures of the upper respiratory tract 1 . Oral penicillin should not be used in those patients at particularly high risk for endocarditis (e.g., those with prosthetic heart valves or surgically constructed systemic pulmonary shunts). Penicillin V should not be used as adjunctive prophylaxis for genitourinary instrumentation or surgery, lower-intestinal tract surgery, sigmoidoscopy, and childbirth. Since it may happen that alpha hemolytic streptococci relatively resistant to penicillin may be found when patients are receiving continuous oral penicillin for secondary prevention of rheumatic fever, prophylactic agents other than penicillin may be chosen for these patients and prescribed in addition to their continuous rheumatic fever prophylactic regimen. NOTE: When selecting antibiotics for the prevention of bacterial endocarditis, the physician or dentist should read the full joint statement of the American Heart Association and the American Dental Association 1 .\nC·∫£nh b√°o: Kh√¥ng c√≥\nT√°c d·ª•ng ph·ª•: ADVERSE REACTIONS Although the incidence of reactions to oral penicillins has been reported with much less frequency than following parenteral therapy, it should be remembered that all degrees of hypersensitivity, including fatal anaphylaxis, have been reported with oral penicillin. The most common reactions to oral penicillin are nausea, vomiting, epigastric distress, diarrhea, and black hairy tongue. The hypersensitivity reactions reported are skin eruptions (maculopapular to exfoliative dermatitis), urticaria and other serum-sickness like reactions, laryngeal edema, and anaphylaxis. Fever and eosinophilia may frequently be the only reaction observed. Hemolytic anemia, leukopenia, thrombocytopenia, neuropathy, and nephropathy are infrequent reactions and usually associated with high doses of parenteral penicillin. To report SUSPECTED ADVERSE REACTIONS, contact Rising Health, LLC at 1-833-395-6928 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.\nPh·ª• n·ªØ mang thai: Kh√¥ng c√≥\n\nH√£y t√≥m t·∫Øt ng·∫Øn g·ªçn theo c√°c m·ª•c: C√¥ng d·ª•ng, Li·ªÅu d√πng, C·∫£nh b√°o, T√°c d·ª•ng ph·ª•, v√† L∆∞u √Ω cho ph·ª• n·ªØ mang thai."}],"model":"gpt-4o-mini"}] as "application/json"
2025-11-02 00:23:59.058 [39mDEBUG[0;39m [http-nio-8081-exec-9] [36mo.s.web.client.RestTemplate[0;39m - Response 200 OK
2025-11-02 00:23:59.059 [39mDEBUG[0;39m [http-nio-8081-exec-9] [36mo.s.web.client.RestTemplate[0;39m - Reading to [java.lang.String] as "application/json"
2025-11-02 00:23:59.062 [39mDEBUG[0;39m [http-nio-8081-exec-9] [36mo.s.web.client.RestTemplate[0;39m - HTTP POST https://api.openai.com/v1/chat/completions
2025-11-02 00:23:59.063 [39mDEBUG[0;39m [http-nio-8081-exec-9] [36mo.s.web.client.RestTemplate[0;39m - Accept=[text/plain, application/json, application/*+json, */*]
2025-11-02 00:23:59.063 [39mDEBUG[0;39m [http-nio-8081-exec-9] [36mo.s.web.client.RestTemplate[0;39m - Writing [{"messages":[{"role":"system","content":"B·∫°n l√† b√°c sƒ© y khoa, h√£y t√≥m t·∫Øt r√µ r√†ng, d·ªÖ hi·ªÉu b·∫±ng ti·∫øng Vi·ªát."},{"role":"user","content":"D∆∞·ªõi ƒë√¢y l√† th√¥ng tin ti·∫øng Anh v·ªÅ thu·ªëc \"Penicillin V Potassium\":\nT√™n thu·ªëc: Penicillin V Potassium\nC√¥ng d·ª•ng: INDICATIONS AND USAGE To reduce the development of drug-resistant bacteria and maintain the effectiveness of penicillin V potassium and other antibacterial drugs, penicillin V potassium should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Penicillin V potassium tablets are indicated in the treatment of mild to moderately severe infections due to penicillin G-sensitive microorganisms. Therapy should be guided by bacteriologic studies (including sensitivity tests) and by clinical response. NOTE: Severe pneumonia, empyema, bacteremia, pericarditis, meningitis, and arthritis should not be treated with penicillin V during the acute stage. Indicated surgical procedures should be performed. The following infections will usually respond to adequate dosage of penicillin V. Streptococcal Infections (without bacteremia) Mild-to-moderate infections of the upper respiratory tract, scarlet fever, and mild erysipelas. NOTE: Streptococci in groups A, C, G, H, L, and M are very sensitive to penicillin. Other groups, including group D (enterococcus), are resistant. Pneumococcal Infections Mild to moderately severe infections of the respiratory tract. Staphylococcal infections \u2013 penicillin G-sensitive Mild infections of the skin and soft tissues. NOTE: Reports indicate an increasing number of strains of staphylococci resistant to penicillin G, emphasizing the need for culture and sensitivity studies in treating suspected staphylococcal infections. Fusospirochetosis (Vincent\u2019s gingivitis and pharyngitis) Mild to moderately severe infections of the oropharynx usually respond to therapy with oral penicillin. NOTE: Necessary dental care should be accomplished in infections involving the gum tissue. Medical conditions in which oral penicillin therapy is indicated as prophylaxis: For the prevention of recurrence following rheumatic fever and/or chorea: Prophylaxis with oral penicillin on a continuing basis has proven effective in preventing recurrence of these conditions. Although no controlled clinical efficacy studies have been conducted, penicillin V has been suggested by the American Heart Association and the American Dental Association for use as an oral regimen for prophylaxis against bacterial endocarditis in patients who have congenital heart disease or rheumatic or other acquired valvular heart disease when they undergo dental procedures and surgical procedures of the upper respiratory tract 1 . Oral penicillin should not be used in those patients at particularly high risk for endocarditis (e.g., those with prosthetic heart valves or surgically constructed systemic pulmonary shunts). Penicillin V should not be used as adjunctive prophylaxis for genitourinary instrumentation or surgery, lower-intestinal tract surgery, sigmoidoscopy, and childbirth. Since it may happen that alpha hemolytic streptococci relatively resistant to penicillin may be found when patients are receiving continuous oral penicillin for secondary prevention of rheumatic fever, prophylactic agents other than penicillin may be chosen for these patients and prescribed in addition to their continuous rheumatic fever prophylactic regimen. NOTE: When selecting antibiotics for the prevention of bacterial endocarditis, the physician or dentist should read the full joint statement of the American Heart Association and the American Dental Association 1 .\nC·∫£nh b√°o: Kh√¥ng c√≥\nT√°c d·ª•ng ph·ª•: ADVERSE REACTIONS Although the incidence of reactions to oral penicillins has been reported with much less frequency than following parenteral therapy, it should be remembered that all degrees of hypersensitivity, including fatal anaphylaxis, have been reported with oral penicillin. The most common reactions to oral penicillin are nausea, vomiting, epigastric distress, diarrhea, and black hairy tongue. The hypersensitivity reactions reported are skin eruptions (maculopapular to exfoliative dermatitis), urticaria and other serum-sickness like reactions, laryngeal edema, and anaphylaxis. Fever and eosinophilia may frequently be the only reaction observed. Hemolytic anemia, leukopenia, thrombocytopenia, neuropathy, and nephropathy are infrequent reactions and usually associated with high doses of parenteral penicillin.\nPh·ª• n·ªØ mang thai: Kh√¥ng c√≥\n\nH√£y t√≥m t·∫Øt ng·∫Øn g·ªçn theo c√°c m·ª•c: C√¥ng d·ª•ng, Li·ªÅu d√πng, C·∫£nh b√°o, T√°c d·ª•ng ph·ª•, v√† L∆∞u √Ω cho ph·ª• n·ªØ mang thai."}],"model":"gpt-4o-mini"}] as "application/json"
2025-11-02 00:24:08.347 [39mDEBUG[0;39m [http-nio-8081-exec-9] [36mo.s.web.client.RestTemplate[0;39m - Response 200 OK
2025-11-02 00:24:08.349 [39mDEBUG[0;39m [http-nio-8081-exec-9] [36mo.s.web.client.RestTemplate[0;39m - Reading to [java.lang.String] as "application/json"
2025-11-02 00:24:08.352 [39mDEBUG[0;39m [http-nio-8081-exec-9] [36mo.s.w.s.m.m.a.HttpEntityMethodProcessor[0;39m - Using 'application/json', given [*/*] and supported [application/json, application/*+json]
2025-11-02 00:24:08.353 [39mDEBUG[0;39m [http-nio-8081-exec-9] [36mo.s.w.s.m.m.a.HttpEntityMethodProcessor[0;39m - Writing [{items=[{T√™n thu·ªëc=BICILLIN L-A, H√£ng s·∫£n xu·∫•t=Pfizer Laboratories Div Pfizer Inc, T√≥m t·∫Øt b√°c sƒ©=BI (truncated)...]
2025-11-02 00:24:08.358 [39mDEBUG[0;39m [http-nio-8081-exec-9] [36mo.s.web.servlet.DispatcherServlet[0;39m - Completed 200 OK
2025-11-02 00:26:31.179 [39mDEBUG[0;39m [http-nio-8081-exec-4] [36mo.s.security.web.FilterChainProxy[0;39m - Securing POST /api/ai/drug-info-full
2025-11-02 00:26:31.202 [39mDEBUG[0;39m [http-nio-8081-exec-4] [36mo.s.w.s.m.m.a.RequestMappingHandlerMapping[0;39m - Mapped to com.nckh.yte.controller.DrugInfoDetailedController#getDrugInfoFull(Map)
2025-11-02 00:26:31.203 [39mDEBUG[0;39m [http-nio-8081-exec-4] [36mo.s.w.s.m.m.a.RequestMappingHandlerMapping[0;39m - Mapped to com.nckh.yte.controller.DrugInfoDetailedController#getDrugInfoFull(Map)
2025-11-02 00:26:31.203 [39mDEBUG[0;39m [http-nio-8081-exec-4] [36mo.s.w.s.m.m.a.RequestMappingHandlerMapping[0;39m - Mapped to com.nckh.yte.controller.DrugInfoDetailedController#getDrugInfoFull(Map)
2025-11-02 00:26:31.204 [39mDEBUG[0;39m [http-nio-8081-exec-4] [36mo.s.w.s.m.m.a.RequestMappingHandlerMapping[0;39m - Mapped to com.nckh.yte.controller.DrugInfoDetailedController#getDrugInfoFull(Map)
2025-11-02 00:26:31.204 [39mDEBUG[0;39m [http-nio-8081-exec-4] [36mo.s.security.web.FilterChainProxy[0;39m - Secured POST /api/ai/drug-info-full
2025-11-02 00:26:31.204 [39mDEBUG[0;39m [http-nio-8081-exec-4] [36mo.s.web.servlet.DispatcherServlet[0;39m - POST "/api/ai/drug-info-full", parameters={}
2025-11-02 00:26:31.205 [39mDEBUG[0;39m [http-nio-8081-exec-4] [36mo.s.w.s.m.m.a.RequestMappingHandlerMapping[0;39m - Mapped to com.nckh.yte.controller.DrugInfoDetailedController#getDrugInfoFull(Map)
2025-11-02 00:26:31.207 [39mDEBUG[0;39m [http-nio-8081-exec-4] [36mo.s.w.s.m.m.a.RequestResponseBodyMethodProcessor[0;39m - Read "application/json;charset=utf-8" to [{drug=penicillin}]
2025-11-02 00:26:31.208 [39mDEBUG[0;39m [http-nio-8081-exec-4] [36mo.s.web.client.RestTemplate[0;39m - HTTP GET https://api.fda.gov/drug/label.json?search=openfda.generic_name:%22penicillin%22%20OR%20openfda.brand_name:%22penicillin%22&limit=3&api_key=YOUR_OPENFDA_KEY
2025-11-02 00:26:31.209 [39mDEBUG[0;39m [http-nio-8081-exec-4] [36mo.s.web.client.RestTemplate[0;39m - Accept=[text/plain, application/json, application/*+json, */*]
2025-11-02 00:26:32.192 [39mDEBUG[0;39m [http-nio-8081-exec-4] [36mo.s.web.client.RestTemplate[0;39m - Response 403 FORBIDDEN
2025-11-02 00:26:32.195 [39mDEBUG[0;39m [http-nio-8081-exec-4] [36mo.s.web.client.RestTemplate[0;39m - HTTP GET https://api.fda.gov/drug/label.json?search=openfda.generic_name:%22penicillin%22%20OR%20openfda.brand_name:%22penicillin%22&limit=3
2025-11-02 00:26:32.196 [39mDEBUG[0;39m [http-nio-8081-exec-4] [36mo.s.web.client.RestTemplate[0;39m - Accept=[text/plain, application/json, application/*+json, */*]
2025-11-02 00:26:32.720 [39mDEBUG[0;39m [http-nio-8081-exec-4] [36mo.s.web.client.RestTemplate[0;39m - Response 200 OK
2025-11-02 00:26:32.720 [39mDEBUG[0;39m [http-nio-8081-exec-4] [36mo.s.web.client.RestTemplate[0;39m - Reading to [java.lang.String] as "application/json;charset=utf-8"
2025-11-02 00:26:34.277 [39mDEBUG[0;39m [http-nio-8081-exec-4] [36mo.s.web.client.RestTemplate[0;39m - HTTP POST https://api.openai.com/v1/chat/completions
2025-11-02 00:26:34.278 [39mDEBUG[0;39m [http-nio-8081-exec-4] [36mo.s.web.client.RestTemplate[0;39m - Accept=[text/plain, application/json, application/*+json, */*]
2025-11-02 00:26:34.278 [39mDEBUG[0;39m [http-nio-8081-exec-4] [36mo.s.web.client.RestTemplate[0;39m - Writing [{"messages":[{"role":"system","content":"B·∫°n l√† b√°c sƒ© y khoa, h√£y t√≥m t·∫Øt r√µ r√†ng, d·ªÖ hi·ªÉu b·∫±ng ti·∫øng Vi·ªát."},{"role":"user","content":"D∆∞·ªõi ƒë√¢y l√† th√¥ng tin ti·∫øng Anh v·ªÅ thu·ªëc \"BICILLIN L-A\":\nT√™n thu·ªëc: BICILLIN L-A\nC√¥ng d·ª•ng: INDICATIONS AND USAGE To reduce the development of drug-resistant bacteria and maintain the effectiveness of Bicillin L-A and other antibacterial drugs, Bicillin L-A should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Intramuscular penicillin G benzathine is indicated in the treatment of infections due to penicillin-G-sensitive microorganisms that are susceptible to the low and very prolonged serum levels common to this particular dosage form. Therapy should be guided by bacteriological studies (including sensitivity tests) and by clinical response. The following infections will usually respond to adequate dosage of intramuscular penicillin G benzathine: Mild-to-moderate infections of the upper-respiratory tract due to susceptible streptococci. Venereal infections \u2014Syphilis, yaws, bejel, and pinta. Medical Conditions in which Penicillin G Benzathine Therapy is indicated as Prophylaxis: Rheumatic fever and/or chorea \u2014Prophylaxis with penicillin G benzathine has proven effective in preventing recurrence of these conditions. It has also been used as follow-up prophylactic therapy for rheumatic heart disease and acute glomerulonephritis.\nC·∫£nh b√°o: Kh√¥ng c√≥\nT√°c d·ª•ng ph·ª•: ADVERSE REACTIONS As with other penicillins, untoward reactions of the sensitivity phenomena are likely to occur, particularly in individuals who have previously demonstrated hypersensitivity to penicillins or in those with a history of allergy, asthma, hay fever, or urticaria. As with other treatments for syphilis, the Jarisch-Herxheimer reaction has been reported. The following adverse reactions have been reported with Bicillin L-A during post-marketing experience: Skin and Appendages: Stevens-Johnson syndrome (SJS) and drug reaction with eosinophilia and systemic symptoms (DRESS). (See WARNINGS .) Immune System Disorders: Acute myocardial ischemia with or without myocardial infarction may occur as part of an allergic reaction (Kounis syndrome). The following have been reported with parenteral penicillin G (the active moiety in Bicillin L-A): General: Hypersensitivity reactions including the following: skin eruptions (maculopapular to exfoliative dermatitis), urticaria, laryngeal edema, fever, eosinophilia; other serum sickness-like reactions (including chills, fever, edema, arthralgia, and prostration); and anaphylaxis including shock and death: severe cutaneous adverse reactions (SCAR), such as toxic epidermal necrolysis (TEN) and acute generalized exanthematous pustulosis (AGEP). (See WARNINGS .) Note: Urticaria, other skin rashes, and serum sickness-like reactions may be controlled with antihistamines and, if necessary, systemic corticosteroids. Whenever such reactions occur, penicillin G should be discontinued unless, in the opinion of the physician, the condition being treated is life-threatening and amenable only to therapy with penicillin G. Serious anaphylactic reactions require immediate emergency treatment with epinephrine. Oxygen, intravenous steroids, and airway management, including intubation, should also be administered as indicated. Gastrointestinal: Pseudomembranous colitis. Onset of pseudomembranous colitis symptoms may occur during or after antibacterial treatment. (See WARNINGS section.) Hematologic: Hemolytic anemia, leukopenia, thrombocytopenia. Neurologic: Neuropathy. Urogenital: Nephropathy. The following adverse events have been temporally associated with parenteral administration of penicillin G benzathine (a component of Bicillin L-A): Body as a Whole: Hypersensitivity reactions including allergic vasculitis, pruritus, fatigue, asthenia, and pain; aggravation of existing disorder; headache, Nicolau syndrome. Cardiovascular: Cardiac arrest; hypotension; tachycardia; palpitations; pulmonary hypertension; pulmonary embolism; vasodilation; vasovagal reaction; cerebrovascular accident; syncope. Gastrointestinal: Nausea, vomiting; blood in stool; intestinal necrosis. Hemic and Lymphatic: Lymphadenopathy. Injection Site: Injection site reactions including pain, inflammation, lump, abscess, necrosis, edema, hemorrhage, cellulitis, hypersensitivity, atrophy, ecchymosis, and skin ulcer. Neurovascular reactions including warmth, vasospasm, pallor, mottling, gangrene, numbness of the extremities, cyanosis of the extremities, and neurovascular damage. Metabolic: Elevated BUN, creatinine, and SGOT. Musculoskeletal: Joint disorder; periostitis; exacerbation of arthritis; myoglobinuria; rhabdomyolysis. Nervous System: Nervousness; tremors; dizziness; somnolence; confusion; anxiety; euphoria; transverse myelitis; seizures; coma. A syndrome manifested by a variety of CNS symptoms such as severe agitation with confusion, visual and auditory hallucinations, and a fear of impending death (Hoigne's syndrome), has been reported after administration of penicillin G procaine and, less commonly, after injection of the combination of penicillin G benzathine and penicillin G procaine. Other symptoms associated with this syndrome, such as psychosis, seizures, dizziness, tinnitus, cyanosis, palpitations, tachycardia, and/or abnormal perception in taste, also may occur. Respiratory: Hypoxia; apnea; dyspnea. Skin: Diaphoresis. Special Senses: Blurred vision; blindness. Urogenital: Neurogenic bladder; hematuria; proteinuria; renal failure; impotence; priapism.\nPh·ª• n·ªØ mang thai: Pregnancy Teratogenic effects Pregnancy Reproduction studies performed in the mouse, rat, and rabbit have revealed no evidence of impaired fertility or harm to the fetus due to penicillin G. Human experience with the penicillins during pregnancy has not shown any positive evidence of adverse effects on the fetus. There are, however, no adequate and well-controlled studies in pregnant women showing conclusively that harmful effects of these drugs on the fetus can be excluded. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.\n\nH√£y t√≥m t·∫Øt ng·∫Øn g·ªçn theo c√°c m·ª•c: C√¥ng d·ª•ng, Li·ªÅu d√πng, C·∫£nh b√°o, T√°c d·ª•ng ph·ª•, v√† L∆∞u √Ω cho ph·ª• n·ªØ mang thai."}],"model":"gpt-4o-mini"}] as "application/json"
2025-11-02 00:26:40.034 [39mDEBUG[0;39m [http-nio-8081-exec-4] [36mo.s.web.client.RestTemplate[0;39m - Response 200 OK
2025-11-02 00:26:40.041 [39mDEBUG[0;39m [http-nio-8081-exec-4] [36mo.s.web.client.RestTemplate[0;39m - Reading to [java.lang.String] as "application/json"
2025-11-02 00:26:40.044 [39mDEBUG[0;39m [http-nio-8081-exec-4] [36mo.s.web.client.RestTemplate[0;39m - HTTP POST https://api.openai.com/v1/chat/completions
2025-11-02 00:26:40.045 [39mDEBUG[0;39m [http-nio-8081-exec-4] [36mo.s.web.client.RestTemplate[0;39m - Accept=[text/plain, application/json, application/*+json, */*]
2025-11-02 00:26:40.046 [39mDEBUG[0;39m [http-nio-8081-exec-4] [36mo.s.web.client.RestTemplate[0;39m - Writing [{"messages":[{"role":"system","content":"B·∫°n l√† b√°c sƒ© y khoa, h√£y t√≥m t·∫Øt r√µ r√†ng, d·ªÖ hi·ªÉu b·∫±ng ti·∫øng Vi·ªát."},{"role":"user","content":"D∆∞·ªõi ƒë√¢y l√† th√¥ng tin ti·∫øng Anh v·ªÅ thu·ªëc \"Penicillin V Potassium\":\nT√™n thu·ªëc: Penicillin V Potassium\nC√¥ng d·ª•ng: INDICATIONS AND USAGE To reduce the development of drug-resistant bacteria and maintain the effectiveness of penicillin V potassium and other antibacterial drugs, penicillin V potassium should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Penicillin V potassium tablets are indicated in the treatment of mild to moderately severe infections due to penicillin G-sensitive microorganisms. Therapy should be guided by bacteriologic studies (including sensitivity tests) and by clinical response. NOTE: Severe pneumonia, empyema, bacteremia, pericarditis, meningitis, and arthritis should not be treated with penicillin V during the acute stage. Indicated surgical procedures should be performed. The following infections will usually respond to adequate dosage of penicillin V. Streptococcal Infections (without bacteremia) Mild-to-moderate infections of the upper respiratory tract, scarlet fever, and mild erysipelas. NOTE: Streptococci in groups A, C, G, H, L, and M are very sensitive to penicillin. Other groups, including group D (enterococcus), are resistant. Pneumococcal Infections Mild to moderately severe infections of the respiratory tract. Staphylococcal infections\u2013 penicillin G-sensitive Mild infections of the skin and soft tissues. NOTE: Reports indicate an increasing number of strains of staphylococci resistant to penicillin G, emphasizing the need for culture and sensitivity studies in treating suspected staphylococcal infections. Fusospirochetosis (Vincent\u2019s gingivitis and pharyngitis) Mild to moderately severe infections of the oropharynx usually respond to therapy with oral penicillin. NOTE: Necessary dental care should be accomplished in infections involving the gum tissue. Medical conditions in which oral penicillin therapy is indicated as prophylaxis: For the prevention of recurrence following rheumatic fever and/or chorea: Prophylaxis with oral penicillin on a continuing basis has proven effective in preventing recurrence of these conditions. Although no controlled clinical efficacy studies have been conducted, penicillin V has been suggested by the American Heart Association and the American Dental Association for use as an oral regimen for prophylaxis against bacterial endocarditis in patients who have congenital heart disease or rheumatic or other acquired valvular heart disease when they undergo dental procedures and surgical procedures of the upper respiratory tract 1 . Oral penicillin should not be used in those patients at particularly high risk for endocarditis (e.g., those with prosthetic heart valves or surgically constructed systemic pulmonary shunts). Penicillin V should not be used as adjunctive prophylaxis for genitourinary instrumentation or surgery, lower-intestinal tract surgery, sigmoidoscopy, and childbirth. Since it may happen that alpha hemolytic streptococci relatively resistant to penicillin may be found when patients are receiving continuous oral penicillin for secondary prevention of rheumatic fever, prophylactic agents other than penicillin may be chosen for these patients and prescribed in addition to their continuous rheumatic fever prophylactic regimen. NOTE: When selecting antibiotics for the prevention of bacterial endocarditis, the physician or dentist should read the full joint statement of the American Heart Association and the American Dental Association 1 .\nC·∫£nh b√°o: Kh√¥ng c√≥\nT√°c d·ª•ng ph·ª•: ADVERSE REACTIONS Although the incidence of reactions to oral penicillins has been reported with much less frequency than following parenteral therapy, it should be remembered that all degrees of hypersensitivity, including fatal anaphylaxis, have been reported with oral penicillin. The most common reactions to oral penicillin are nausea, vomiting, epigastric distress, diarrhea, and black hairy tongue. The hypersensitivity reactions reported are skin eruptions (maculopapular to exfoliative dermatitis), urticaria and other serum-sickness like reactions, laryngeal edema, and anaphylaxis. Fever and eosinophilia may frequently be the only reaction observed. Hemolytic anemia, leukopenia, thrombocytopenia, neuropathy, and nephropathy are infrequent reactions and usually associated with high doses of parenteral penicillin. To report SUSPECTED ADVERSE REACTIONS, contact Rising Health, LLC at 1-833-395-6928 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.\nPh·ª• n·ªØ mang thai: Kh√¥ng c√≥\n\nH√£y t√≥m t·∫Øt ng·∫Øn g·ªçn theo c√°c m·ª•c: C√¥ng d·ª•ng, Li·ªÅu d√πng, C·∫£nh b√°o, T√°c d·ª•ng ph·ª•, v√† L∆∞u √Ω cho ph·ª• n·ªØ mang thai."}],"model":"gpt-4o-mini"}] as "application/json"
2025-11-02 00:26:46.655 [39mDEBUG[0;39m [http-nio-8081-exec-4] [36mo.s.web.client.RestTemplate[0;39m - Response 200 OK
2025-11-02 00:26:46.662 [39mDEBUG[0;39m [http-nio-8081-exec-4] [36mo.s.web.client.RestTemplate[0;39m - Reading to [java.lang.String] as "application/json"
2025-11-02 00:26:46.666 [39mDEBUG[0;39m [http-nio-8081-exec-4] [36mo.s.web.client.RestTemplate[0;39m - HTTP POST https://api.openai.com/v1/chat/completions
2025-11-02 00:26:46.667 [39mDEBUG[0;39m [http-nio-8081-exec-4] [36mo.s.web.client.RestTemplate[0;39m - Accept=[text/plain, application/json, application/*+json, */*]
2025-11-02 00:26:46.668 [39mDEBUG[0;39m [http-nio-8081-exec-4] [36mo.s.web.client.RestTemplate[0;39m - Writing [{"messages":[{"role":"system","content":"B·∫°n l√† b√°c sƒ© y khoa, h√£y t√≥m t·∫Øt r√µ r√†ng, d·ªÖ hi·ªÉu b·∫±ng ti·∫øng Vi·ªát."},{"role":"user","content":"D∆∞·ªõi ƒë√¢y l√† th√¥ng tin ti·∫øng Anh v·ªÅ thu·ªëc \"Penicillin V Potassium\":\nT√™n thu·ªëc: Penicillin V Potassium\nC√¥ng d·ª•ng: INDICATIONS AND USAGE To reduce the development of drug-resistant bacteria and maintain the effectiveness of penicillin V potassium and other antibacterial drugs, penicillin V potassium should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Penicillin V potassium tablets are indicated in the treatment of mild to moderately severe infections due to penicillin G-sensitive microorganisms. Therapy should be guided by bacteriologic studies (including sensitivity tests) and by clinical response. NOTE: Severe pneumonia, empyema, bacteremia, pericarditis, meningitis, and arthritis should not be treated with penicillin V during the acute stage. Indicated surgical procedures should be performed. The following infections will usually respond to adequate dosage of penicillin V. Streptococcal Infections (without bacteremia) Mild-to-moderate infections of the upper respiratory tract, scarlet fever, and mild erysipelas. NOTE: Streptococci in groups A, C, G, H, L, and M are very sensitive to penicillin. Other groups, including group D (enterococcus), are resistant. Pneumococcal Infections Mild to moderately severe infections of the respiratory tract. Staphylococcal infections \u2013 penicillin G-sensitive Mild infections of the skin and soft tissues. NOTE: Reports indicate an increasing number of strains of staphylococci resistant to penicillin G, emphasizing the need for culture and sensitivity studies in treating suspected staphylococcal infections. Fusospirochetosis (Vincent\u2019s gingivitis and pharyngitis) Mild to moderately severe infections of the oropharynx usually respond to therapy with oral penicillin. NOTE: Necessary dental care should be accomplished in infections involving the gum tissue. Medical conditions in which oral penicillin therapy is indicated as prophylaxis: For the prevention of recurrence following rheumatic fever and/or chorea: Prophylaxis with oral penicillin on a continuing basis has proven effective in preventing recurrence of these conditions. Although no controlled clinical efficacy studies have been conducted, penicillin V has been suggested by the American Heart Association and the American Dental Association for use as an oral regimen for prophylaxis against bacterial endocarditis in patients who have congenital heart disease or rheumatic or other acquired valvular heart disease when they undergo dental procedures and surgical procedures of the upper respiratory tract 1 . Oral penicillin should not be used in those patients at particularly high risk for endocarditis (e.g., those with prosthetic heart valves or surgically constructed systemic pulmonary shunts). Penicillin V should not be used as adjunctive prophylaxis for genitourinary instrumentation or surgery, lower-intestinal tract surgery, sigmoidoscopy, and childbirth. Since it may happen that alpha hemolytic streptococci relatively resistant to penicillin may be found when patients are receiving continuous oral penicillin for secondary prevention of rheumatic fever, prophylactic agents other than penicillin may be chosen for these patients and prescribed in addition to their continuous rheumatic fever prophylactic regimen. NOTE: When selecting antibiotics for the prevention of bacterial endocarditis, the physician or dentist should read the full joint statement of the American Heart Association and the American Dental Association 1 .\nC·∫£nh b√°o: Kh√¥ng c√≥\nT√°c d·ª•ng ph·ª•: ADVERSE REACTIONS Although the incidence of reactions to oral penicillins has been reported with much less frequency than following parenteral therapy, it should be remembered that all degrees of hypersensitivity, including fatal anaphylaxis, have been reported with oral penicillin. The most common reactions to oral penicillin are nausea, vomiting, epigastric distress, diarrhea, and black hairy tongue. The hypersensitivity reactions reported are skin eruptions (maculopapular to exfoliative dermatitis), urticaria and other serum-sickness like reactions, laryngeal edema, and anaphylaxis. Fever and eosinophilia may frequently be the only reaction observed. Hemolytic anemia, leukopenia, thrombocytopenia, neuropathy, and nephropathy are infrequent reactions and usually associated with high doses of parenteral penicillin.\nPh·ª• n·ªØ mang thai: Kh√¥ng c√≥\n\nH√£y t√≥m t·∫Øt ng·∫Øn g·ªçn theo c√°c m·ª•c: C√¥ng d·ª•ng, Li·ªÅu d√πng, C·∫£nh b√°o, T√°c d·ª•ng ph·ª•, v√† L∆∞u √Ω cho ph·ª• n·ªØ mang thai."}],"model":"gpt-4o-mini"}] as "application/json"
2025-11-02 00:26:52.539 [39mDEBUG[0;39m [http-nio-8081-exec-4] [36mo.s.web.client.RestTemplate[0;39m - Response 200 OK
2025-11-02 00:26:52.539 [39mDEBUG[0;39m [http-nio-8081-exec-4] [36mo.s.web.client.RestTemplate[0;39m - Reading to [java.lang.String] as "application/json"
2025-11-02 00:26:52.550 [39mDEBUG[0;39m [http-nio-8081-exec-4] [36mo.s.w.s.m.m.a.HttpEntityMethodProcessor[0;39m - Using 'application/json', given [*/*] and supported [application/json, application/*+json]
2025-11-02 00:26:52.551 [39mDEBUG[0;39m [http-nio-8081-exec-4] [36mo.s.w.s.m.m.a.HttpEntityMethodProcessor[0;39m - Writing [{items=[{T√™n thu·ªëc=BICILLIN L-A, H√£ng s·∫£n xu·∫•t=Pfizer Laboratories Div Pfizer Inc, T√≥m t·∫Øt b√°c sƒ©=C√¥ (truncated)...]
2025-11-02 00:26:52.552 [39mDEBUG[0;39m [http-nio-8081-exec-4] [36mo.s.web.servlet.DispatcherServlet[0;39m - Completed 200 OK
2025-11-02 00:28:03.082 [39mDEBUG[0;39m [http-nio-8081-exec-6] [36mo.s.security.web.FilterChainProxy[0;39m - Securing POST /api/ai/drug-info-full
2025-11-02 00:28:03.099 [39mDEBUG[0;39m [http-nio-8081-exec-6] [36mo.s.w.s.m.m.a.RequestMappingHandlerMapping[0;39m - Mapped to com.nckh.yte.controller.DrugInfoDetailedController#getDrugInfoFull(Map)
2025-11-02 00:28:03.099 [39mDEBUG[0;39m [http-nio-8081-exec-6] [36mo.s.w.s.m.m.a.RequestMappingHandlerMapping[0;39m - Mapped to com.nckh.yte.controller.DrugInfoDetailedController#getDrugInfoFull(Map)
2025-11-02 00:28:03.099 [39mDEBUG[0;39m [http-nio-8081-exec-6] [36mo.s.w.s.m.m.a.RequestMappingHandlerMapping[0;39m - Mapped to com.nckh.yte.controller.DrugInfoDetailedController#getDrugInfoFull(Map)
2025-11-02 00:28:03.102 [39mDEBUG[0;39m [http-nio-8081-exec-6] [36mo.s.w.s.m.m.a.RequestMappingHandlerMapping[0;39m - Mapped to com.nckh.yte.controller.DrugInfoDetailedController#getDrugInfoFull(Map)
2025-11-02 00:28:03.102 [39mDEBUG[0;39m [http-nio-8081-exec-6] [36mo.s.security.web.FilterChainProxy[0;39m - Secured POST /api/ai/drug-info-full
2025-11-02 00:28:03.102 [39mDEBUG[0;39m [http-nio-8081-exec-6] [36mo.s.web.servlet.DispatcherServlet[0;39m - POST "/api/ai/drug-info-full", parameters={}
2025-11-02 00:28:03.102 [39mDEBUG[0;39m [http-nio-8081-exec-6] [36mo.s.w.s.m.m.a.RequestMappingHandlerMapping[0;39m - Mapped to com.nckh.yte.controller.DrugInfoDetailedController#getDrugInfoFull(Map)
2025-11-02 00:28:03.102 [39mDEBUG[0;39m [http-nio-8081-exec-6] [36mo.s.w.s.m.m.a.RequestResponseBodyMethodProcessor[0;39m - Read "application/json;charset=utf-8" to [{drug=penicillin}]
2025-11-02 00:28:03.105 [39mDEBUG[0;39m [http-nio-8081-exec-6] [36mo.s.web.client.RestTemplate[0;39m - HTTP GET https://api.fda.gov/drug/label.json?search=openfda.generic_name:%22penicillin%22%20OR%20openfda.brand_name:%22penicillin%22&limit=3&api_key=YOUR_OPENFDA_KEY
2025-11-02 00:28:03.105 [39mDEBUG[0;39m [http-nio-8081-exec-6] [36mo.s.web.client.RestTemplate[0;39m - Accept=[text/plain, application/json, application/*+json, */*]
2025-11-02 00:28:03.925 [39mDEBUG[0;39m [http-nio-8081-exec-6] [36mo.s.web.client.RestTemplate[0;39m - Response 403 FORBIDDEN
2025-11-02 00:28:03.928 [39mDEBUG[0;39m [http-nio-8081-exec-6] [36mo.s.web.client.RestTemplate[0;39m - HTTP GET https://api.fda.gov/drug/label.json?search=openfda.generic_name:%22penicillin%22%20OR%20openfda.brand_name:%22penicillin%22&limit=3
2025-11-02 00:28:03.928 [39mDEBUG[0;39m [http-nio-8081-exec-6] [36mo.s.web.client.RestTemplate[0;39m - Accept=[text/plain, application/json, application/*+json, */*]
2025-11-02 00:28:04.692 [39mDEBUG[0;39m [http-nio-8081-exec-6] [36mo.s.web.client.RestTemplate[0;39m - Response 200 OK
2025-11-02 00:28:04.692 [39mDEBUG[0;39m [http-nio-8081-exec-6] [36mo.s.web.client.RestTemplate[0;39m - Reading to [java.lang.String] as "application/json;charset=utf-8"
2025-11-02 00:28:05.630 [39mDEBUG[0;39m [http-nio-8081-exec-6] [36mo.s.web.client.RestTemplate[0;39m - HTTP POST https://api.openai.com/v1/chat/completions
2025-11-02 00:28:05.630 [39mDEBUG[0;39m [http-nio-8081-exec-6] [36mo.s.web.client.RestTemplate[0;39m - Accept=[text/plain, application/json, application/*+json, */*]
2025-11-02 00:28:05.631 [39mDEBUG[0;39m [http-nio-8081-exec-6] [36mo.s.web.client.RestTemplate[0;39m - Writing [{"messages":[{"role":"system","content":"B·∫°n l√† b√°c sƒ© y khoa, h√£y t√≥m t·∫Øt r√µ r√†ng, d·ªÖ hi·ªÉu b·∫±ng ti·∫øng Vi·ªát."},{"role":"user","content":"D∆∞·ªõi ƒë√¢y l√† th√¥ng tin ti·∫øng Anh v·ªÅ thu·ªëc \"BICILLIN L-A\":\nT√™n thu·ªëc: BICILLIN L-A\nC√¥ng d·ª•ng: INDICATIONS AND USAGE To reduce the development of drug-resistant bacteria and maintain the effectiveness of Bicillin L-A and other antibacterial drugs, Bicillin L-A should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Intramuscular penicillin G benzathine is indicated in the treatment of infections due to penicillin-G-sensitive microorganisms that are susceptible to the low and very prolonged serum levels common to this particular dosage form. Therapy should be guided by bacteriological studies (including sensitivity tests) and by clinical response. The following infections will usually respond to adequate dosage of intramuscular penicillin G benzathine: Mild-to-moderate infections of the upper-respiratory tract due to susceptible streptococci. Venereal infections \u2014Syphilis, yaws, bejel, and pinta. Medical Conditions in which Penicillin G Benzathine Therapy is indicated as Prophylaxis: Rheumatic fever and/or chorea \u2014Prophylaxis with penicillin G benzathine has proven effective in preventing recurrence of these conditions. It has also been used as follow-up prophylactic therapy for rheumatic heart disease and acute glomerulonephritis.\nC·∫£nh b√°o: Kh√¥ng c√≥\nT√°c d·ª•ng ph·ª•: ADVERSE REACTIONS As with other penicillins, untoward reactions of the sensitivity phenomena are likely to occur, particularly in individuals who have previously demonstrated hypersensitivity to penicillins or in those with a history of allergy, asthma, hay fever, or urticaria. As with other treatments for syphilis, the Jarisch-Herxheimer reaction has been reported. The following adverse reactions have been reported with Bicillin L-A during post-marketing experience: Skin and Appendages: Stevens-Johnson syndrome (SJS) and drug reaction with eosinophilia and systemic symptoms (DRESS). (See WARNINGS .) Immune System Disorders: Acute myocardial ischemia with or without myocardial infarction may occur as part of an allergic reaction (Kounis syndrome). The following have been reported with parenteral penicillin G (the active moiety in Bicillin L-A): General: Hypersensitivity reactions including the following: skin eruptions (maculopapular to exfoliative dermatitis), urticaria, laryngeal edema, fever, eosinophilia; other serum sickness-like reactions (including chills, fever, edema, arthralgia, and prostration); and anaphylaxis including shock and death: severe cutaneous adverse reactions (SCAR), such as toxic epidermal necrolysis (TEN) and acute generalized exanthematous pustulosis (AGEP). (See WARNINGS .) Note: Urticaria, other skin rashes, and serum sickness-like reactions may be controlled with antihistamines and, if necessary, systemic corticosteroids. Whenever such reactions occur, penicillin G should be discontinued unless, in the opinion of the physician, the condition being treated is life-threatening and amenable only to therapy with penicillin G. Serious anaphylactic reactions require immediate emergency treatment with epinephrine. Oxygen, intravenous steroids, and airway management, including intubation, should also be administered as indicated. Gastrointestinal: Pseudomembranous colitis. Onset of pseudomembranous colitis symptoms may occur during or after antibacterial treatment. (See WARNINGS section.) Hematologic: Hemolytic anemia, leukopenia, thrombocytopenia. Neurologic: Neuropathy. Urogenital: Nephropathy. The following adverse events have been temporally associated with parenteral administration of penicillin G benzathine (a component of Bicillin L-A): Body as a Whole: Hypersensitivity reactions including allergic vasculitis, pruritus, fatigue, asthenia, and pain; aggravation of existing disorder; headache, Nicolau syndrome. Cardiovascular: Cardiac arrest; hypotension; tachycardia; palpitations; pulmonary hypertension; pulmonary embolism; vasodilation; vasovagal reaction; cerebrovascular accident; syncope. Gastrointestinal: Nausea, vomiting; blood in stool; intestinal necrosis. Hemic and Lymphatic: Lymphadenopathy. Injection Site: Injection site reactions including pain, inflammation, lump, abscess, necrosis, edema, hemorrhage, cellulitis, hypersensitivity, atrophy, ecchymosis, and skin ulcer. Neurovascular reactions including warmth, vasospasm, pallor, mottling, gangrene, numbness of the extremities, cyanosis of the extremities, and neurovascular damage. Metabolic: Elevated BUN, creatinine, and SGOT. Musculoskeletal: Joint disorder; periostitis; exacerbation of arthritis; myoglobinuria; rhabdomyolysis. Nervous System: Nervousness; tremors; dizziness; somnolence; confusion; anxiety; euphoria; transverse myelitis; seizures; coma. A syndrome manifested by a variety of CNS symptoms such as severe agitation with confusion, visual and auditory hallucinations, and a fear of impending death (Hoigne's syndrome), has been reported after administration of penicillin G procaine and, less commonly, after injection of the combination of penicillin G benzathine and penicillin G procaine. Other symptoms associated with this syndrome, such as psychosis, seizures, dizziness, tinnitus, cyanosis, palpitations, tachycardia, and/or abnormal perception in taste, also may occur. Respiratory: Hypoxia; apnea; dyspnea. Skin: Diaphoresis. Special Senses: Blurred vision; blindness. Urogenital: Neurogenic bladder; hematuria; proteinuria; renal failure; impotence; priapism.\nPh·ª• n·ªØ mang thai: Pregnancy Teratogenic effects Pregnancy Reproduction studies performed in the mouse, rat, and rabbit have revealed no evidence of impaired fertility or harm to the fetus due to penicillin G. Human experience with the penicillins during pregnancy has not shown any positive evidence of adverse effects on the fetus. There are, however, no adequate and well-controlled studies in pregnant women showing conclusively that harmful effects of these drugs on the fetus can be excluded. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.\n\nH√£y t√≥m t·∫Øt ng·∫Øn g·ªçn theo c√°c m·ª•c: C√¥ng d·ª•ng, Li·ªÅu d√πng, C·∫£nh b√°o, T√°c d·ª•ng ph·ª•, v√† L∆∞u √Ω cho ph·ª• n·ªØ mang thai."}],"model":"gpt-4o-mini"}] as "application/json"
2025-11-02 00:28:13.409 [39mDEBUG[0;39m [http-nio-8081-exec-6] [36mo.s.web.client.RestTemplate[0;39m - Response 200 OK
2025-11-02 00:28:13.409 [39mDEBUG[0;39m [http-nio-8081-exec-6] [36mo.s.web.client.RestTemplate[0;39m - Reading to [java.lang.String] as "application/json"
2025-11-02 00:28:13.417 [39mDEBUG[0;39m [http-nio-8081-exec-6] [36mo.s.web.client.RestTemplate[0;39m - HTTP POST https://api.openai.com/v1/chat/completions
2025-11-02 00:28:13.417 [39mDEBUG[0;39m [http-nio-8081-exec-6] [36mo.s.web.client.RestTemplate[0;39m - Accept=[text/plain, application/json, application/*+json, */*]
2025-11-02 00:28:13.417 [39mDEBUG[0;39m [http-nio-8081-exec-6] [36mo.s.web.client.RestTemplate[0;39m - Writing [{"messages":[{"role":"system","content":"B·∫°n l√† b√°c sƒ© y khoa, h√£y t√≥m t·∫Øt r√µ r√†ng, d·ªÖ hi·ªÉu b·∫±ng ti·∫øng Vi·ªát."},{"role":"user","content":"D∆∞·ªõi ƒë√¢y l√† th√¥ng tin ti·∫øng Anh v·ªÅ thu·ªëc \"Penicillin V Potassium\":\nT√™n thu·ªëc: Penicillin V Potassium\nC√¥ng d·ª•ng: INDICATIONS AND USAGE To reduce the development of drug-resistant bacteria and maintain the effectiveness of penicillin V potassium and other antibacterial drugs, penicillin V potassium should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Penicillin V potassium tablets are indicated in the treatment of mild to moderately severe infections due to penicillin G-sensitive microorganisms. Therapy should be guided by bacteriologic studies (including sensitivity tests) and by clinical response. NOTE: Severe pneumonia, empyema, bacteremia, pericarditis, meningitis, and arthritis should not be treated with penicillin V during the acute stage. Indicated surgical procedures should be performed. The following infections will usually respond to adequate dosage of penicillin V. Streptococcal Infections (without bacteremia) Mild-to-moderate infections of the upper respiratory tract, scarlet fever, and mild erysipelas. NOTE: Streptococci in groups A, C, G, H, L, and M are very sensitive to penicillin. Other groups, including group D (enterococcus), are resistant. Pneumococcal Infections Mild to moderately severe infections of the respiratory tract. Staphylococcal infections\u2013 penicillin G-sensitive Mild infections of the skin and soft tissues. NOTE: Reports indicate an increasing number of strains of staphylococci resistant to penicillin G, emphasizing the need for culture and sensitivity studies in treating suspected staphylococcal infections. Fusospirochetosis (Vincent\u2019s gingivitis and pharyngitis) Mild to moderately severe infections of the oropharynx usually respond to therapy with oral penicillin. NOTE: Necessary dental care should be accomplished in infections involving the gum tissue. Medical conditions in which oral penicillin therapy is indicated as prophylaxis: For the prevention of recurrence following rheumatic fever and/or chorea: Prophylaxis with oral penicillin on a continuing basis has proven effective in preventing recurrence of these conditions. Although no controlled clinical efficacy studies have been conducted, penicillin V has been suggested by the American Heart Association and the American Dental Association for use as an oral regimen for prophylaxis against bacterial endocarditis in patients who have congenital heart disease or rheumatic or other acquired valvular heart disease when they undergo dental procedures and surgical procedures of the upper respiratory tract 1 . Oral penicillin should not be used in those patients at particularly high risk for endocarditis (e.g., those with prosthetic heart valves or surgically constructed systemic pulmonary shunts). Penicillin V should not be used as adjunctive prophylaxis for genitourinary instrumentation or surgery, lower-intestinal tract surgery, sigmoidoscopy, and childbirth. Since it may happen that alpha hemolytic streptococci relatively resistant to penicillin may be found when patients are receiving continuous oral penicillin for secondary prevention of rheumatic fever, prophylactic agents other than penicillin may be chosen for these patients and prescribed in addition to their continuous rheumatic fever prophylactic regimen. NOTE: When selecting antibiotics for the prevention of bacterial endocarditis, the physician or dentist should read the full joint statement of the American Heart Association and the American Dental Association 1 .\nC·∫£nh b√°o: Kh√¥ng c√≥\nT√°c d·ª•ng ph·ª•: ADVERSE REACTIONS Although the incidence of reactions to oral penicillins has been reported with much less frequency than following parenteral therapy, it should be remembered that all degrees of hypersensitivity, including fatal anaphylaxis, have been reported with oral penicillin. The most common reactions to oral penicillin are nausea, vomiting, epigastric distress, diarrhea, and black hairy tongue. The hypersensitivity reactions reported are skin eruptions (maculopapular to exfoliative dermatitis), urticaria and other serum-sickness like reactions, laryngeal edema, and anaphylaxis. Fever and eosinophilia may frequently be the only reaction observed. Hemolytic anemia, leukopenia, thrombocytopenia, neuropathy, and nephropathy are infrequent reactions and usually associated with high doses of parenteral penicillin. To report SUSPECTED ADVERSE REACTIONS, contact Rising Health, LLC at 1-833-395-6928 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.\nPh·ª• n·ªØ mang thai: Kh√¥ng c√≥\n\nH√£y t√≥m t·∫Øt ng·∫Øn g·ªçn theo c√°c m·ª•c: C√¥ng d·ª•ng, Li·ªÅu d√πng, C·∫£nh b√°o, T√°c d·ª•ng ph·ª•, v√† L∆∞u √Ω cho ph·ª• n·ªØ mang thai."}],"model":"gpt-4o-mini"}] as "application/json"
2025-11-02 00:28:19.829 [39mDEBUG[0;39m [http-nio-8081-exec-6] [36mo.s.web.client.RestTemplate[0;39m - Response 200 OK
2025-11-02 00:28:19.831 [39mDEBUG[0;39m [http-nio-8081-exec-6] [36mo.s.web.client.RestTemplate[0;39m - Reading to [java.lang.String] as "application/json"
2025-11-02 00:28:19.833 [39mDEBUG[0;39m [http-nio-8081-exec-6] [36mo.s.web.client.RestTemplate[0;39m - HTTP POST https://api.openai.com/v1/chat/completions
2025-11-02 00:28:19.833 [39mDEBUG[0;39m [http-nio-8081-exec-6] [36mo.s.web.client.RestTemplate[0;39m - Accept=[text/plain, application/json, application/*+json, */*]
2025-11-02 00:28:19.833 [39mDEBUG[0;39m [http-nio-8081-exec-6] [36mo.s.web.client.RestTemplate[0;39m - Writing [{"messages":[{"role":"system","content":"B·∫°n l√† b√°c sƒ© y khoa, h√£y t√≥m t·∫Øt r√µ r√†ng, d·ªÖ hi·ªÉu b·∫±ng ti·∫øng Vi·ªát."},{"role":"user","content":"D∆∞·ªõi ƒë√¢y l√† th√¥ng tin ti·∫øng Anh v·ªÅ thu·ªëc \"Penicillin V Potassium\":\nT√™n thu·ªëc: Penicillin V Potassium\nC√¥ng d·ª•ng: INDICATIONS AND USAGE To reduce the development of drug-resistant bacteria and maintain the effectiveness of penicillin V potassium and other antibacterial drugs, penicillin V potassium should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Penicillin V potassium tablets are indicated in the treatment of mild to moderately severe infections due to penicillin G-sensitive microorganisms. Therapy should be guided by bacteriologic studies (including sensitivity tests) and by clinical response. NOTE: Severe pneumonia, empyema, bacteremia, pericarditis, meningitis, and arthritis should not be treated with penicillin V during the acute stage. Indicated surgical procedures should be performed. The following infections will usually respond to adequate dosage of penicillin V. Streptococcal Infections (without bacteremia) Mild-to-moderate infections of the upper respiratory tract, scarlet fever, and mild erysipelas. NOTE: Streptococci in groups A, C, G, H, L, and M are very sensitive to penicillin. Other groups, including group D (enterococcus), are resistant. Pneumococcal Infections Mild to moderately severe infections of the respiratory tract. Staphylococcal infections \u2013 penicillin G-sensitive Mild infections of the skin and soft tissues. NOTE: Reports indicate an increasing number of strains of staphylococci resistant to penicillin G, emphasizing the need for culture and sensitivity studies in treating suspected staphylococcal infections. Fusospirochetosis (Vincent\u2019s gingivitis and pharyngitis) Mild to moderately severe infections of the oropharynx usually respond to therapy with oral penicillin. NOTE: Necessary dental care should be accomplished in infections involving the gum tissue. Medical conditions in which oral penicillin therapy is indicated as prophylaxis: For the prevention of recurrence following rheumatic fever and/or chorea: Prophylaxis with oral penicillin on a continuing basis has proven effective in preventing recurrence of these conditions. Although no controlled clinical efficacy studies have been conducted, penicillin V has been suggested by the American Heart Association and the American Dental Association for use as an oral regimen for prophylaxis against bacterial endocarditis in patients who have congenital heart disease or rheumatic or other acquired valvular heart disease when they undergo dental procedures and surgical procedures of the upper respiratory tract 1 . Oral penicillin should not be used in those patients at particularly high risk for endocarditis (e.g., those with prosthetic heart valves or surgically constructed systemic pulmonary shunts). Penicillin V should not be used as adjunctive prophylaxis for genitourinary instrumentation or surgery, lower-intestinal tract surgery, sigmoidoscopy, and childbirth. Since it may happen that alpha hemolytic streptococci relatively resistant to penicillin may be found when patients are receiving continuous oral penicillin for secondary prevention of rheumatic fever, prophylactic agents other than penicillin may be chosen for these patients and prescribed in addition to their continuous rheumatic fever prophylactic regimen. NOTE: When selecting antibiotics for the prevention of bacterial endocarditis, the physician or dentist should read the full joint statement of the American Heart Association and the American Dental Association 1 .\nC·∫£nh b√°o: Kh√¥ng c√≥\nT√°c d·ª•ng ph·ª•: ADVERSE REACTIONS Although the incidence of reactions to oral penicillins has been reported with much less frequency than following parenteral therapy, it should be remembered that all degrees of hypersensitivity, including fatal anaphylaxis, have been reported with oral penicillin. The most common reactions to oral penicillin are nausea, vomiting, epigastric distress, diarrhea, and black hairy tongue. The hypersensitivity reactions reported are skin eruptions (maculopapular to exfoliative dermatitis), urticaria and other serum-sickness like reactions, laryngeal edema, and anaphylaxis. Fever and eosinophilia may frequently be the only reaction observed. Hemolytic anemia, leukopenia, thrombocytopenia, neuropathy, and nephropathy are infrequent reactions and usually associated with high doses of parenteral penicillin.\nPh·ª• n·ªØ mang thai: Kh√¥ng c√≥\n\nH√£y t√≥m t·∫Øt ng·∫Øn g·ªçn theo c√°c m·ª•c: C√¥ng d·ª•ng, Li·ªÅu d√πng, C·∫£nh b√°o, T√°c d·ª•ng ph·ª•, v√† L∆∞u √Ω cho ph·ª• n·ªØ mang thai."}],"model":"gpt-4o-mini"}] as "application/json"
2025-11-02 00:28:25.278 [39mDEBUG[0;39m [http-nio-8081-exec-6] [36mo.s.web.client.RestTemplate[0;39m - Response 200 OK
2025-11-02 00:28:25.286 [39mDEBUG[0;39m [http-nio-8081-exec-6] [36mo.s.web.client.RestTemplate[0;39m - Reading to [java.lang.String] as "application/json"
2025-11-02 00:28:25.289 [39mDEBUG[0;39m [http-nio-8081-exec-6] [36mo.s.w.s.m.m.a.HttpEntityMethodProcessor[0;39m - Using 'application/json', given [*/*] and supported [application/json, application/*+json]
2025-11-02 00:28:25.290 [39mDEBUG[0;39m [http-nio-8081-exec-6] [36mo.s.w.s.m.m.a.HttpEntityMethodProcessor[0;39m - Writing [{items=[{T√™n thu·ªëc=BICILLIN L-A, H√£ng s·∫£n xu·∫•t=Pfizer Laboratories Div Pfizer Inc, T√≥m t·∫Øt b√°c sƒ©=BI (truncated)...]
2025-11-02 00:28:25.293 [39mDEBUG[0;39m [http-nio-8081-exec-6] [36mo.s.web.servlet.DispatcherServlet[0;39m - Completed 200 OK
2025-11-02 00:31:41.628 [39mDEBUG[0;39m [http-nio-8081-exec-8] [36mo.s.security.web.FilterChainProxy[0;39m - Securing POST /api/ai/drug-info-full
2025-11-02 00:31:41.645 [39mDEBUG[0;39m [http-nio-8081-exec-8] [36mo.s.w.s.m.m.a.RequestMappingHandlerMapping[0;39m - Mapped to com.nckh.yte.controller.DrugInfoDetailedController#getDrugInfoFull(Map)
2025-11-02 00:31:41.647 [39mDEBUG[0;39m [http-nio-8081-exec-8] [36mo.s.w.s.m.m.a.RequestMappingHandlerMapping[0;39m - Mapped to com.nckh.yte.controller.DrugInfoDetailedController#getDrugInfoFull(Map)
2025-11-02 00:31:41.647 [39mDEBUG[0;39m [http-nio-8081-exec-8] [36mo.s.w.s.m.m.a.RequestMappingHandlerMapping[0;39m - Mapped to com.nckh.yte.controller.DrugInfoDetailedController#getDrugInfoFull(Map)
2025-11-02 00:31:41.648 [39mDEBUG[0;39m [http-nio-8081-exec-8] [36mo.s.w.s.m.m.a.RequestMappingHandlerMapping[0;39m - Mapped to com.nckh.yte.controller.DrugInfoDetailedController#getDrugInfoFull(Map)
2025-11-02 00:31:41.649 [39mDEBUG[0;39m [http-nio-8081-exec-8] [36mo.s.security.web.FilterChainProxy[0;39m - Secured POST /api/ai/drug-info-full
2025-11-02 00:31:41.649 [39mDEBUG[0;39m [http-nio-8081-exec-8] [36mo.s.web.servlet.DispatcherServlet[0;39m - POST "/api/ai/drug-info-full", parameters={}
2025-11-02 00:31:41.650 [39mDEBUG[0;39m [http-nio-8081-exec-8] [36mo.s.w.s.m.m.a.RequestMappingHandlerMapping[0;39m - Mapped to com.nckh.yte.controller.DrugInfoDetailedController#getDrugInfoFull(Map)
2025-11-02 00:31:41.651 [39mDEBUG[0;39m [http-nio-8081-exec-8] [36mo.s.w.s.m.m.a.RequestResponseBodyMethodProcessor[0;39m - Read "application/json;charset=utf-8" to [{drug=penicillin}]
2025-11-02 00:31:41.653 [39mDEBUG[0;39m [http-nio-8081-exec-8] [36mo.s.web.client.RestTemplate[0;39m - HTTP GET https://api.fda.gov/drug/label.json?search=openfda.generic_name:%22penicillin%22%20OR%20openfda.brand_name:%22penicillin%22&limit=3&api_key=YOUR_OPENFDA_KEY
2025-11-02 00:31:41.653 [39mDEBUG[0;39m [http-nio-8081-exec-8] [36mo.s.web.client.RestTemplate[0;39m - Accept=[text/plain, application/json, application/*+json, */*]
2025-11-02 00:31:42.377 [39mDEBUG[0;39m [http-nio-8081-exec-8] [36mo.s.web.client.RestTemplate[0;39m - Response 403 FORBIDDEN
2025-11-02 00:31:42.381 [39mDEBUG[0;39m [http-nio-8081-exec-8] [36mo.s.web.client.RestTemplate[0;39m - HTTP GET https://api.fda.gov/drug/label.json?search=openfda.generic_name:%22penicillin%22%20OR%20openfda.brand_name:%22penicillin%22&limit=3
2025-11-02 00:31:42.382 [39mDEBUG[0;39m [http-nio-8081-exec-8] [36mo.s.web.client.RestTemplate[0;39m - Accept=[text/plain, application/json, application/*+json, */*]
2025-11-02 00:31:42.700 [39mDEBUG[0;39m [http-nio-8081-exec-8] [36mo.s.web.client.RestTemplate[0;39m - Response 200 OK
2025-11-02 00:31:42.700 [39mDEBUG[0;39m [http-nio-8081-exec-8] [36mo.s.web.client.RestTemplate[0;39m - Reading to [java.lang.String] as "application/json;charset=utf-8"
2025-11-02 00:31:43.617 [39mDEBUG[0;39m [http-nio-8081-exec-8] [36mo.s.web.client.RestTemplate[0;39m - HTTP POST https://api.openai.com/v1/chat/completions
2025-11-02 00:31:43.618 [39mDEBUG[0;39m [http-nio-8081-exec-8] [36mo.s.web.client.RestTemplate[0;39m - Accept=[text/plain, application/json, application/*+json, */*]
2025-11-02 00:31:43.619 [39mDEBUG[0;39m [http-nio-8081-exec-8] [36mo.s.web.client.RestTemplate[0;39m - Writing [{"messages":[{"role":"system","content":"B·∫°n l√† b√°c sƒ© y khoa, h√£y t√≥m t·∫Øt r√µ r√†ng, d·ªÖ hi·ªÉu b·∫±ng ti·∫øng Vi·ªát."},{"role":"user","content":"D∆∞·ªõi ƒë√¢y l√† th√¥ng tin ti·∫øng Anh v·ªÅ thu·ªëc \"BICILLIN L-A\":\nT√™n thu·ªëc: BICILLIN L-A\nC√¥ng d·ª•ng: INDICATIONS AND USAGE To reduce the development of drug-resistant bacteria and maintain the effectiveness of Bicillin L-A and other antibacterial drugs, Bicillin L-A should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Intramuscular penicillin G benzathine is indicated in the treatment of infections due to penicillin-G-sensitive microorganisms that are susceptible to the low and very prolonged serum levels common to this particular dosage form. Therapy should be guided by bacteriological studies (including sensitivity tests) and by clinical response. The following infections will usually respond to adequate dosage of intramuscular penicillin G benzathine: Mild-to-moderate infections of the upper-respiratory tract due to susceptible streptococci. Venereal infections \u2014Syphilis, yaws, bejel, and pinta. Medical Conditions in which Penicillin G Benzathine Therapy is indicated as Prophylaxis: Rheumatic fever and/or chorea \u2014Prophylaxis with penicillin G benzathine has proven effective in preventing recurrence of these conditions. It has also been used as follow-up prophylactic therapy for rheumatic heart disease and acute glomerulonephritis.\nC·∫£nh b√°o: Kh√¥ng c√≥\nT√°c d·ª•ng ph·ª•: ADVERSE REACTIONS As with other penicillins, untoward reactions of the sensitivity phenomena are likely to occur, particularly in individuals who have previously demonstrated hypersensitivity to penicillins or in those with a history of allergy, asthma, hay fever, or urticaria. As with other treatments for syphilis, the Jarisch-Herxheimer reaction has been reported. The following adverse reactions have been reported with Bicillin L-A during post-marketing experience: Skin and Appendages: Stevens-Johnson syndrome (SJS) and drug reaction with eosinophilia and systemic symptoms (DRESS). (See WARNINGS .) Immune System Disorders: Acute myocardial ischemia with or without myocardial infarction may occur as part of an allergic reaction (Kounis syndrome). The following have been reported with parenteral penicillin G (the active moiety in Bicillin L-A): General: Hypersensitivity reactions including the following: skin eruptions (maculopapular to exfoliative dermatitis), urticaria, laryngeal edema, fever, eosinophilia; other serum sickness-like reactions (including chills, fever, edema, arthralgia, and prostration); and anaphylaxis including shock and death: severe cutaneous adverse reactions (SCAR), such as toxic epidermal necrolysis (TEN) and acute generalized exanthematous pustulosis (AGEP). (See WARNINGS .) Note: Urticaria, other skin rashes, and serum sickness-like reactions may be controlled with antihistamines and, if necessary, systemic corticosteroids. Whenever such reactions occur, penicillin G should be discontinued unless, in the opinion of the physician, the condition being treated is life-threatening and amenable only to therapy with penicillin G. Serious anaphylactic reactions require immediate emergency treatment with epinephrine. Oxygen, intravenous steroids, and airway management, including intubation, should also be administered as indicated. Gastrointestinal: Pseudomembranous colitis. Onset of pseudomembranous colitis symptoms may occur during or after antibacterial treatment. (See WARNINGS section.) Hematologic: Hemolytic anemia, leukopenia, thrombocytopenia. Neurologic: Neuropathy. Urogenital: Nephropathy. The following adverse events have been temporally associated with parenteral administration of penicillin G benzathine (a component of Bicillin L-A): Body as a Whole: Hypersensitivity reactions including allergic vasculitis, pruritus, fatigue, asthenia, and pain; aggravation of existing disorder; headache, Nicolau syndrome. Cardiovascular: Cardiac arrest; hypotension; tachycardia; palpitations; pulmonary hypertension; pulmonary embolism; vasodilation; vasovagal reaction; cerebrovascular accident; syncope. Gastrointestinal: Nausea, vomiting; blood in stool; intestinal necrosis. Hemic and Lymphatic: Lymphadenopathy. Injection Site: Injection site reactions including pain, inflammation, lump, abscess, necrosis, edema, hemorrhage, cellulitis, hypersensitivity, atrophy, ecchymosis, and skin ulcer. Neurovascular reactions including warmth, vasospasm, pallor, mottling, gangrene, numbness of the extremities, cyanosis of the extremities, and neurovascular damage. Metabolic: Elevated BUN, creatinine, and SGOT. Musculoskeletal: Joint disorder; periostitis; exacerbation of arthritis; myoglobinuria; rhabdomyolysis. Nervous System: Nervousness; tremors; dizziness; somnolence; confusion; anxiety; euphoria; transverse myelitis; seizures; coma. A syndrome manifested by a variety of CNS symptoms such as severe agitation with confusion, visual and auditory hallucinations, and a fear of impending death (Hoigne's syndrome), has been reported after administration of penicillin G procaine and, less commonly, after injection of the combination of penicillin G benzathine and penicillin G procaine. Other symptoms associated with this syndrome, such as psychosis, seizures, dizziness, tinnitus, cyanosis, palpitations, tachycardia, and/or abnormal perception in taste, also may occur. Respiratory: Hypoxia; apnea; dyspnea. Skin: Diaphoresis. Special Senses: Blurred vision; blindness. Urogenital: Neurogenic bladder; hematuria; proteinuria; renal failure; impotence; priapism.\nPh·ª• n·ªØ mang thai: Pregnancy Teratogenic effects Pregnancy Reproduction studies performed in the mouse, rat, and rabbit have revealed no evidence of impaired fertility or harm to the fetus due to penicillin G. Human experience with the penicillins during pregnancy has not shown any positive evidence of adverse effects on the fetus. There are, however, no adequate and well-controlled studies in pregnant women showing conclusively that harmful effects of these drugs on the fetus can be excluded. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.\n\nH√£y t√≥m t·∫Øt ng·∫Øn g·ªçn theo c√°c m·ª•c: C√¥ng d·ª•ng, Li·ªÅu d√πng, C·∫£nh b√°o, T√°c d·ª•ng ph·ª•, v√† L∆∞u √Ω cho ph·ª• n·ªØ mang thai."}],"model":"gpt-4o-mini"}] as "application/json"
2025-11-02 00:31:49.613 [39mDEBUG[0;39m [http-nio-8081-exec-8] [36mo.s.web.client.RestTemplate[0;39m - Response 200 OK
2025-11-02 00:31:49.614 [39mDEBUG[0;39m [http-nio-8081-exec-8] [36mo.s.web.client.RestTemplate[0;39m - Reading to [java.lang.String] as "application/json"
2025-11-02 00:31:49.625 [39mDEBUG[0;39m [http-nio-8081-exec-8] [36mo.s.web.client.RestTemplate[0;39m - HTTP POST https://api.openai.com/v1/chat/completions
2025-11-02 00:31:49.626 [39mDEBUG[0;39m [http-nio-8081-exec-8] [36mo.s.web.client.RestTemplate[0;39m - Accept=[text/plain, application/json, application/*+json, */*]
2025-11-02 00:31:49.626 [39mDEBUG[0;39m [http-nio-8081-exec-8] [36mo.s.web.client.RestTemplate[0;39m - Writing [{"messages":[{"role":"system","content":"B·∫°n l√† b√°c sƒ© y khoa, h√£y t√≥m t·∫Øt r√µ r√†ng, d·ªÖ hi·ªÉu b·∫±ng ti·∫øng Vi·ªát."},{"role":"user","content":"D∆∞·ªõi ƒë√¢y l√† th√¥ng tin ti·∫øng Anh v·ªÅ thu·ªëc \"Penicillin V Potassium\":\nT√™n thu·ªëc: Penicillin V Potassium\nC√¥ng d·ª•ng: INDICATIONS AND USAGE To reduce the development of drug-resistant bacteria and maintain the effectiveness of penicillin V potassium and other antibacterial drugs, penicillin V potassium should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Penicillin V potassium tablets are indicated in the treatment of mild to moderately severe infections due to penicillin G-sensitive microorganisms. Therapy should be guided by bacteriologic studies (including sensitivity tests) and by clinical response. NOTE: Severe pneumonia, empyema, bacteremia, pericarditis, meningitis, and arthritis should not be treated with penicillin V during the acute stage. Indicated surgical procedures should be performed. The following infections will usually respond to adequate dosage of penicillin V. Streptococcal Infections (without bacteremia) Mild-to-moderate infections of the upper respiratory tract, scarlet fever, and mild erysipelas. NOTE: Streptococci in groups A, C, G, H, L, and M are very sensitive to penicillin. Other groups, including group D (enterococcus), are resistant. Pneumococcal Infections Mild to moderately severe infections of the respiratory tract. Staphylococcal infections\u2013 penicillin G-sensitive Mild infections of the skin and soft tissues. NOTE: Reports indicate an increasing number of strains of staphylococci resistant to penicillin G, emphasizing the need for culture and sensitivity studies in treating suspected staphylococcal infections. Fusospirochetosis (Vincent\u2019s gingivitis and pharyngitis) Mild to moderately severe infections of the oropharynx usually respond to therapy with oral penicillin. NOTE: Necessary dental care should be accomplished in infections involving the gum tissue. Medical conditions in which oral penicillin therapy is indicated as prophylaxis: For the prevention of recurrence following rheumatic fever and/or chorea: Prophylaxis with oral penicillin on a continuing basis has proven effective in preventing recurrence of these conditions. Although no controlled clinical efficacy studies have been conducted, penicillin V has been suggested by the American Heart Association and the American Dental Association for use as an oral regimen for prophylaxis against bacterial endocarditis in patients who have congenital heart disease or rheumatic or other acquired valvular heart disease when they undergo dental procedures and surgical procedures of the upper respiratory tract 1 . Oral penicillin should not be used in those patients at particularly high risk for endocarditis (e.g., those with prosthetic heart valves or surgically constructed systemic pulmonary shunts). Penicillin V should not be used as adjunctive prophylaxis for genitourinary instrumentation or surgery, lower-intestinal tract surgery, sigmoidoscopy, and childbirth. Since it may happen that alpha hemolytic streptococci relatively resistant to penicillin may be found when patients are receiving continuous oral penicillin for secondary prevention of rheumatic fever, prophylactic agents other than penicillin may be chosen for these patients and prescribed in addition to their continuous rheumatic fever prophylactic regimen. NOTE: When selecting antibiotics for the prevention of bacterial endocarditis, the physician or dentist should read the full joint statement of the American Heart Association and the American Dental Association 1 .\nC·∫£nh b√°o: Kh√¥ng c√≥\nT√°c d·ª•ng ph·ª•: ADVERSE REACTIONS Although the incidence of reactions to oral penicillins has been reported with much less frequency than following parenteral therapy, it should be remembered that all degrees of hypersensitivity, including fatal anaphylaxis, have been reported with oral penicillin. The most common reactions to oral penicillin are nausea, vomiting, epigastric distress, diarrhea, and black hairy tongue. The hypersensitivity reactions reported are skin eruptions (maculopapular to exfoliative dermatitis), urticaria and other serum-sickness like reactions, laryngeal edema, and anaphylaxis. Fever and eosinophilia may frequently be the only reaction observed. Hemolytic anemia, leukopenia, thrombocytopenia, neuropathy, and nephropathy are infrequent reactions and usually associated with high doses of parenteral penicillin. To report SUSPECTED ADVERSE REACTIONS, contact Rising Health, LLC at 1-833-395-6928 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.\nPh·ª• n·ªØ mang thai: Kh√¥ng c√≥\n\nH√£y t√≥m t·∫Øt ng·∫Øn g·ªçn theo c√°c m·ª•c: C√¥ng d·ª•ng, Li·ªÅu d√πng, C·∫£nh b√°o, T√°c d·ª•ng ph·ª•, v√† L∆∞u √Ω cho ph·ª• n·ªØ mang thai."}],"model":"gpt-4o-mini"}] as "application/json"
2025-11-02 00:31:56.942 [39mDEBUG[0;39m [http-nio-8081-exec-8] [36mo.s.web.client.RestTemplate[0;39m - Response 200 OK
2025-11-02 00:31:56.944 [39mDEBUG[0;39m [http-nio-8081-exec-8] [36mo.s.web.client.RestTemplate[0;39m - Reading to [java.lang.String] as "application/json"
2025-11-02 00:31:56.945 [39mDEBUG[0;39m [http-nio-8081-exec-8] [36mo.s.web.client.RestTemplate[0;39m - HTTP POST https://api.openai.com/v1/chat/completions
2025-11-02 00:31:56.946 [39mDEBUG[0;39m [http-nio-8081-exec-8] [36mo.s.web.client.RestTemplate[0;39m - Accept=[text/plain, application/json, application/*+json, */*]
2025-11-02 00:31:56.946 [39mDEBUG[0;39m [http-nio-8081-exec-8] [36mo.s.web.client.RestTemplate[0;39m - Writing [{"messages":[{"role":"system","content":"B·∫°n l√† b√°c sƒ© y khoa, h√£y t√≥m t·∫Øt r√µ r√†ng, d·ªÖ hi·ªÉu b·∫±ng ti·∫øng Vi·ªát."},{"role":"user","content":"D∆∞·ªõi ƒë√¢y l√† th√¥ng tin ti·∫øng Anh v·ªÅ thu·ªëc \"Penicillin V Potassium\":\nT√™n thu·ªëc: Penicillin V Potassium\nC√¥ng d·ª•ng: INDICATIONS AND USAGE To reduce the development of drug-resistant bacteria and maintain the effectiveness of penicillin V potassium and other antibacterial drugs, penicillin V potassium should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Penicillin V potassium tablets are indicated in the treatment of mild to moderately severe infections due to penicillin G-sensitive microorganisms. Therapy should be guided by bacteriologic studies (including sensitivity tests) and by clinical response. NOTE: Severe pneumonia, empyema, bacteremia, pericarditis, meningitis, and arthritis should not be treated with penicillin V during the acute stage. Indicated surgical procedures should be performed. The following infections will usually respond to adequate dosage of penicillin V. Streptococcal Infections (without bacteremia) Mild-to-moderate infections of the upper respiratory tract, scarlet fever, and mild erysipelas. NOTE: Streptococci in groups A, C, G, H, L, and M are very sensitive to penicillin. Other groups, including group D (enterococcus), are resistant. Pneumococcal Infections Mild to moderately severe infections of the respiratory tract. Staphylococcal infections \u2013 penicillin G-sensitive Mild infections of the skin and soft tissues. NOTE: Reports indicate an increasing number of strains of staphylococci resistant to penicillin G, emphasizing the need for culture and sensitivity studies in treating suspected staphylococcal infections. Fusospirochetosis (Vincent\u2019s gingivitis and pharyngitis) Mild to moderately severe infections of the oropharynx usually respond to therapy with oral penicillin. NOTE: Necessary dental care should be accomplished in infections involving the gum tissue. Medical conditions in which oral penicillin therapy is indicated as prophylaxis: For the prevention of recurrence following rheumatic fever and/or chorea: Prophylaxis with oral penicillin on a continuing basis has proven effective in preventing recurrence of these conditions. Although no controlled clinical efficacy studies have been conducted, penicillin V has been suggested by the American Heart Association and the American Dental Association for use as an oral regimen for prophylaxis against bacterial endocarditis in patients who have congenital heart disease or rheumatic or other acquired valvular heart disease when they undergo dental procedures and surgical procedures of the upper respiratory tract 1 . Oral penicillin should not be used in those patients at particularly high risk for endocarditis (e.g., those with prosthetic heart valves or surgically constructed systemic pulmonary shunts). Penicillin V should not be used as adjunctive prophylaxis for genitourinary instrumentation or surgery, lower-intestinal tract surgery, sigmoidoscopy, and childbirth. Since it may happen that alpha hemolytic streptococci relatively resistant to penicillin may be found when patients are receiving continuous oral penicillin for secondary prevention of rheumatic fever, prophylactic agents other than penicillin may be chosen for these patients and prescribed in addition to their continuous rheumatic fever prophylactic regimen. NOTE: When selecting antibiotics for the prevention of bacterial endocarditis, the physician or dentist should read the full joint statement of the American Heart Association and the American Dental Association 1 .\nC·∫£nh b√°o: Kh√¥ng c√≥\nT√°c d·ª•ng ph·ª•: ADVERSE REACTIONS Although the incidence of reactions to oral penicillins has been reported with much less frequency than following parenteral therapy, it should be remembered that all degrees of hypersensitivity, including fatal anaphylaxis, have been reported with oral penicillin. The most common reactions to oral penicillin are nausea, vomiting, epigastric distress, diarrhea, and black hairy tongue. The hypersensitivity reactions reported are skin eruptions (maculopapular to exfoliative dermatitis), urticaria and other serum-sickness like reactions, laryngeal edema, and anaphylaxis. Fever and eosinophilia may frequently be the only reaction observed. Hemolytic anemia, leukopenia, thrombocytopenia, neuropathy, and nephropathy are infrequent reactions and usually associated with high doses of parenteral penicillin.\nPh·ª• n·ªØ mang thai: Kh√¥ng c√≥\n\nH√£y t√≥m t·∫Øt ng·∫Øn g·ªçn theo c√°c m·ª•c: C√¥ng d·ª•ng, Li·ªÅu d√πng, C·∫£nh b√°o, T√°c d·ª•ng ph·ª•, v√† L∆∞u √Ω cho ph·ª• n·ªØ mang thai."}],"model":"gpt-4o-mini"}] as "application/json"
2025-11-02 00:32:01.955 [39mDEBUG[0;39m [http-nio-8081-exec-8] [36mo.s.web.client.RestTemplate[0;39m - Response 200 OK
2025-11-02 00:32:01.962 [39mDEBUG[0;39m [http-nio-8081-exec-8] [36mo.s.web.client.RestTemplate[0;39m - Reading to [java.lang.String] as "application/json"
2025-11-02 00:32:01.964 [39mDEBUG[0;39m [http-nio-8081-exec-8] [36mo.s.w.s.m.m.a.HttpEntityMethodProcessor[0;39m - Using 'application/json', given [*/*] and supported [application/json, application/*+json]
2025-11-02 00:32:01.965 [39mDEBUG[0;39m [http-nio-8081-exec-8] [36mo.s.w.s.m.m.a.HttpEntityMethodProcessor[0;39m - Writing [{items=[{T√™n thu·ªëc=BICILLIN L-A, H√£ng s·∫£n xu·∫•t=Pfizer Laboratories Div Pfizer Inc, T√≥m t·∫Øt b√°c sƒ©=C√¥ (truncated)...]
2025-11-02 00:32:01.968 [39mDEBUG[0;39m [http-nio-8081-exec-8] [36mo.s.web.servlet.DispatcherServlet[0;39m - Completed 200 OK
2025-11-02 00:32:31.018 [39mDEBUG[0;39m [http-nio-8081-exec-1] [36mo.s.security.web.FilterChainProxy[0;39m - Securing POST /api/ai/drug-info-full
2025-11-02 00:32:31.036 [39mDEBUG[0;39m [http-nio-8081-exec-1] [36mo.s.w.s.m.m.a.RequestMappingHandlerMapping[0;39m - Mapped to com.nckh.yte.controller.DrugInfoDetailedController#getDrugInfoFull(Map)
2025-11-02 00:32:31.037 [39mDEBUG[0;39m [http-nio-8081-exec-1] [36mo.s.w.s.m.m.a.RequestMappingHandlerMapping[0;39m - Mapped to com.nckh.yte.controller.DrugInfoDetailedController#getDrugInfoFull(Map)
2025-11-02 00:32:31.037 [39mDEBUG[0;39m [http-nio-8081-exec-1] [36mo.s.w.s.m.m.a.RequestMappingHandlerMapping[0;39m - Mapped to com.nckh.yte.controller.DrugInfoDetailedController#getDrugInfoFull(Map)
2025-11-02 00:32:31.038 [39mDEBUG[0;39m [http-nio-8081-exec-1] [36mo.s.w.s.m.m.a.RequestMappingHandlerMapping[0;39m - Mapped to com.nckh.yte.controller.DrugInfoDetailedController#getDrugInfoFull(Map)
2025-11-02 00:32:31.038 [39mDEBUG[0;39m [http-nio-8081-exec-1] [36mo.s.security.web.FilterChainProxy[0;39m - Secured POST /api/ai/drug-info-full
2025-11-02 00:32:31.038 [39mDEBUG[0;39m [http-nio-8081-exec-1] [36mo.s.web.servlet.DispatcherServlet[0;39m - POST "/api/ai/drug-info-full", parameters={}
2025-11-02 00:32:31.039 [39mDEBUG[0;39m [http-nio-8081-exec-1] [36mo.s.w.s.m.m.a.RequestMappingHandlerMapping[0;39m - Mapped to com.nckh.yte.controller.DrugInfoDetailedController#getDrugInfoFull(Map)
2025-11-02 00:32:31.040 [39mDEBUG[0;39m [http-nio-8081-exec-1] [36mo.s.w.s.m.m.a.RequestResponseBodyMethodProcessor[0;39m - Read "application/json;charset=utf-8" to [{drug=penicillin}]
2025-11-02 00:32:31.040 [39mDEBUG[0;39m [http-nio-8081-exec-1] [36mo.s.web.client.RestTemplate[0;39m - HTTP GET https://api.fda.gov/drug/label.json?search=openfda.generic_name:%22penicillin%22%20OR%20openfda.brand_name:%22penicillin%22&limit=3&api_key=YOUR_OPENFDA_KEY
2025-11-02 00:32:31.040 [39mDEBUG[0;39m [http-nio-8081-exec-1] [36mo.s.web.client.RestTemplate[0;39m - Accept=[text/plain, application/json, application/*+json, */*]
2025-11-02 00:32:31.675 [39mDEBUG[0;39m [http-nio-8081-exec-1] [36mo.s.web.client.RestTemplate[0;39m - Response 403 FORBIDDEN
2025-11-02 00:32:31.678 [39mDEBUG[0;39m [http-nio-8081-exec-1] [36mo.s.web.client.RestTemplate[0;39m - HTTP GET https://api.fda.gov/drug/label.json?search=openfda.generic_name:%22penicillin%22%20OR%20openfda.brand_name:%22penicillin%22&limit=3
2025-11-02 00:32:31.678 [39mDEBUG[0;39m [http-nio-8081-exec-1] [36mo.s.web.client.RestTemplate[0;39m - Accept=[text/plain, application/json, application/*+json, */*]
2025-11-02 00:32:32.201 [39mDEBUG[0;39m [http-nio-8081-exec-1] [36mo.s.web.client.RestTemplate[0;39m - Response 200 OK
2025-11-02 00:32:32.202 [39mDEBUG[0;39m [http-nio-8081-exec-1] [36mo.s.web.client.RestTemplate[0;39m - Reading to [java.lang.String] as "application/json;charset=utf-8"
2025-11-02 00:32:33.439 [39mDEBUG[0;39m [http-nio-8081-exec-1] [36mo.s.web.client.RestTemplate[0;39m - HTTP POST https://api.openai.com/v1/chat/completions
2025-11-02 00:32:33.439 [39mDEBUG[0;39m [http-nio-8081-exec-1] [36mo.s.web.client.RestTemplate[0;39m - Accept=[text/plain, application/json, application/*+json, */*]
2025-11-02 00:32:33.439 [39mDEBUG[0;39m [http-nio-8081-exec-1] [36mo.s.web.client.RestTemplate[0;39m - Writing [{"messages":[{"role":"system","content":"B·∫°n l√† b√°c sƒ© y khoa, h√£y t√≥m t·∫Øt r√µ r√†ng, d·ªÖ hi·ªÉu b·∫±ng ti·∫øng Vi·ªát."},{"role":"user","content":"D∆∞·ªõi ƒë√¢y l√† th√¥ng tin ti·∫øng Anh v·ªÅ thu·ªëc \"BICILLIN L-A\":\nT√™n thu·ªëc: BICILLIN L-A\nC√¥ng d·ª•ng: INDICATIONS AND USAGE To reduce the development of drug-resistant bacteria and maintain the effectiveness of Bicillin L-A and other antibacterial drugs, Bicillin L-A should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Intramuscular penicillin G benzathine is indicated in the treatment of infections due to penicillin-G-sensitive microorganisms that are susceptible to the low and very prolonged serum levels common to this particular dosage form. Therapy should be guided by bacteriological studies (including sensitivity tests) and by clinical response. The following infections will usually respond to adequate dosage of intramuscular penicillin G benzathine: Mild-to-moderate infections of the upper-respiratory tract due to susceptible streptococci. Venereal infections \u2014Syphilis, yaws, bejel, and pinta. Medical Conditions in which Penicillin G Benzathine Therapy is indicated as Prophylaxis: Rheumatic fever and/or chorea \u2014Prophylaxis with penicillin G benzathine has proven effective in preventing recurrence of these conditions. It has also been used as follow-up prophylactic therapy for rheumatic heart disease and acute glomerulonephritis.\nC·∫£nh b√°o: Kh√¥ng c√≥\nT√°c d·ª•ng ph·ª•: ADVERSE REACTIONS As with other penicillins, untoward reactions of the sensitivity phenomena are likely to occur, particularly in individuals who have previously demonstrated hypersensitivity to penicillins or in those with a history of allergy, asthma, hay fever, or urticaria. As with other treatments for syphilis, the Jarisch-Herxheimer reaction has been reported. The following adverse reactions have been reported with Bicillin L-A during post-marketing experience: Skin and Appendages: Stevens-Johnson syndrome (SJS) and drug reaction with eosinophilia and systemic symptoms (DRESS). (See WARNINGS .) Immune System Disorders: Acute myocardial ischemia with or without myocardial infarction may occur as part of an allergic reaction (Kounis syndrome). The following have been reported with parenteral penicillin G (the active moiety in Bicillin L-A): General: Hypersensitivity reactions including the following: skin eruptions (maculopapular to exfoliative dermatitis), urticaria, laryngeal edema, fever, eosinophilia; other serum sickness-like reactions (including chills, fever, edema, arthralgia, and prostration); and anaphylaxis including shock and death: severe cutaneous adverse reactions (SCAR), such as toxic epidermal necrolysis (TEN) and acute generalized exanthematous pustulosis (AGEP). (See WARNINGS .) Note: Urticaria, other skin rashes, and serum sickness-like reactions may be controlled with antihistamines and, if necessary, systemic corticosteroids. Whenever such reactions occur, penicillin G should be discontinued unless, in the opinion of the physician, the condition being treated is life-threatening and amenable only to therapy with penicillin G. Serious anaphylactic reactions require immediate emergency treatment with epinephrine. Oxygen, intravenous steroids, and airway management, including intubation, should also be administered as indicated. Gastrointestinal: Pseudomembranous colitis. Onset of pseudomembranous colitis symptoms may occur during or after antibacterial treatment. (See WARNINGS section.) Hematologic: Hemolytic anemia, leukopenia, thrombocytopenia. Neurologic: Neuropathy. Urogenital: Nephropathy. The following adverse events have been temporally associated with parenteral administration of penicillin G benzathine (a component of Bicillin L-A): Body as a Whole: Hypersensitivity reactions including allergic vasculitis, pruritus, fatigue, asthenia, and pain; aggravation of existing disorder; headache, Nicolau syndrome. Cardiovascular: Cardiac arrest; hypotension; tachycardia; palpitations; pulmonary hypertension; pulmonary embolism; vasodilation; vasovagal reaction; cerebrovascular accident; syncope. Gastrointestinal: Nausea, vomiting; blood in stool; intestinal necrosis. Hemic and Lymphatic: Lymphadenopathy. Injection Site: Injection site reactions including pain, inflammation, lump, abscess, necrosis, edema, hemorrhage, cellulitis, hypersensitivity, atrophy, ecchymosis, and skin ulcer. Neurovascular reactions including warmth, vasospasm, pallor, mottling, gangrene, numbness of the extremities, cyanosis of the extremities, and neurovascular damage. Metabolic: Elevated BUN, creatinine, and SGOT. Musculoskeletal: Joint disorder; periostitis; exacerbation of arthritis; myoglobinuria; rhabdomyolysis. Nervous System: Nervousness; tremors; dizziness; somnolence; confusion; anxiety; euphoria; transverse myelitis; seizures; coma. A syndrome manifested by a variety of CNS symptoms such as severe agitation with confusion, visual and auditory hallucinations, and a fear of impending death (Hoigne's syndrome), has been reported after administration of penicillin G procaine and, less commonly, after injection of the combination of penicillin G benzathine and penicillin G procaine. Other symptoms associated with this syndrome, such as psychosis, seizures, dizziness, tinnitus, cyanosis, palpitations, tachycardia, and/or abnormal perception in taste, also may occur. Respiratory: Hypoxia; apnea; dyspnea. Skin: Diaphoresis. Special Senses: Blurred vision; blindness. Urogenital: Neurogenic bladder; hematuria; proteinuria; renal failure; impotence; priapism.\nPh·ª• n·ªØ mang thai: Pregnancy Teratogenic effects Pregnancy Reproduction studies performed in the mouse, rat, and rabbit have revealed no evidence of impaired fertility or harm to the fetus due to penicillin G. Human experience with the penicillins during pregnancy has not shown any positive evidence of adverse effects on the fetus. There are, however, no adequate and well-controlled studies in pregnant women showing conclusively that harmful effects of these drugs on the fetus can be excluded. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.\n\nH√£y t√≥m t·∫Øt ng·∫Øn g·ªçn theo c√°c m·ª•c: C√¥ng d·ª•ng, Li·ªÅu d√πng, C·∫£nh b√°o, T√°c d·ª•ng ph·ª•, v√† L∆∞u √Ω cho ph·ª• n·ªØ mang thai."}],"model":"gpt-4o-mini"}] as "application/json"
2025-11-02 00:32:43.272 [39mDEBUG[0;39m [http-nio-8081-exec-1] [36mo.s.web.client.RestTemplate[0;39m - Response 200 OK
2025-11-02 00:32:43.273 [39mDEBUG[0;39m [http-nio-8081-exec-1] [36mo.s.web.client.RestTemplate[0;39m - Reading to [java.lang.String] as "application/json"
2025-11-02 00:32:43.275 [39mDEBUG[0;39m [http-nio-8081-exec-1] [36mo.s.web.client.RestTemplate[0;39m - HTTP POST https://api.openai.com/v1/chat/completions
2025-11-02 00:32:43.276 [39mDEBUG[0;39m [http-nio-8081-exec-1] [36mo.s.web.client.RestTemplate[0;39m - Accept=[text/plain, application/json, application/*+json, */*]
2025-11-02 00:32:43.276 [39mDEBUG[0;39m [http-nio-8081-exec-1] [36mo.s.web.client.RestTemplate[0;39m - Writing [{"messages":[{"role":"system","content":"B·∫°n l√† b√°c sƒ© y khoa, h√£y t√≥m t·∫Øt r√µ r√†ng, d·ªÖ hi·ªÉu b·∫±ng ti·∫øng Vi·ªát."},{"role":"user","content":"D∆∞·ªõi ƒë√¢y l√† th√¥ng tin ti·∫øng Anh v·ªÅ thu·ªëc \"Penicillin V Potassium\":\nT√™n thu·ªëc: Penicillin V Potassium\nC√¥ng d·ª•ng: INDICATIONS AND USAGE To reduce the development of drug-resistant bacteria and maintain the effectiveness of penicillin V potassium and other antibacterial drugs, penicillin V potassium should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Penicillin V potassium tablets are indicated in the treatment of mild to moderately severe infections due to penicillin G-sensitive microorganisms. Therapy should be guided by bacteriologic studies (including sensitivity tests) and by clinical response. NOTE: Severe pneumonia, empyema, bacteremia, pericarditis, meningitis, and arthritis should not be treated with penicillin V during the acute stage. Indicated surgical procedures should be performed. The following infections will usually respond to adequate dosage of penicillin V. Streptococcal Infections (without bacteremia) Mild-to-moderate infections of the upper respiratory tract, scarlet fever, and mild erysipelas. NOTE: Streptococci in groups A, C, G, H, L, and M are very sensitive to penicillin. Other groups, including group D (enterococcus), are resistant. Pneumococcal Infections Mild to moderately severe infections of the respiratory tract. Staphylococcal infections\u2013 penicillin G-sensitive Mild infections of the skin and soft tissues. NOTE: Reports indicate an increasing number of strains of staphylococci resistant to penicillin G, emphasizing the need for culture and sensitivity studies in treating suspected staphylococcal infections. Fusospirochetosis (Vincent\u2019s gingivitis and pharyngitis) Mild to moderately severe infections of the oropharynx usually respond to therapy with oral penicillin. NOTE: Necessary dental care should be accomplished in infections involving the gum tissue. Medical conditions in which oral penicillin therapy is indicated as prophylaxis: For the prevention of recurrence following rheumatic fever and/or chorea: Prophylaxis with oral penicillin on a continuing basis has proven effective in preventing recurrence of these conditions. Although no controlled clinical efficacy studies have been conducted, penicillin V has been suggested by the American Heart Association and the American Dental Association for use as an oral regimen for prophylaxis against bacterial endocarditis in patients who have congenital heart disease or rheumatic or other acquired valvular heart disease when they undergo dental procedures and surgical procedures of the upper respiratory tract 1 . Oral penicillin should not be used in those patients at particularly high risk for endocarditis (e.g., those with prosthetic heart valves or surgically constructed systemic pulmonary shunts). Penicillin V should not be used as adjunctive prophylaxis for genitourinary instrumentation or surgery, lower-intestinal tract surgery, sigmoidoscopy, and childbirth. Since it may happen that alpha hemolytic streptococci relatively resistant to penicillin may be found when patients are receiving continuous oral penicillin for secondary prevention of rheumatic fever, prophylactic agents other than penicillin may be chosen for these patients and prescribed in addition to their continuous rheumatic fever prophylactic regimen. NOTE: When selecting antibiotics for the prevention of bacterial endocarditis, the physician or dentist should read the full joint statement of the American Heart Association and the American Dental Association 1 .\nC·∫£nh b√°o: Kh√¥ng c√≥\nT√°c d·ª•ng ph·ª•: ADVERSE REACTIONS Although the incidence of reactions to oral penicillins has been reported with much less frequency than following parenteral therapy, it should be remembered that all degrees of hypersensitivity, including fatal anaphylaxis, have been reported with oral penicillin. The most common reactions to oral penicillin are nausea, vomiting, epigastric distress, diarrhea, and black hairy tongue. The hypersensitivity reactions reported are skin eruptions (maculopapular to exfoliative dermatitis), urticaria and other serum-sickness like reactions, laryngeal edema, and anaphylaxis. Fever and eosinophilia may frequently be the only reaction observed. Hemolytic anemia, leukopenia, thrombocytopenia, neuropathy, and nephropathy are infrequent reactions and usually associated with high doses of parenteral penicillin. To report SUSPECTED ADVERSE REACTIONS, contact Rising Health, LLC at 1-833-395-6928 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.\nPh·ª• n·ªØ mang thai: Kh√¥ng c√≥\n\nH√£y t√≥m t·∫Øt ng·∫Øn g·ªçn theo c√°c m·ª•c: C√¥ng d·ª•ng, Li·ªÅu d√πng, C·∫£nh b√°o, T√°c d·ª•ng ph·ª•, v√† L∆∞u √Ω cho ph·ª• n·ªØ mang thai."}],"model":"gpt-4o-mini"}] as "application/json"
2025-11-02 00:32:51.491 [39mDEBUG[0;39m [http-nio-8081-exec-1] [36mo.s.web.client.RestTemplate[0;39m - Response 200 OK
2025-11-02 00:32:51.498 [39mDEBUG[0;39m [http-nio-8081-exec-1] [36mo.s.web.client.RestTemplate[0;39m - Reading to [java.lang.String] as "application/json"
2025-11-02 00:32:51.500 [39mDEBUG[0;39m [http-nio-8081-exec-1] [36mo.s.web.client.RestTemplate[0;39m - HTTP POST https://api.openai.com/v1/chat/completions
2025-11-02 00:32:51.501 [39mDEBUG[0;39m [http-nio-8081-exec-1] [36mo.s.web.client.RestTemplate[0;39m - Accept=[text/plain, application/json, application/*+json, */*]
2025-11-02 00:32:51.502 [39mDEBUG[0;39m [http-nio-8081-exec-1] [36mo.s.web.client.RestTemplate[0;39m - Writing [{"messages":[{"role":"system","content":"B·∫°n l√† b√°c sƒ© y khoa, h√£y t√≥m t·∫Øt r√µ r√†ng, d·ªÖ hi·ªÉu b·∫±ng ti·∫øng Vi·ªát."},{"role":"user","content":"D∆∞·ªõi ƒë√¢y l√† th√¥ng tin ti·∫øng Anh v·ªÅ thu·ªëc \"Penicillin V Potassium\":\nT√™n thu·ªëc: Penicillin V Potassium\nC√¥ng d·ª•ng: INDICATIONS AND USAGE To reduce the development of drug-resistant bacteria and maintain the effectiveness of penicillin V potassium and other antibacterial drugs, penicillin V potassium should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Penicillin V potassium tablets are indicated in the treatment of mild to moderately severe infections due to penicillin G-sensitive microorganisms. Therapy should be guided by bacteriologic studies (including sensitivity tests) and by clinical response. NOTE: Severe pneumonia, empyema, bacteremia, pericarditis, meningitis, and arthritis should not be treated with penicillin V during the acute stage. Indicated surgical procedures should be performed. The following infections will usually respond to adequate dosage of penicillin V. Streptococcal Infections (without bacteremia) Mild-to-moderate infections of the upper respiratory tract, scarlet fever, and mild erysipelas. NOTE: Streptococci in groups A, C, G, H, L, and M are very sensitive to penicillin. Other groups, including group D (enterococcus), are resistant. Pneumococcal Infections Mild to moderately severe infections of the respiratory tract. Staphylococcal infections \u2013 penicillin G-sensitive Mild infections of the skin and soft tissues. NOTE: Reports indicate an increasing number of strains of staphylococci resistant to penicillin G, emphasizing the need for culture and sensitivity studies in treating suspected staphylococcal infections. Fusospirochetosis (Vincent\u2019s gingivitis and pharyngitis) Mild to moderately severe infections of the oropharynx usually respond to therapy with oral penicillin. NOTE: Necessary dental care should be accomplished in infections involving the gum tissue. Medical conditions in which oral penicillin therapy is indicated as prophylaxis: For the prevention of recurrence following rheumatic fever and/or chorea: Prophylaxis with oral penicillin on a continuing basis has proven effective in preventing recurrence of these conditions. Although no controlled clinical efficacy studies have been conducted, penicillin V has been suggested by the American Heart Association and the American Dental Association for use as an oral regimen for prophylaxis against bacterial endocarditis in patients who have congenital heart disease or rheumatic or other acquired valvular heart disease when they undergo dental procedures and surgical procedures of the upper respiratory tract 1 . Oral penicillin should not be used in those patients at particularly high risk for endocarditis (e.g., those with prosthetic heart valves or surgically constructed systemic pulmonary shunts). Penicillin V should not be used as adjunctive prophylaxis for genitourinary instrumentation or surgery, lower-intestinal tract surgery, sigmoidoscopy, and childbirth. Since it may happen that alpha hemolytic streptococci relatively resistant to penicillin may be found when patients are receiving continuous oral penicillin for secondary prevention of rheumatic fever, prophylactic agents other than penicillin may be chosen for these patients and prescribed in addition to their continuous rheumatic fever prophylactic regimen. NOTE: When selecting antibiotics for the prevention of bacterial endocarditis, the physician or dentist should read the full joint statement of the American Heart Association and the American Dental Association 1 .\nC·∫£nh b√°o: Kh√¥ng c√≥\nT√°c d·ª•ng ph·ª•: ADVERSE REACTIONS Although the incidence of reactions to oral penicillins has been reported with much less frequency than following parenteral therapy, it should be remembered that all degrees of hypersensitivity, including fatal anaphylaxis, have been reported with oral penicillin. The most common reactions to oral penicillin are nausea, vomiting, epigastric distress, diarrhea, and black hairy tongue. The hypersensitivity reactions reported are skin eruptions (maculopapular to exfoliative dermatitis), urticaria and other serum-sickness like reactions, laryngeal edema, and anaphylaxis. Fever and eosinophilia may frequently be the only reaction observed. Hemolytic anemia, leukopenia, thrombocytopenia, neuropathy, and nephropathy are infrequent reactions and usually associated with high doses of parenteral penicillin.\nPh·ª• n·ªØ mang thai: Kh√¥ng c√≥\n\nH√£y t√≥m t·∫Øt ng·∫Øn g·ªçn theo c√°c m·ª•c: C√¥ng d·ª•ng, Li·ªÅu d√πng, C·∫£nh b√°o, T√°c d·ª•ng ph·ª•, v√† L∆∞u √Ω cho ph·ª• n·ªØ mang thai."}],"model":"gpt-4o-mini"}] as "application/json"
2025-11-02 00:32:59.155 [39mDEBUG[0;39m [http-nio-8081-exec-1] [36mo.s.web.client.RestTemplate[0;39m - Response 200 OK
2025-11-02 00:32:59.158 [39mDEBUG[0;39m [http-nio-8081-exec-1] [36mo.s.web.client.RestTemplate[0;39m - Reading to [java.lang.String] as "application/json"
2025-11-02 00:32:59.160 [39mDEBUG[0;39m [http-nio-8081-exec-1] [36mo.s.w.s.m.m.a.HttpEntityMethodProcessor[0;39m - Using 'application/json', given [*/*] and supported [application/json, application/*+json]
2025-11-02 00:32:59.160 [39mDEBUG[0;39m [http-nio-8081-exec-1] [36mo.s.w.s.m.m.a.HttpEntityMethodProcessor[0;39m - Writing [{items=[{T√™n thu·ªëc=BICILLIN L-A, H√£ng s·∫£n xu·∫•t=Pfizer Laboratories Div Pfizer Inc, T√≥m t·∫Øt b√°c sƒ©=C√¥ (truncated)...]
2025-11-02 00:32:59.163 [39mDEBUG[0;39m [http-nio-8081-exec-1] [36mo.s.web.servlet.DispatcherServlet[0;39m - Completed 200 OK
2025-11-02 00:57:59.032 [34mINFO [0;39m [background-preinit] [36mo.h.validator.internal.util.Version[0;39m - HV000001: Hibernate Validator 8.0.1.Final
2025-11-02 00:57:59.083 [34mINFO [0;39m [main] [36mcom.nckh.yte.YteApplication[0;39m - Starting YteApplication using Java 17.0.12 with PID 16284 (C:\Users\nhatn\java_project\yte\target\classes started by nhatn in C:\Users\nhatn\java_project\yte)
2025-11-02 00:57:59.084 [39mDEBUG[0;39m [main] [36mcom.nckh.yte.YteApplication[0;39m - Running with Spring Boot v3.1.4, Spring v6.0.12
2025-11-02 00:57:59.085 [34mINFO [0;39m [main] [36mcom.nckh.yte.YteApplication[0;39m - No active profile set, falling back to 1 default profile: "default"
2025-11-02 00:57:59.729 [34mINFO [0;39m [main] [36mo.s.d.r.c.RepositoryConfigurationDelegate[0;39m - Bootstrapping Spring Data JPA repositories in DEFAULT mode.
2025-11-02 00:57:59.818 [34mINFO [0;39m [main] [36mo.s.d.r.c.RepositoryConfigurationDelegate[0;39m - Finished Spring Data repository scanning in 79 ms. Found 7 JPA repository interfaces.
2025-11-02 00:58:00.465 [34mINFO [0;39m [main] [36mo.s.b.w.e.tomcat.TomcatWebServer[0;39m - Tomcat initialized with port(s): 8081 (http)
2025-11-02 00:58:00.478 [34mINFO [0;39m [main] [36mo.a.coyote.http11.Http11NioProtocol[0;39m - Initializing ProtocolHandler ["http-nio-8081"]
2025-11-02 00:58:00.480 [34mINFO [0;39m [main] [36mo.a.catalina.core.StandardService[0;39m - Starting service [Tomcat]
2025-11-02 00:58:00.481 [34mINFO [0;39m [main] [36mo.a.catalina.core.StandardEngine[0;39m - Starting Servlet engine: [Apache Tomcat/10.1.13]
2025-11-02 00:58:00.583 [34mINFO [0;39m [main] [36mo.a.c.c.C.[Tomcat].[localhost].[/][0;39m - Initializing Spring embedded WebApplicationContext
2025-11-02 00:58:00.584 [34mINFO [0;39m [main] [36mo.s.b.w.s.c.ServletWebServerApplicationContext[0;39m - Root WebApplicationContext: initialization completed in 1461 ms
2025-11-02 00:58:00.706 [34mINFO [0;39m [main] [36mo.h.jpa.internal.util.LogHelper[0;39m - HHH000204: Processing PersistenceUnitInfo [name: default]
2025-11-02 00:58:00.782 [34mINFO [0;39m [main] [36morg.hibernate.Version[0;39m - HHH000412: Hibernate ORM core version 6.2.9.Final
2025-11-02 00:58:00.785 [34mINFO [0;39m [main] [36morg.hibernate.cfg.Environment[0;39m - HHH000406: Using bytecode reflection optimizer
2025-11-02 00:58:00.922 [34mINFO [0;39m [main] [36mo.h.b.i.BytecodeProviderInitiator[0;39m - HHH000021: Bytecode provider name : bytebuddy
2025-11-02 00:58:01.077 [34mINFO [0;39m [main] [36mo.s.o.j.p.SpringPersistenceUnitInfo[0;39m - No LoadTimeWeaver setup: ignoring JPA class transformer
2025-11-02 00:58:01.098 [34mINFO [0;39m [main] [36mcom.zaxxer.hikari.HikariDataSource[0;39m - HikariPool-1 - Starting...
2025-11-02 00:58:01.427 [34mINFO [0;39m [main] [36mcom.zaxxer.hikari.pool.HikariPool[0;39m - HikariPool-1 - Added connection org.postgresql.jdbc.PgConnection@50bf795f
2025-11-02 00:58:01.432 [34mINFO [0;39m [main] [36mcom.zaxxer.hikari.HikariDataSource[0;39m - HikariPool-1 - Start completed.
2025-11-02 00:58:01.772 [34mINFO [0;39m [main] [36mo.h.b.i.BytecodeProviderInitiator[0;39m - HHH000021: Bytecode provider name : bytebuddy
2025-11-02 00:58:02.542 [34mINFO [0;39m [main] [36mo.h.e.t.j.p.i.JtaPlatformInitiator[0;39m - HHH000490: Using JtaPlatform implementation: [org.hibernate.engine.transaction.jta.platform.internal.NoJtaPlatform]
2025-11-02 00:58:02.633 [31mWARN [0;39m [main] [36mo.h.e.jdbc.spi.SqlExceptionHelper[0;39m - SQL Warning Code: 0, SQLState: 00000
2025-11-02 00:58:02.633 [31mWARN [0;39m [main] [36mo.h.e.jdbc.spi.SqlExceptionHelper[0;39m - constraint "uk_7pclwdcntw8qoid4bf4hhro1c" of relation "information" does not exist, skipping
2025-11-02 00:58:02.704 [34mINFO [0;39m [main] [36mo.s.o.j.LocalContainerEntityManagerFactoryBean[0;39m - Initialized JPA EntityManagerFactory for persistence unit 'default'
2025-11-02 00:58:03.010 [39mDEBUG[0;39m [main] [36mcom.nckh.yte.security.JwtAuthFilter[0;39m - Filter 'jwtAuthFilter' configured for use
2025-11-02 00:58:03.391 [31mWARN [0;39m [main] [36mo.s.b.a.o.j.JpaBaseConfiguration$JpaWebConfiguration[0;39m - spring.jpa.open-in-view is enabled by default. Therefore, database queries may be performed during view rendering. Explicitly configure spring.jpa.open-in-view to disable this warning
2025-11-02 00:58:03.552 [39mDEBUG[0;39m [main] [36mo.s.w.s.m.m.a.RequestMappingHandlerMapping[0;39m - 29 mappings in 'requestMappingHandlerMapping'
2025-11-02 00:58:03.641 [39mDEBUG[0;39m [main] [36mo.s.w.s.h.SimpleUrlHandlerMapping[0;39m - Patterns [/webjars/**, /**, /swagger-ui*/*swagger-initializer.js, /swagger-ui*/**] in 'resourceHandlerMapping'
2025-11-02 00:58:03.672 [34mINFO [0;39m [main] [36mo.s.s.web.DefaultSecurityFilterChain[0;39m - Will secure any request with [org.springframework.security.web.session.DisableEncodeUrlFilter@5dfb65d5, org.springframework.security.web.context.request.async.WebAsyncManagerIntegrationFilter@f4aec23, org.springframework.security.web.context.SecurityContextHolderFilter@671c71e8, org.springframework.security.web.header.HeaderWriterFilter@4fe4b8b6, org.springframework.web.filter.CorsFilter@713c8cbb, org.springframework.security.web.authentication.logout.LogoutFilter@60c68c7b, com.nckh.yte.security.JwtAuthFilter@66df362c, org.springframework.security.web.savedrequest.RequestCacheAwareFilter@31d791c0, org.springframework.security.web.servletapi.SecurityContextHolderAwareRequestFilter@1d6ed085, org.springframework.security.web.authentication.AnonymousAuthenticationFilter@7680beac, org.springframework.security.web.session.SessionManagementFilter@473c491, org.springframework.security.web.access.ExceptionTranslationFilter@554db19d, org.springframework.security.web.access.intercept.AuthorizationFilter@23ee31b8]
2025-11-02 00:58:03.718 [39mDEBUG[0;39m [main] [36mo.s.w.s.m.m.a.RequestMappingHandlerAdapter[0;39m - ControllerAdvice beans: 0 @ModelAttribute, 0 @InitBinder, 1 RequestBodyAdvice, 1 ResponseBodyAdvice
2025-11-02 00:58:03.745 [39mDEBUG[0;39m [main] [36mo.s.w.s.m.m.a.ExceptionHandlerExceptionResolver[0;39m - ControllerAdvice beans: 1 @ExceptionHandler, 1 ResponseBodyAdvice
2025-11-02 00:58:03.888 [34mINFO [0;39m [main] [36mo.a.coyote.http11.Http11NioProtocol[0;39m - Starting ProtocolHandler ["http-nio-8081"]
2025-11-02 00:58:03.908 [34mINFO [0;39m [main] [36mo.s.b.w.e.tomcat.TomcatWebServer[0;39m - Tomcat started on port(s): 8081 (http) with context path ''
2025-11-02 00:58:03.917 [34mINFO [0;39m [main] [36mcom.nckh.yte.YteApplication[0;39m - Started YteApplication in 5.4 seconds (process running for 5.738)
2025-11-02 00:58:56.515 [34mINFO [0;39m [http-nio-8081-exec-1] [36mo.a.c.c.C.[Tomcat].[localhost].[/][0;39m - Initializing Spring DispatcherServlet 'dispatcherServlet'
2025-11-02 00:58:56.515 [34mINFO [0;39m [http-nio-8081-exec-1] [36mo.s.web.servlet.DispatcherServlet[0;39m - Initializing Servlet 'dispatcherServlet'
2025-11-02 00:58:56.515 [39mDEBUG[0;39m [http-nio-8081-exec-1] [36mo.s.web.servlet.DispatcherServlet[0;39m - Detected StandardServletMultipartResolver
2025-11-02 00:58:56.515 [39mDEBUG[0;39m [http-nio-8081-exec-1] [36mo.s.web.servlet.DispatcherServlet[0;39m - Detected AcceptHeaderLocaleResolver
2025-11-02 00:58:56.515 [39mDEBUG[0;39m [http-nio-8081-exec-1] [36mo.s.web.servlet.DispatcherServlet[0;39m - Detected FixedThemeResolver
2025-11-02 00:58:56.515 [39mDEBUG[0;39m [http-nio-8081-exec-1] [36mo.s.web.servlet.DispatcherServlet[0;39m - Detected org.springframework.web.servlet.view.DefaultRequestToViewNameTranslator@68e6856c
2025-11-02 00:58:56.515 [39mDEBUG[0;39m [http-nio-8081-exec-1] [36mo.s.web.servlet.DispatcherServlet[0;39m - Detected org.springframework.web.servlet.support.SessionFlashMapManager@170b27a7
2025-11-02 00:58:56.515 [39mDEBUG[0;39m [http-nio-8081-exec-1] [36mo.s.web.servlet.DispatcherServlet[0;39m - enableLoggingRequestDetails='false': request parameters and headers will be masked to prevent unsafe logging of potentially sensitive data
2025-11-02 00:58:56.515 [34mINFO [0;39m [http-nio-8081-exec-1] [36mo.s.web.servlet.DispatcherServlet[0;39m - Completed initialization in 0 ms
2025-11-02 00:58:56.535 [39mDEBUG[0;39m [http-nio-8081-exec-1] [36mo.s.security.web.FilterChainProxy[0;39m - Securing OPTIONS /api/auth/login
2025-11-02 00:58:56.554 [39mDEBUG[0;39m [http-nio-8081-exec-2] [36mo.s.security.web.FilterChainProxy[0;39m - Securing POST /api/auth/login
2025-11-02 00:58:56.554 [39mDEBUG[0;39m [http-nio-8081-exec-2] [36mo.s.s.w.a.AnonymousAuthenticationFilter[0;39m - Set SecurityContextHolder to anonymous SecurityContext
2025-11-02 00:58:56.571 [39mDEBUG[0;39m [http-nio-8081-exec-2] [36mo.s.w.s.m.m.a.RequestMappingHandlerMapping[0;39m - Mapped to com.nckh.yte.controller.AuthController#login(LoginRequest)
2025-11-02 00:58:56.571 [39mDEBUG[0;39m [http-nio-8081-exec-2] [36mo.s.security.web.FilterChainProxy[0;39m - Secured POST /api/auth/login
2025-11-02 00:58:56.571 [39mDEBUG[0;39m [http-nio-8081-exec-2] [36mo.s.web.servlet.DispatcherServlet[0;39m - POST "/api/auth/login", parameters={}
2025-11-02 00:58:56.571 [39mDEBUG[0;39m [http-nio-8081-exec-2] [36mo.s.w.s.m.m.a.RequestMappingHandlerMapping[0;39m - Mapped to com.nckh.yte.controller.AuthController#login(LoginRequest)
2025-11-02 00:58:56.669 [39mDEBUG[0;39m [http-nio-8081-exec-2] [36mo.s.w.s.m.m.a.RequestResponseBodyMethodProcessor[0;39m - Read "application/json;charset=UTF-8" to [com.nckh.yte.dto.LoginRequest@527ae8c8]
2025-11-02 00:58:56.878 [39mDEBUG[0;39m [http-nio-8081-exec-2] [36mo.s.s.a.d.DaoAuthenticationProvider[0;39m - Authenticated user
2025-11-02 00:58:56.941 [39mDEBUG[0;39m [http-nio-8081-exec-2] [36mo.s.w.s.m.m.a.HttpEntityMethodProcessor[0;39m - Using 'application/json', given [application/json] and supported [application/json, application/*+json]
2025-11-02 00:58:56.942 [39mDEBUG[0;39m [http-nio-8081-exec-2] [36mo.s.w.s.m.m.a.HttpEntityMethodProcessor[0;39m - Writing [com.nckh.yte.dto.AuthResponse@517b927]
2025-11-02 00:58:56.948 [39mDEBUG[0;39m [http-nio-8081-exec-2] [36mo.s.web.servlet.DispatcherServlet[0;39m - Completed 200 OK
2025-11-02 00:58:57.160 [39mDEBUG[0;39m [http-nio-8081-exec-3] [36mo.s.security.web.FilterChainProxy[0;39m - Securing OPTIONS /api/patients
2025-11-02 00:58:57.166 [39mDEBUG[0;39m [http-nio-8081-exec-5] [36mo.s.security.web.FilterChainProxy[0;39m - Securing GET /api/patients
2025-11-02 00:58:57.211 [39mDEBUG[0;39m [http-nio-8081-exec-5] [36mo.s.w.s.m.m.a.RequestMappingHandlerMapping[0;39m - Mapped to com.nckh.yte.controller.PatientController#list()
2025-11-02 00:58:57.212 [39mDEBUG[0;39m [http-nio-8081-exec-5] [36mo.s.w.s.m.m.a.RequestMappingHandlerMapping[0;39m - Mapped to com.nckh.yte.controller.PatientController#list()
2025-11-02 00:58:57.212 [39mDEBUG[0;39m [http-nio-8081-exec-5] [36mo.s.w.s.m.m.a.RequestMappingHandlerMapping[0;39m - Mapped to com.nckh.yte.controller.PatientController#list()
2025-11-02 00:58:57.213 [39mDEBUG[0;39m [http-nio-8081-exec-5] [36mo.s.w.s.m.m.a.RequestMappingHandlerMapping[0;39m - Mapped to com.nckh.yte.controller.PatientController#list()
2025-11-02 00:58:57.213 [39mDEBUG[0;39m [http-nio-8081-exec-5] [36mo.s.w.s.m.m.a.RequestMappingHandlerMapping[0;39m - Mapped to com.nckh.yte.controller.PatientController#list()
2025-11-02 00:58:57.213 [39mDEBUG[0;39m [http-nio-8081-exec-5] [36mo.s.w.s.m.m.a.RequestMappingHandlerMapping[0;39m - Mapped to com.nckh.yte.controller.PatientController#list()
2025-11-02 00:58:57.214 [39mDEBUG[0;39m [http-nio-8081-exec-5] [36mo.s.w.s.m.m.a.RequestMappingHandlerMapping[0;39m - Mapped to com.nckh.yte.controller.PatientController#list()
2025-11-02 00:58:57.214 [39mDEBUG[0;39m [http-nio-8081-exec-5] [36mo.s.w.s.m.m.a.RequestMappingHandlerMapping[0;39m - Mapped to com.nckh.yte.controller.PatientController#list()
2025-11-02 00:58:57.215 [39mDEBUG[0;39m [http-nio-8081-exec-5] [36mo.s.security.web.FilterChainProxy[0;39m - Secured GET /api/patients
2025-11-02 00:58:57.215 [39mDEBUG[0;39m [http-nio-8081-exec-5] [36mo.s.web.servlet.DispatcherServlet[0;39m - GET "/api/patients", parameters={}
2025-11-02 00:58:57.216 [39mDEBUG[0;39m [http-nio-8081-exec-5] [36mo.s.w.s.m.m.a.RequestMappingHandlerMapping[0;39m - Mapped to com.nckh.yte.controller.PatientController#list()
2025-11-02 00:58:57.240 [39mDEBUG[0;39m [http-nio-8081-exec-5] [36mo.s.w.s.m.m.a.HttpEntityMethodProcessor[0;39m - Using 'application/json', given [*/*] and supported [application/json, application/*+json]
2025-11-02 00:58:57.240 [39mDEBUG[0;39m [http-nio-8081-exec-5] [36mo.s.w.s.m.m.a.HttpEntityMethodProcessor[0;39m - Writing [[com.nckh.yte.entity.User@7488ed32]]
2025-11-02 00:58:57.245 [39mDEBUG[0;39m [http-nio-8081-exec-5] [36mo.s.web.servlet.DispatcherServlet[0;39m - Completed 200 OK
2025-11-02 00:59:03.449 [39mDEBUG[0;39m [http-nio-8081-exec-7] [36mo.s.security.web.FilterChainProxy[0;39m - Securing OPTIONS /api/ai/drug-info-full
2025-11-02 00:59:03.452 [39mDEBUG[0;39m [http-nio-8081-exec-6] [36mo.s.security.web.FilterChainProxy[0;39m - Securing POST /api/ai/drug-info-full
2025-11-02 00:59:03.471 [39mDEBUG[0;39m [http-nio-8081-exec-6] [36mo.s.w.s.m.m.a.RequestMappingHandlerMapping[0;39m - Mapped to com.nckh.yte.controller.DrugInfoDetailedController#getDrugInfoFull(Map)
2025-11-02 00:59:03.472 [39mDEBUG[0;39m [http-nio-8081-exec-6] [36mo.s.w.s.m.m.a.RequestMappingHandlerMapping[0;39m - Mapped to com.nckh.yte.controller.DrugInfoDetailedController#getDrugInfoFull(Map)
2025-11-02 00:59:03.472 [39mDEBUG[0;39m [http-nio-8081-exec-6] [36mo.s.w.s.m.m.a.RequestMappingHandlerMapping[0;39m - Mapped to com.nckh.yte.controller.DrugInfoDetailedController#getDrugInfoFull(Map)
2025-11-02 00:59:03.474 [39mDEBUG[0;39m [http-nio-8081-exec-6] [36mo.s.w.s.m.m.a.RequestMappingHandlerMapping[0;39m - Mapped to com.nckh.yte.controller.DrugInfoDetailedController#getDrugInfoFull(Map)
2025-11-02 00:59:03.474 [39mDEBUG[0;39m [http-nio-8081-exec-6] [36mo.s.security.web.FilterChainProxy[0;39m - Secured POST /api/ai/drug-info-full
2025-11-02 00:59:03.475 [39mDEBUG[0;39m [http-nio-8081-exec-6] [36mo.s.web.servlet.DispatcherServlet[0;39m - POST "/api/ai/drug-info-full", parameters={}
2025-11-02 00:59:03.475 [39mDEBUG[0;39m [http-nio-8081-exec-6] [36mo.s.w.s.m.m.a.RequestMappingHandlerMapping[0;39m - Mapped to com.nckh.yte.controller.DrugInfoDetailedController#getDrugInfoFull(Map)
2025-11-02 00:59:03.479 [39mDEBUG[0;39m [http-nio-8081-exec-6] [36mo.s.w.s.m.m.a.RequestResponseBodyMethodProcessor[0;39m - Read "application/json;charset=utf-8" to [{drug=penicillin}]
2025-11-02 00:59:03.640 [39mDEBUG[0;39m [http-nio-8081-exec-6] [36mo.s.web.client.RestTemplate[0;39m - HTTP GET https://api.fda.gov/drug/label.json?search=openfda.generic_name:%22penicillin%22%20OR%20openfda.brand_name:%22penicillin%22&limit=3&api_key=YOUR_OPENFDA_KEY
2025-11-02 00:59:03.645 [39mDEBUG[0;39m [http-nio-8081-exec-6] [36mo.s.web.client.RestTemplate[0;39m - Accept=[text/plain, application/json, application/*+json, */*]
2025-11-02 00:59:04.644 [39mDEBUG[0;39m [http-nio-8081-exec-6] [36mo.s.web.client.RestTemplate[0;39m - Response 403 FORBIDDEN
2025-11-02 00:59:04.658 [39mDEBUG[0;39m [http-nio-8081-exec-6] [36mo.s.web.client.RestTemplate[0;39m - HTTP GET https://api.fda.gov/drug/label.json?search=openfda.generic_name:%22penicillin%22%20OR%20openfda.brand_name:%22penicillin%22&limit=3
2025-11-02 00:59:04.658 [39mDEBUG[0;39m [http-nio-8081-exec-6] [36mo.s.web.client.RestTemplate[0;39m - Accept=[text/plain, application/json, application/*+json, */*]
2025-11-02 00:59:05.178 [39mDEBUG[0;39m [http-nio-8081-exec-6] [36mo.s.web.client.RestTemplate[0;39m - Response 200 OK
2025-11-02 00:59:05.178 [39mDEBUG[0;39m [http-nio-8081-exec-6] [36mo.s.web.client.RestTemplate[0;39m - Reading to [java.lang.String] as "application/json;charset=utf-8"
2025-11-02 00:59:06.026 [39mDEBUG[0;39m [http-nio-8081-exec-6] [36mo.s.web.client.RestTemplate[0;39m - HTTP POST https://api.openai.com/v1/chat/completions
2025-11-02 00:59:06.026 [39mDEBUG[0;39m [http-nio-8081-exec-6] [36mo.s.web.client.RestTemplate[0;39m - Accept=[text/plain, application/json, application/*+json, */*]
2025-11-02 00:59:06.026 [39mDEBUG[0;39m [http-nio-8081-exec-6] [36mo.s.web.client.RestTemplate[0;39m - Writing [{"messages":[{"role":"system","content":"B·∫°n l√† b√°c sƒ© y khoa, h√£y t√≥m t·∫Øt r√µ r√†ng, d·ªÖ hi·ªÉu b·∫±ng ti·∫øng Vi·ªát."},{"role":"user","content":"D∆∞·ªõi ƒë√¢y l√† th√¥ng tin ti·∫øng Anh v·ªÅ thu·ªëc \"BICILLIN L-A\":\nT√™n thu·ªëc: BICILLIN L-A\nC√¥ng d·ª•ng: INDICATIONS AND USAGE To reduce the development of drug-resistant bacteria and maintain the effectiveness of Bicillin L-A and other antibacterial drugs, Bicillin L-A should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Intramuscular penicillin G benzathine is indicated in the treatment of infections due to penicillin-G-sensitive microorganisms that are susceptible to the low and very prolonged serum levels common to this particular dosage form. Therapy should be guided by bacteriological studies (including sensitivity tests) and by clinical response. The following infections will usually respond to adequate dosage of intramuscular penicillin G benzathine: Mild-to-moderate infections of the upper-respiratory tract due to susceptible streptococci. Venereal infections \u2014Syphilis, yaws, bejel, and pinta. Medical Conditions in which Penicillin G Benzathine Therapy is indicated as Prophylaxis: Rheumatic fever and/or chorea \u2014Prophylaxis with penicillin G benzathine has proven effective in preventing recurrence of these conditions. It has also been used as follow-up prophylactic therapy for rheumatic heart disease and acute glomerulonephritis.\nC·∫£nh b√°o: Kh√¥ng c√≥\nT√°c d·ª•ng ph·ª•: ADVERSE REACTIONS As with other penicillins, untoward reactions of the sensitivity phenomena are likely to occur, particularly in individuals who have previously demonstrated hypersensitivity to penicillins or in those with a history of allergy, asthma, hay fever, or urticaria. As with other treatments for syphilis, the Jarisch-Herxheimer reaction has been reported. The following adverse reactions have been reported with Bicillin L-A during post-marketing experience: Skin and Appendages: Stevens-Johnson syndrome (SJS) and drug reaction with eosinophilia and systemic symptoms (DRESS). (See WARNINGS .) Immune System Disorders: Acute myocardial ischemia with or without myocardial infarction may occur as part of an allergic reaction (Kounis syndrome). The following have been reported with parenteral penicillin G (the active moiety in Bicillin L-A): General: Hypersensitivity reactions including the following: skin eruptions (maculopapular to exfoliative dermatitis), urticaria, laryngeal edema, fever, eosinophilia; other serum sickness-like reactions (including chills, fever, edema, arthralgia, and prostration); and anaphylaxis including shock and death: severe cutaneous adverse reactions (SCAR), such as toxic epidermal necrolysis (TEN) and acute generalized exanthematous pustulosis (AGEP). (See WARNINGS .) Note: Urticaria, other skin rashes, and serum sickness-like reactions may be controlled with antihistamines and, if necessary, systemic corticosteroids. Whenever such reactions occur, penicillin G should be discontinued unless, in the opinion of the physician, the condition being treated is life-threatening and amenable only to therapy with penicillin G. Serious anaphylactic reactions require immediate emergency treatment with epinephrine. Oxygen, intravenous steroids, and airway management, including intubation, should also be administered as indicated. Gastrointestinal: Pseudomembranous colitis. Onset of pseudomembranous colitis symptoms may occur during or after antibacterial treatment. (See WARNINGS section.) Hematologic: Hemolytic anemia, leukopenia, thrombocytopenia. Neurologic: Neuropathy. Urogenital: Nephropathy. The following adverse events have been temporally associated with parenteral administration of penicillin G benzathine (a component of Bicillin L-A): Body as a Whole: Hypersensitivity reactions including allergic vasculitis, pruritus, fatigue, asthenia, and pain; aggravation of existing disorder; headache, Nicolau syndrome. Cardiovascular: Cardiac arrest; hypotension; tachycardia; palpitations; pulmonary hypertension; pulmonary embolism; vasodilation; vasovagal reaction; cerebrovascular accident; syncope. Gastrointestinal: Nausea, vomiting; blood in stool; intestinal necrosis. Hemic and Lymphatic: Lymphadenopathy. Injection Site: Injection site reactions including pain, inflammation, lump, abscess, necrosis, edema, hemorrhage, cellulitis, hypersensitivity, atrophy, ecchymosis, and skin ulcer. Neurovascular reactions including warmth, vasospasm, pallor, mottling, gangrene, numbness of the extremities, cyanosis of the extremities, and neurovascular damage. Metabolic: Elevated BUN, creatinine, and SGOT. Musculoskeletal: Joint disorder; periostitis; exacerbation of arthritis; myoglobinuria; rhabdomyolysis. Nervous System: Nervousness; tremors; dizziness; somnolence; confusion; anxiety; euphoria; transverse myelitis; seizures; coma. A syndrome manifested by a variety of CNS symptoms such as severe agitation with confusion, visual and auditory hallucinations, and a fear of impending death (Hoigne's syndrome), has been reported after administration of penicillin G procaine and, less commonly, after injection of the combination of penicillin G benzathine and penicillin G procaine. Other symptoms associated with this syndrome, such as psychosis, seizures, dizziness, tinnitus, cyanosis, palpitations, tachycardia, and/or abnormal perception in taste, also may occur. Respiratory: Hypoxia; apnea; dyspnea. Skin: Diaphoresis. Special Senses: Blurred vision; blindness. Urogenital: Neurogenic bladder; hematuria; proteinuria; renal failure; impotence; priapism.\nPh·ª• n·ªØ mang thai: Pregnancy Teratogenic effects Pregnancy Reproduction studies performed in the mouse, rat, and rabbit have revealed no evidence of impaired fertility or harm to the fetus due to penicillin G. Human experience with the penicillins during pregnancy has not shown any positive evidence of adverse effects on the fetus. There are, however, no adequate and well-controlled studies in pregnant women showing conclusively that harmful effects of these drugs on the fetus can be excluded. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.\n\nH√£y t√≥m t·∫Øt ng·∫Øn g·ªçn theo c√°c m·ª•c: C√¥ng d·ª•ng, Li·ªÅu d√πng, C·∫£nh b√°o, T√°c d·ª•ng ph·ª•, v√† L∆∞u √Ω cho ph·ª• n·ªØ mang thai."}],"model":"gpt-4o-mini"}] as "application/json"
2025-11-02 00:59:12.460 [39mDEBUG[0;39m [http-nio-8081-exec-6] [36mo.s.web.client.RestTemplate[0;39m - Response 200 OK
2025-11-02 00:59:12.461 [39mDEBUG[0;39m [http-nio-8081-exec-6] [36mo.s.web.client.RestTemplate[0;39m - Reading to [java.lang.String] as "application/json"
2025-11-02 00:59:12.466 [39mDEBUG[0;39m [http-nio-8081-exec-6] [36mo.s.web.client.RestTemplate[0;39m - HTTP POST https://api.openai.com/v1/chat/completions
2025-11-02 00:59:12.468 [39mDEBUG[0;39m [http-nio-8081-exec-6] [36mo.s.web.client.RestTemplate[0;39m - Accept=[text/plain, application/json, application/*+json, */*]
2025-11-02 00:59:12.469 [39mDEBUG[0;39m [http-nio-8081-exec-6] [36mo.s.web.client.RestTemplate[0;39m - Writing [{"messages":[{"role":"system","content":"B·∫°n l√† b√°c sƒ© y khoa, h√£y t√≥m t·∫Øt r√µ r√†ng, d·ªÖ hi·ªÉu b·∫±ng ti·∫øng Vi·ªát."},{"role":"user","content":"D∆∞·ªõi ƒë√¢y l√† th√¥ng tin ti·∫øng Anh v·ªÅ thu·ªëc \"Penicillin V Potassium\":\nT√™n thu·ªëc: Penicillin V Potassium\nC√¥ng d·ª•ng: INDICATIONS AND USAGE To reduce the development of drug-resistant bacteria and maintain the effectiveness of penicillin V potassium and other antibacterial drugs, penicillin V potassium should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Penicillin V potassium tablets are indicated in the treatment of mild to moderately severe infections due to penicillin G-sensitive microorganisms. Therapy should be guided by bacteriologic studies (including sensitivity tests) and by clinical response. NOTE: Severe pneumonia, empyema, bacteremia, pericarditis, meningitis, and arthritis should not be treated with penicillin V during the acute stage. Indicated surgical procedures should be performed. The following infections will usually respond to adequate dosage of penicillin V. Streptococcal Infections (without bacteremia) Mild-to-moderate infections of the upper respiratory tract, scarlet fever, and mild erysipelas. NOTE: Streptococci in groups A, C, G, H, L, and M are very sensitive to penicillin. Other groups, including group D (enterococcus), are resistant. Pneumococcal Infections Mild to moderately severe infections of the respiratory tract. Staphylococcal infections\u2013 penicillin G-sensitive Mild infections of the skin and soft tissues. NOTE: Reports indicate an increasing number of strains of staphylococci resistant to penicillin G, emphasizing the need for culture and sensitivity studies in treating suspected staphylococcal infections. Fusospirochetosis (Vincent\u2019s gingivitis and pharyngitis) Mild to moderately severe infections of the oropharynx usually respond to therapy with oral penicillin. NOTE: Necessary dental care should be accomplished in infections involving the gum tissue. Medical conditions in which oral penicillin therapy is indicated as prophylaxis: For the prevention of recurrence following rheumatic fever and/or chorea: Prophylaxis with oral penicillin on a continuing basis has proven effective in preventing recurrence of these conditions. Although no controlled clinical efficacy studies have been conducted, penicillin V has been suggested by the American Heart Association and the American Dental Association for use as an oral regimen for prophylaxis against bacterial endocarditis in patients who have congenital heart disease or rheumatic or other acquired valvular heart disease when they undergo dental procedures and surgical procedures of the upper respiratory tract 1 . Oral penicillin should not be used in those patients at particularly high risk for endocarditis (e.g., those with prosthetic heart valves or surgically constructed systemic pulmonary shunts). Penicillin V should not be used as adjunctive prophylaxis for genitourinary instrumentation or surgery, lower-intestinal tract surgery, sigmoidoscopy, and childbirth. Since it may happen that alpha hemolytic streptococci relatively resistant to penicillin may be found when patients are receiving continuous oral penicillin for secondary prevention of rheumatic fever, prophylactic agents other than penicillin may be chosen for these patients and prescribed in addition to their continuous rheumatic fever prophylactic regimen. NOTE: When selecting antibiotics for the prevention of bacterial endocarditis, the physician or dentist should read the full joint statement of the American Heart Association and the American Dental Association 1 .\nC·∫£nh b√°o: Kh√¥ng c√≥\nT√°c d·ª•ng ph·ª•: ADVERSE REACTIONS Although the incidence of reactions to oral penicillins has been reported with much less frequency than following parenteral therapy, it should be remembered that all degrees of hypersensitivity, including fatal anaphylaxis, have been reported with oral penicillin. The most common reactions to oral penicillin are nausea, vomiting, epigastric distress, diarrhea, and black hairy tongue. The hypersensitivity reactions reported are skin eruptions (maculopapular to exfoliative dermatitis), urticaria and other serum-sickness like reactions, laryngeal edema, and anaphylaxis. Fever and eosinophilia may frequently be the only reaction observed. Hemolytic anemia, leukopenia, thrombocytopenia, neuropathy, and nephropathy are infrequent reactions and usually associated with high doses of parenteral penicillin. To report SUSPECTED ADVERSE REACTIONS, contact Rising Health, LLC at 1-833-395-6928 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.\nPh·ª• n·ªØ mang thai: Kh√¥ng c√≥\n\nH√£y t√≥m t·∫Øt ng·∫Øn g·ªçn theo c√°c m·ª•c: C√¥ng d·ª•ng, Li·ªÅu d√πng, C·∫£nh b√°o, T√°c d·ª•ng ph·ª•, v√† L∆∞u √Ω cho ph·ª• n·ªØ mang thai."}],"model":"gpt-4o-mini"}] as "application/json"
2025-11-02 00:59:21.786 [39mDEBUG[0;39m [http-nio-8081-exec-6] [36mo.s.web.client.RestTemplate[0;39m - Response 200 OK
2025-11-02 00:59:21.786 [39mDEBUG[0;39m [http-nio-8081-exec-6] [36mo.s.web.client.RestTemplate[0;39m - Reading to [java.lang.String] as "application/json"
2025-11-02 00:59:21.797 [39mDEBUG[0;39m [http-nio-8081-exec-6] [36mo.s.web.client.RestTemplate[0;39m - HTTP POST https://api.openai.com/v1/chat/completions
2025-11-02 00:59:21.797 [39mDEBUG[0;39m [http-nio-8081-exec-6] [36mo.s.web.client.RestTemplate[0;39m - Accept=[text/plain, application/json, application/*+json, */*]
2025-11-02 00:59:21.797 [39mDEBUG[0;39m [http-nio-8081-exec-6] [36mo.s.web.client.RestTemplate[0;39m - Writing [{"messages":[{"role":"system","content":"B·∫°n l√† b√°c sƒ© y khoa, h√£y t√≥m t·∫Øt r√µ r√†ng, d·ªÖ hi·ªÉu b·∫±ng ti·∫øng Vi·ªát."},{"role":"user","content":"D∆∞·ªõi ƒë√¢y l√† th√¥ng tin ti·∫øng Anh v·ªÅ thu·ªëc \"Penicillin V Potassium\":\nT√™n thu·ªëc: Penicillin V Potassium\nC√¥ng d·ª•ng: INDICATIONS AND USAGE To reduce the development of drug-resistant bacteria and maintain the effectiveness of penicillin V potassium and other antibacterial drugs, penicillin V potassium should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Penicillin V potassium tablets are indicated in the treatment of mild to moderately severe infections due to penicillin G-sensitive microorganisms. Therapy should be guided by bacteriologic studies (including sensitivity tests) and by clinical response. NOTE: Severe pneumonia, empyema, bacteremia, pericarditis, meningitis, and arthritis should not be treated with penicillin V during the acute stage. Indicated surgical procedures should be performed. The following infections will usually respond to adequate dosage of penicillin V. Streptococcal Infections (without bacteremia) Mild-to-moderate infections of the upper respiratory tract, scarlet fever, and mild erysipelas. NOTE: Streptococci in groups A, C, G, H, L, and M are very sensitive to penicillin. Other groups, including group D (enterococcus), are resistant. Pneumococcal Infections Mild to moderately severe infections of the respiratory tract. Staphylococcal infections \u2013 penicillin G-sensitive Mild infections of the skin and soft tissues. NOTE: Reports indicate an increasing number of strains of staphylococci resistant to penicillin G, emphasizing the need for culture and sensitivity studies in treating suspected staphylococcal infections. Fusospirochetosis (Vincent\u2019s gingivitis and pharyngitis) Mild to moderately severe infections of the oropharynx usually respond to therapy with oral penicillin. NOTE: Necessary dental care should be accomplished in infections involving the gum tissue. Medical conditions in which oral penicillin therapy is indicated as prophylaxis: For the prevention of recurrence following rheumatic fever and/or chorea: Prophylaxis with oral penicillin on a continuing basis has proven effective in preventing recurrence of these conditions. Although no controlled clinical efficacy studies have been conducted, penicillin V has been suggested by the American Heart Association and the American Dental Association for use as an oral regimen for prophylaxis against bacterial endocarditis in patients who have congenital heart disease or rheumatic or other acquired valvular heart disease when they undergo dental procedures and surgical procedures of the upper respiratory tract 1 . Oral penicillin should not be used in those patients at particularly high risk for endocarditis (e.g., those with prosthetic heart valves or surgically constructed systemic pulmonary shunts). Penicillin V should not be used as adjunctive prophylaxis for genitourinary instrumentation or surgery, lower-intestinal tract surgery, sigmoidoscopy, and childbirth. Since it may happen that alpha hemolytic streptococci relatively resistant to penicillin may be found when patients are receiving continuous oral penicillin for secondary prevention of rheumatic fever, prophylactic agents other than penicillin may be chosen for these patients and prescribed in addition to their continuous rheumatic fever prophylactic regimen. NOTE: When selecting antibiotics for the prevention of bacterial endocarditis, the physician or dentist should read the full joint statement of the American Heart Association and the American Dental Association 1 .\nC·∫£nh b√°o: Kh√¥ng c√≥\nT√°c d·ª•ng ph·ª•: ADVERSE REACTIONS Although the incidence of reactions to oral penicillins has been reported with much less frequency than following parenteral therapy, it should be remembered that all degrees of hypersensitivity, including fatal anaphylaxis, have been reported with oral penicillin. The most common reactions to oral penicillin are nausea, vomiting, epigastric distress, diarrhea, and black hairy tongue. The hypersensitivity reactions reported are skin eruptions (maculopapular to exfoliative dermatitis), urticaria and other serum-sickness like reactions, laryngeal edema, and anaphylaxis. Fever and eosinophilia may frequently be the only reaction observed. Hemolytic anemia, leukopenia, thrombocytopenia, neuropathy, and nephropathy are infrequent reactions and usually associated with high doses of parenteral penicillin.\nPh·ª• n·ªØ mang thai: Kh√¥ng c√≥\n\nH√£y t√≥m t·∫Øt ng·∫Øn g·ªçn theo c√°c m·ª•c: C√¥ng d·ª•ng, Li·ªÅu d√πng, C·∫£nh b√°o, T√°c d·ª•ng ph·ª•, v√† L∆∞u √Ω cho ph·ª• n·ªØ mang thai."}],"model":"gpt-4o-mini"}] as "application/json"
2025-11-02 00:59:27.094 [39mDEBUG[0;39m [http-nio-8081-exec-6] [36mo.s.web.client.RestTemplate[0;39m - Response 200 OK
2025-11-02 00:59:27.096 [39mDEBUG[0;39m [http-nio-8081-exec-6] [36mo.s.web.client.RestTemplate[0;39m - Reading to [java.lang.String] as "application/json"
2025-11-02 00:59:27.172 [39mDEBUG[0;39m [http-nio-8081-exec-6] [36mo.s.w.s.m.m.a.HttpEntityMethodProcessor[0;39m - Using 'application/json', given [*/*] and supported [application/json, application/*+json]
2025-11-02 00:59:27.173 [39mDEBUG[0;39m [http-nio-8081-exec-6] [36mo.s.w.s.m.m.a.HttpEntityMethodProcessor[0;39m - Writing [{items=[{T√™n thu·ªëc=BICILLIN L-A, H√£ng s·∫£n xu·∫•t=Pfizer Laboratories Div Pfizer Inc, T√≥m t·∫Øt b√°c sƒ©=T√≥ (truncated)...]
2025-11-02 00:59:27.174 [39mDEBUG[0;39m [http-nio-8081-exec-6] [36mo.s.web.servlet.DispatcherServlet[0;39m - Completed 200 OK
2025-11-02 01:00:07.649 [39mDEBUG[0;39m [http-nio-8081-exec-4] [36mo.s.security.web.FilterChainProxy[0;39m - Securing POST /api/ai/drug-info-full
2025-11-02 01:00:07.670 [39mDEBUG[0;39m [http-nio-8081-exec-4] [36mo.s.w.s.m.m.a.RequestMappingHandlerMapping[0;39m - Mapped to com.nckh.yte.controller.DrugInfoDetailedController#getDrugInfoFull(Map)
2025-11-02 01:00:07.672 [39mDEBUG[0;39m [http-nio-8081-exec-4] [36mo.s.w.s.m.m.a.RequestMappingHandlerMapping[0;39m - Mapped to com.nckh.yte.controller.DrugInfoDetailedController#getDrugInfoFull(Map)
2025-11-02 01:00:07.673 [39mDEBUG[0;39m [http-nio-8081-exec-4] [36mo.s.w.s.m.m.a.RequestMappingHandlerMapping[0;39m - Mapped to com.nckh.yte.controller.DrugInfoDetailedController#getDrugInfoFull(Map)
2025-11-02 01:00:07.673 [39mDEBUG[0;39m [http-nio-8081-exec-4] [36mo.s.w.s.m.m.a.RequestMappingHandlerMapping[0;39m - Mapped to com.nckh.yte.controller.DrugInfoDetailedController#getDrugInfoFull(Map)
2025-11-02 01:00:07.673 [39mDEBUG[0;39m [http-nio-8081-exec-4] [36mo.s.security.web.FilterChainProxy[0;39m - Secured POST /api/ai/drug-info-full
2025-11-02 01:00:07.674 [39mDEBUG[0;39m [http-nio-8081-exec-4] [36mo.s.web.servlet.DispatcherServlet[0;39m - POST "/api/ai/drug-info-full", parameters={}
2025-11-02 01:00:07.674 [39mDEBUG[0;39m [http-nio-8081-exec-4] [36mo.s.w.s.m.m.a.RequestMappingHandlerMapping[0;39m - Mapped to com.nckh.yte.controller.DrugInfoDetailedController#getDrugInfoFull(Map)
2025-11-02 01:00:07.676 [39mDEBUG[0;39m [http-nio-8081-exec-4] [36mo.s.w.s.m.m.a.RequestResponseBodyMethodProcessor[0;39m - Read "application/json;charset=utf-8" to [{drug=aceminotaphen}]
2025-11-02 01:00:07.680 [39mDEBUG[0;39m [http-nio-8081-exec-4] [36mo.s.web.client.RestTemplate[0;39m - HTTP GET https://api.fda.gov/drug/label.json?search=openfda.generic_name:%22aceminotaphen%22%20OR%20openfda.brand_name:%22aceminotaphen%22&limit=3&api_key=YOUR_OPENFDA_KEY
2025-11-02 01:00:07.681 [39mDEBUG[0;39m [http-nio-8081-exec-4] [36mo.s.web.client.RestTemplate[0;39m - Accept=[text/plain, application/json, application/*+json, */*]
2025-11-02 01:00:08.694 [39mDEBUG[0;39m [http-nio-8081-exec-4] [36mo.s.web.client.RestTemplate[0;39m - Response 403 FORBIDDEN
2025-11-02 01:00:08.696 [39mDEBUG[0;39m [http-nio-8081-exec-4] [36mo.s.web.client.RestTemplate[0;39m - HTTP GET https://api.fda.gov/drug/label.json?search=openfda.generic_name:%22aceminotaphen%22%20OR%20openfda.brand_name:%22aceminotaphen%22&limit=3
2025-11-02 01:00:08.697 [39mDEBUG[0;39m [http-nio-8081-exec-4] [36mo.s.web.client.RestTemplate[0;39m - Accept=[text/plain, application/json, application/*+json, */*]
2025-11-02 01:00:08.999 [39mDEBUG[0;39m [http-nio-8081-exec-4] [36mo.s.web.client.RestTemplate[0;39m - Response 404 NOT_FOUND
2025-11-02 01:00:09.005 [39mDEBUG[0;39m [http-nio-8081-exec-4] [36mo.s.w.s.m.m.a.HttpEntityMethodProcessor[0;39m - Using 'application/json', given [*/*] and supported [application/json, application/*+json]
2025-11-02 01:00:09.006 [39mDEBUG[0;39m [http-nio-8081-exec-4] [36mo.s.w.s.m.m.a.HttpEntityMethodProcessor[0;39m - Writing [{error=Upstream HTTP error: 404 NOT_FOUND, detail={<EOL>  "error": {<EOL>    "code": "NOT_FOUND",<EOL>    "messa (truncated)...]
2025-11-02 01:00:09.008 [39mDEBUG[0;39m [http-nio-8081-exec-4] [36mo.s.web.servlet.DispatcherServlet[0;39m - Completed 502 BAD_GATEWAY
2025-11-02 01:00:35.884 [39mDEBUG[0;39m [http-nio-8081-exec-8] [36mo.s.security.web.FilterChainProxy[0;39m - Securing POST /api/ai/drug-info-full
2025-11-02 01:00:35.906 [39mDEBUG[0;39m [http-nio-8081-exec-8] [36mo.s.w.s.m.m.a.RequestMappingHandlerMapping[0;39m - Mapped to com.nckh.yte.controller.DrugInfoDetailedController#getDrugInfoFull(Map)
2025-11-02 01:00:35.907 [39mDEBUG[0;39m [http-nio-8081-exec-8] [36mo.s.w.s.m.m.a.RequestMappingHandlerMapping[0;39m - Mapped to com.nckh.yte.controller.DrugInfoDetailedController#getDrugInfoFull(Map)
2025-11-02 01:00:35.907 [39mDEBUG[0;39m [http-nio-8081-exec-8] [36mo.s.w.s.m.m.a.RequestMappingHandlerMapping[0;39m - Mapped to com.nckh.yte.controller.DrugInfoDetailedController#getDrugInfoFull(Map)
2025-11-02 01:00:35.908 [39mDEBUG[0;39m [http-nio-8081-exec-8] [36mo.s.w.s.m.m.a.RequestMappingHandlerMapping[0;39m - Mapped to com.nckh.yte.controller.DrugInfoDetailedController#getDrugInfoFull(Map)
2025-11-02 01:00:35.909 [39mDEBUG[0;39m [http-nio-8081-exec-8] [36mo.s.security.web.FilterChainProxy[0;39m - Secured POST /api/ai/drug-info-full
2025-11-02 01:00:35.909 [39mDEBUG[0;39m [http-nio-8081-exec-8] [36mo.s.web.servlet.DispatcherServlet[0;39m - POST "/api/ai/drug-info-full", parameters={}
2025-11-02 01:00:35.910 [39mDEBUG[0;39m [http-nio-8081-exec-8] [36mo.s.w.s.m.m.a.RequestMappingHandlerMapping[0;39m - Mapped to com.nckh.yte.controller.DrugInfoDetailedController#getDrugInfoFull(Map)
2025-11-02 01:00:35.912 [39mDEBUG[0;39m [http-nio-8081-exec-8] [36mo.s.w.s.m.m.a.RequestResponseBodyMethodProcessor[0;39m - Read "application/json;charset=utf-8" to [{drug=paracetamol}]
2025-11-02 01:00:35.916 [39mDEBUG[0;39m [http-nio-8081-exec-8] [36mo.s.web.client.RestTemplate[0;39m - HTTP GET https://api.fda.gov/drug/label.json?search=openfda.generic_name:%22paracetamol%22%20OR%20openfda.brand_name:%22paracetamol%22&limit=3&api_key=YOUR_OPENFDA_KEY
2025-11-02 01:00:35.916 [39mDEBUG[0;39m [http-nio-8081-exec-8] [36mo.s.web.client.RestTemplate[0;39m - Accept=[text/plain, application/json, application/*+json, */*]
2025-11-02 01:00:36.554 [39mDEBUG[0;39m [http-nio-8081-exec-8] [36mo.s.web.client.RestTemplate[0;39m - Response 403 FORBIDDEN
2025-11-02 01:00:36.557 [39mDEBUG[0;39m [http-nio-8081-exec-8] [36mo.s.web.client.RestTemplate[0;39m - HTTP GET https://api.fda.gov/drug/label.json?search=openfda.generic_name:%22paracetamol%22%20OR%20openfda.brand_name:%22paracetamol%22&limit=3
2025-11-02 01:00:36.557 [39mDEBUG[0;39m [http-nio-8081-exec-8] [36mo.s.web.client.RestTemplate[0;39m - Accept=[text/plain, application/json, application/*+json, */*]
2025-11-02 01:00:36.859 [39mDEBUG[0;39m [http-nio-8081-exec-8] [36mo.s.web.client.RestTemplate[0;39m - Response 404 NOT_FOUND
2025-11-02 01:00:36.862 [39mDEBUG[0;39m [http-nio-8081-exec-8] [36mo.s.w.s.m.m.a.HttpEntityMethodProcessor[0;39m - Using 'application/json', given [*/*] and supported [application/json, application/*+json]
2025-11-02 01:00:36.863 [39mDEBUG[0;39m [http-nio-8081-exec-8] [36mo.s.w.s.m.m.a.HttpEntityMethodProcessor[0;39m - Writing [{error=Upstream HTTP error: 404 NOT_FOUND, detail={<EOL>  "error": {<EOL>    "code": "NOT_FOUND",<EOL>    "messa (truncated)...]
2025-11-02 01:00:36.866 [39mDEBUG[0;39m [http-nio-8081-exec-8] [36mo.s.web.servlet.DispatcherServlet[0;39m - Completed 502 BAD_GATEWAY
2025-11-02 01:00:55.670 [39mDEBUG[0;39m [http-nio-8081-exec-9] [36mo.s.security.web.FilterChainProxy[0;39m - Securing POST /api/ai/drug-info-full
2025-11-02 01:00:55.692 [39mDEBUG[0;39m [http-nio-8081-exec-9] [36mo.s.w.s.m.m.a.RequestMappingHandlerMapping[0;39m - Mapped to com.nckh.yte.controller.DrugInfoDetailedController#getDrugInfoFull(Map)
2025-11-02 01:00:55.693 [39mDEBUG[0;39m [http-nio-8081-exec-9] [36mo.s.w.s.m.m.a.RequestMappingHandlerMapping[0;39m - Mapped to com.nckh.yte.controller.DrugInfoDetailedController#getDrugInfoFull(Map)
2025-11-02 01:00:55.695 [39mDEBUG[0;39m [http-nio-8081-exec-9] [36mo.s.w.s.m.m.a.RequestMappingHandlerMapping[0;39m - Mapped to com.nckh.yte.controller.DrugInfoDetailedController#getDrugInfoFull(Map)
2025-11-02 01:00:55.697 [39mDEBUG[0;39m [http-nio-8081-exec-9] [36mo.s.w.s.m.m.a.RequestMappingHandlerMapping[0;39m - Mapped to com.nckh.yte.controller.DrugInfoDetailedController#getDrugInfoFull(Map)
2025-11-02 01:00:55.698 [39mDEBUG[0;39m [http-nio-8081-exec-9] [36mo.s.security.web.FilterChainProxy[0;39m - Secured POST /api/ai/drug-info-full
2025-11-02 01:00:55.698 [39mDEBUG[0;39m [http-nio-8081-exec-9] [36mo.s.web.servlet.DispatcherServlet[0;39m - POST "/api/ai/drug-info-full", parameters={}
2025-11-02 01:00:55.699 [39mDEBUG[0;39m [http-nio-8081-exec-9] [36mo.s.w.s.m.m.a.RequestMappingHandlerMapping[0;39m - Mapped to com.nckh.yte.controller.DrugInfoDetailedController#getDrugInfoFull(Map)
2025-11-02 01:00:55.702 [39mDEBUG[0;39m [http-nio-8081-exec-9] [36mo.s.w.s.m.m.a.RequestResponseBodyMethodProcessor[0;39m - Read "application/json;charset=utf-8" to [{drug=morphin}]
2025-11-02 01:00:55.708 [39mDEBUG[0;39m [http-nio-8081-exec-9] [36mo.s.web.client.RestTemplate[0;39m - HTTP GET https://api.fda.gov/drug/label.json?search=openfda.generic_name:%22morphin%22%20OR%20openfda.brand_name:%22morphin%22&limit=3&api_key=YOUR_OPENFDA_KEY
2025-11-02 01:00:55.710 [39mDEBUG[0;39m [http-nio-8081-exec-9] [36mo.s.web.client.RestTemplate[0;39m - Accept=[text/plain, application/json, application/*+json, */*]
2025-11-02 01:00:56.392 [39mDEBUG[0;39m [http-nio-8081-exec-9] [36mo.s.web.client.RestTemplate[0;39m - Response 403 FORBIDDEN
2025-11-02 01:00:56.396 [39mDEBUG[0;39m [http-nio-8081-exec-9] [36mo.s.web.client.RestTemplate[0;39m - HTTP GET https://api.fda.gov/drug/label.json?search=openfda.generic_name:%22morphin%22%20OR%20openfda.brand_name:%22morphin%22&limit=3
2025-11-02 01:00:56.397 [39mDEBUG[0;39m [http-nio-8081-exec-9] [36mo.s.web.client.RestTemplate[0;39m - Accept=[text/plain, application/json, application/*+json, */*]
2025-11-02 01:00:56.702 [39mDEBUG[0;39m [http-nio-8081-exec-9] [36mo.s.web.client.RestTemplate[0;39m - Response 404 NOT_FOUND
2025-11-02 01:00:56.707 [39mDEBUG[0;39m [http-nio-8081-exec-9] [36mo.s.w.s.m.m.a.HttpEntityMethodProcessor[0;39m - Using 'application/json', given [*/*] and supported [application/json, application/*+json]
2025-11-02 01:00:56.708 [39mDEBUG[0;39m [http-nio-8081-exec-9] [36mo.s.w.s.m.m.a.HttpEntityMethodProcessor[0;39m - Writing [{error=Upstream HTTP error: 404 NOT_FOUND, detail={<EOL>  "error": {<EOL>    "code": "NOT_FOUND",<EOL>    "messa (truncated)...]
2025-11-02 01:00:56.712 [39mDEBUG[0;39m [http-nio-8081-exec-9] [36mo.s.web.servlet.DispatcherServlet[0;39m - Completed 502 BAD_GATEWAY
2025-11-02 01:01:34.433 [39mDEBUG[0;39m [http-nio-8081-exec-10] [36mo.s.security.web.FilterChainProxy[0;39m - Securing POST /api/ai/drug-info-full
2025-11-02 01:01:34.450 [39mDEBUG[0;39m [http-nio-8081-exec-10] [36mo.s.w.s.m.m.a.RequestMappingHandlerMapping[0;39m - Mapped to com.nckh.yte.controller.DrugInfoDetailedController#getDrugInfoFull(Map)
2025-11-02 01:01:34.451 [39mDEBUG[0;39m [http-nio-8081-exec-10] [36mo.s.w.s.m.m.a.RequestMappingHandlerMapping[0;39m - Mapped to com.nckh.yte.controller.DrugInfoDetailedController#getDrugInfoFull(Map)
2025-11-02 01:01:34.452 [39mDEBUG[0;39m [http-nio-8081-exec-10] [36mo.s.w.s.m.m.a.RequestMappingHandlerMapping[0;39m - Mapped to com.nckh.yte.controller.DrugInfoDetailedController#getDrugInfoFull(Map)
2025-11-02 01:01:34.452 [39mDEBUG[0;39m [http-nio-8081-exec-10] [36mo.s.w.s.m.m.a.RequestMappingHandlerMapping[0;39m - Mapped to com.nckh.yte.controller.DrugInfoDetailedController#getDrugInfoFull(Map)
2025-11-02 01:01:34.453 [39mDEBUG[0;39m [http-nio-8081-exec-10] [36mo.s.security.web.FilterChainProxy[0;39m - Secured POST /api/ai/drug-info-full
2025-11-02 01:01:34.454 [39mDEBUG[0;39m [http-nio-8081-exec-10] [36mo.s.web.servlet.DispatcherServlet[0;39m - POST "/api/ai/drug-info-full", parameters={}
2025-11-02 01:01:34.454 [39mDEBUG[0;39m [http-nio-8081-exec-10] [36mo.s.w.s.m.m.a.RequestMappingHandlerMapping[0;39m - Mapped to com.nckh.yte.controller.DrugInfoDetailedController#getDrugInfoFull(Map)
2025-11-02 01:01:34.456 [39mDEBUG[0;39m [http-nio-8081-exec-10] [36mo.s.w.s.m.m.a.RequestResponseBodyMethodProcessor[0;39m - Read "application/json;charset=utf-8" to [{drug=acetaminophen}]
2025-11-02 01:01:34.460 [39mDEBUG[0;39m [http-nio-8081-exec-10] [36mo.s.web.client.RestTemplate[0;39m - HTTP GET https://api.fda.gov/drug/label.json?search=openfda.generic_name:%22acetaminophen%22%20OR%20openfda.brand_name:%22acetaminophen%22&limit=3&api_key=YOUR_OPENFDA_KEY
2025-11-02 01:01:34.461 [39mDEBUG[0;39m [http-nio-8081-exec-10] [36mo.s.web.client.RestTemplate[0;39m - Accept=[text/plain, application/json, application/*+json, */*]
2025-11-02 01:01:35.235 [39mDEBUG[0;39m [http-nio-8081-exec-10] [36mo.s.web.client.RestTemplate[0;39m - Response 403 FORBIDDEN
2025-11-02 01:01:35.239 [39mDEBUG[0;39m [http-nio-8081-exec-10] [36mo.s.web.client.RestTemplate[0;39m - HTTP GET https://api.fda.gov/drug/label.json?search=openfda.generic_name:%22acetaminophen%22%20OR%20openfda.brand_name:%22acetaminophen%22&limit=3
2025-11-02 01:01:35.240 [39mDEBUG[0;39m [http-nio-8081-exec-10] [36mo.s.web.client.RestTemplate[0;39m - Accept=[text/plain, application/json, application/*+json, */*]
2025-11-02 01:01:35.756 [39mDEBUG[0;39m [http-nio-8081-exec-10] [36mo.s.web.client.RestTemplate[0;39m - Response 200 OK
2025-11-02 01:01:35.757 [39mDEBUG[0;39m [http-nio-8081-exec-10] [36mo.s.web.client.RestTemplate[0;39m - Reading to [java.lang.String] as "application/json;charset=utf-8"
2025-11-02 01:01:35.761 [39mDEBUG[0;39m [http-nio-8081-exec-10] [36mo.s.web.client.RestTemplate[0;39m - HTTP POST https://api.openai.com/v1/chat/completions
2025-11-02 01:01:35.762 [39mDEBUG[0;39m [http-nio-8081-exec-10] [36mo.s.web.client.RestTemplate[0;39m - Accept=[text/plain, application/json, application/*+json, */*]
2025-11-02 01:01:35.763 [39mDEBUG[0;39m [http-nio-8081-exec-10] [36mo.s.web.client.RestTemplate[0;39m - Writing [{"messages":[{"role":"system","content":"B·∫°n l√† b√°c sƒ© y khoa, h√£y t√≥m t·∫Øt r√µ r√†ng, d·ªÖ hi·ªÉu b·∫±ng ti·∫øng Vi·ªát."},{"role":"user","content":"D∆∞·ªõi ƒë√¢y l√† th√¥ng tin ti·∫øng Anh v·ªÅ thu·ªëc \"Pain Reliever Extra Strength\":\nT√™n thu·ªëc: Pain Reliever Extra Strength\nC√¥ng d·ª•ng: Uses temporarily relieves minor aches and pains due to: headache the common cold backache minor pain of arthritis toothache muscular aches premenstrual and menstrual cramps temporarily reduces fever\nC·∫£nh b√°o: Kh√¥ng c√≥\nT√°c d·ª•ng ph·ª•: Kh√¥ng c√≥\nPh·ª• n·ªØ mang thai: Kh√¥ng c√≥\n\nH√£y t√≥m t·∫Øt ng·∫Øn g·ªçn theo c√°c m·ª•c: C√¥ng d·ª•ng, Li·ªÅu d√πng, C·∫£nh b√°o, T√°c d·ª•ng ph·ª•, v√† L∆∞u √Ω cho ph·ª• n·ªØ mang thai."}],"model":"gpt-4o-mini"}] as "application/json"
2025-11-02 01:01:40.177 [39mDEBUG[0;39m [http-nio-8081-exec-10] [36mo.s.web.client.RestTemplate[0;39m - Response 200 OK
2025-11-02 01:01:40.190 [39mDEBUG[0;39m [http-nio-8081-exec-10] [36mo.s.web.client.RestTemplate[0;39m - Reading to [java.lang.String] as "application/json"
2025-11-02 01:01:40.192 [39mDEBUG[0;39m [http-nio-8081-exec-10] [36mo.s.web.client.RestTemplate[0;39m - HTTP POST https://api.openai.com/v1/chat/completions
2025-11-02 01:01:40.193 [39mDEBUG[0;39m [http-nio-8081-exec-10] [36mo.s.web.client.RestTemplate[0;39m - Accept=[text/plain, application/json, application/*+json, */*]
2025-11-02 01:01:40.193 [39mDEBUG[0;39m [http-nio-8081-exec-10] [36mo.s.web.client.RestTemplate[0;39m - Writing [{"messages":[{"role":"system","content":"B·∫°n l√† b√°c sƒ© y khoa, h√£y t√≥m t·∫Øt r√µ r√†ng, d·ªÖ hi·ªÉu b·∫±ng ti·∫øng Vi·ªát."},{"role":"user","content":"D∆∞·ªõi ƒë√¢y l√† th√¥ng tin ti·∫øng Anh v·ªÅ thu·ªëc \"basic care acetaminophen\":\nT√™n thu·ªëc: basic care acetaminophen\nC√¥ng d·ª•ng: Uses \u2022 temporarily relieves minor aches and pains due to: \u2022 headache \u2022 muscular aches \u2022 backache \u2022 minor pain of arthritis \u2022 the common cold \u2022 toothache \u2022 premenstrual and menstrual cramps \u2022 temporarily reduces fever\nC·∫£nh b√°o: Kh√¥ng c√≥\nT√°c d·ª•ng ph·ª•: Kh√¥ng c√≥\nPh·ª• n·ªØ mang thai: Kh√¥ng c√≥\n\nH√£y t√≥m t·∫Øt ng·∫Øn g·ªçn theo c√°c m·ª•c: C√¥ng d·ª•ng, Li·ªÅu d√πng, C·∫£nh b√°o, T√°c d·ª•ng ph·ª•, v√† L∆∞u √Ω cho ph·ª• n·ªØ mang thai."}],"model":"gpt-4o-mini"}] as "application/json"
2025-11-02 01:01:46.680 [39mDEBUG[0;39m [http-nio-8081-exec-10] [36mo.s.web.client.RestTemplate[0;39m - Response 200 OK
2025-11-02 01:01:46.682 [39mDEBUG[0;39m [http-nio-8081-exec-10] [36mo.s.web.client.RestTemplate[0;39m - Reading to [java.lang.String] as "application/json"
2025-11-02 01:01:46.685 [39mDEBUG[0;39m [http-nio-8081-exec-10] [36mo.s.web.client.RestTemplate[0;39m - HTTP POST https://api.openai.com/v1/chat/completions
2025-11-02 01:01:46.686 [39mDEBUG[0;39m [http-nio-8081-exec-10] [36mo.s.web.client.RestTemplate[0;39m - Accept=[text/plain, application/json, application/*+json, */*]
2025-11-02 01:01:46.688 [39mDEBUG[0;39m [http-nio-8081-exec-10] [36mo.s.web.client.RestTemplate[0;39m - Writing [{"messages":[{"role":"system","content":"B·∫°n l√† b√°c sƒ© y khoa, h√£y t√≥m t·∫Øt r√µ r√†ng, d·ªÖ hi·ªÉu b·∫±ng ti·∫øng Vi·ªát."},{"role":"user","content":"D∆∞·ªõi ƒë√¢y l√† th√¥ng tin ti·∫øng Anh v·ªÅ thu·ªëc \"Acetaminophen\":\nT√™n thu·ªëc: Acetaminophen\nC√¥ng d·ª•ng: Uses temporarily relieves minor aches and pains due to: minor pain of arthritis muscular aches backache premenstrual and menstrual cramp toothache the common cold headache toothache temporarily reduces fever\nC·∫£nh b√°o: Kh√¥ng c√≥\nT√°c d·ª•ng ph·ª•: Kh√¥ng c√≥\nPh·ª• n·ªØ mang thai: Kh√¥ng c√≥\n\nH√£y t√≥m t·∫Øt ng·∫Øn g·ªçn theo c√°c m·ª•c: C√¥ng d·ª•ng, Li·ªÅu d√πng, C·∫£nh b√°o, T√°c d·ª•ng ph·ª•, v√† L∆∞u √Ω cho ph·ª• n·ªØ mang thai."}],"model":"gpt-4o-mini"}] as "application/json"
2025-11-02 01:01:50.639 [39mDEBUG[0;39m [http-nio-8081-exec-10] [36mo.s.web.client.RestTemplate[0;39m - Response 200 OK
2025-11-02 01:01:50.644 [39mDEBUG[0;39m [http-nio-8081-exec-10] [36mo.s.web.client.RestTemplate[0;39m - Reading to [java.lang.String] as "application/json"
2025-11-02 01:01:50.654 [39mDEBUG[0;39m [http-nio-8081-exec-10] [36mo.s.w.s.m.m.a.HttpEntityMethodProcessor[0;39m - Using 'application/json', given [*/*] and supported [application/json, application/*+json]
2025-11-02 01:01:50.654 [39mDEBUG[0;39m [http-nio-8081-exec-10] [36mo.s.w.s.m.m.a.HttpEntityMethodProcessor[0;39m - Writing [{items=[{T√™n thu·ªëc=Pain Reliever Extra Strength, H√£ng s·∫£n xu·∫•t=Valu Merchandisers Company, T√≥m t·∫Øt b (truncated)...]
2025-11-02 01:01:50.657 [39mDEBUG[0;39m [http-nio-8081-exec-10] [36mo.s.web.servlet.DispatcherServlet[0;39m - Completed 200 OK
2025-11-02 01:02:13.484 [39mDEBUG[0;39m [http-nio-8081-exec-2] [36mo.s.security.web.FilterChainProxy[0;39m - Securing POST /api/ai/drug-info-full
2025-11-02 01:02:13.501 [39mDEBUG[0;39m [http-nio-8081-exec-2] [36mo.s.w.s.m.m.a.RequestMappingHandlerMapping[0;39m - Mapped to com.nckh.yte.controller.DrugInfoDetailedController#getDrugInfoFull(Map)
2025-11-02 01:02:13.502 [39mDEBUG[0;39m [http-nio-8081-exec-2] [36mo.s.w.s.m.m.a.RequestMappingHandlerMapping[0;39m - Mapped to com.nckh.yte.controller.DrugInfoDetailedController#getDrugInfoFull(Map)
2025-11-02 01:02:13.502 [39mDEBUG[0;39m [http-nio-8081-exec-2] [36mo.s.w.s.m.m.a.RequestMappingHandlerMapping[0;39m - Mapped to com.nckh.yte.controller.DrugInfoDetailedController#getDrugInfoFull(Map)
2025-11-02 01:02:13.503 [39mDEBUG[0;39m [http-nio-8081-exec-2] [36mo.s.w.s.m.m.a.RequestMappingHandlerMapping[0;39m - Mapped to com.nckh.yte.controller.DrugInfoDetailedController#getDrugInfoFull(Map)
2025-11-02 01:02:13.505 [39mDEBUG[0;39m [http-nio-8081-exec-2] [36mo.s.security.web.FilterChainProxy[0;39m - Secured POST /api/ai/drug-info-full
2025-11-02 01:02:13.505 [39mDEBUG[0;39m [http-nio-8081-exec-2] [36mo.s.web.servlet.DispatcherServlet[0;39m - POST "/api/ai/drug-info-full", parameters={}
2025-11-02 01:02:13.506 [39mDEBUG[0;39m [http-nio-8081-exec-2] [36mo.s.w.s.m.m.a.RequestMappingHandlerMapping[0;39m - Mapped to com.nckh.yte.controller.DrugInfoDetailedController#getDrugInfoFull(Map)
2025-11-02 01:02:13.507 [39mDEBUG[0;39m [http-nio-8081-exec-2] [36mo.s.w.s.m.m.a.RequestResponseBodyMethodProcessor[0;39m - Read "application/json;charset=utf-8" to [{drug=penicillin}]
2025-11-02 01:02:13.511 [39mDEBUG[0;39m [http-nio-8081-exec-2] [36mo.s.w.s.m.m.a.HttpEntityMethodProcessor[0;39m - Using 'application/json', given [*/*] and supported [application/json, application/*+json]
2025-11-02 01:02:13.513 [39mDEBUG[0;39m [http-nio-8081-exec-2] [36mo.s.w.s.m.m.a.HttpEntityMethodProcessor[0;39m - Writing [{items=[{T√≥m t·∫Øt b√°c sƒ©=T√≥m t·∫Øt th√¥ng tin thu·ªëc BICILLIN L-A: C√¥ng d·ª•ng: BICILLIN L-A ƒë∆∞·ª£c s·ª≠ d·ª•ng ƒë (truncated)...]
2025-11-02 01:02:13.514 [39mDEBUG[0;39m [http-nio-8081-exec-2] [36mo.s.web.servlet.DispatcherServlet[0;39m - Completed 200 OK
